Stages of empyema.
\r\n\tOver the years, the concept of maintenance became more comprehensive, reducing fault occurrence and increasing industrial system availability. Besides, reliability, safety, and criticality requirements were associated with the system or equipment under analysis. Maintenance strategies or schemes can be classified as corrective (run-to-break), preventive (time-based), and predictive (condition-based maintenance). Corrective maintenance is only performed after an occurrence of a fault. Therefore, it involves unexpected breakdowns, high costs, changes in the production chain, and it could lead to catastrophic events. Preventive maintenance and interventions occur based on a scheduled maintenance plan or the equipment's mean time between failures. Although it is more effective than corrective maintenance, unexpected failure may still occur by preventing most failures. Additionally, the process cost is still high, especially the costs associated with labor, inventory, and unnecessary replacement of equipment or components.
\r\n\tOn the other hand, predictive maintenance analyses the equipment condition so that a possible fault can still be identified at an early stage. Predictive maintenance aims to identify a machine anomaly so that it does not result in a fault. Such maintenance involves advanced monitoring, processing, and signal analysis techniques, which are generally performed non-invasively and, in many cases, in real-time. In the case of machines or processes, these techniques can be developed based on vibration, temperature, acoustic emission, or electrical current signal monitoring. It should be noted that monitoring such signals or parameters to verify the operating condition is called condition monitoring. Condition monitoring aims to observe the machine's current operational condition and predict its future condition, keeping it under a systematic analysis during its remaining life. In this sense, a fault condition can be detected and identified from systematic machine condition monitoring. A diagnosis procedure can be established, whereby properly investigating the fault symptoms and prognosis.
\r\n\t
\r\n\tThis book will aim to merge all these ideas in a single volume, aggregate new maintenance experiences, apply new techniques and approaches, and report field experiences to establish new maintenance processes and management paradigms.
\r\n\t
High-grade gliomas are the most common and aggressive group of primary central nervous system tumors, and are characterized by grim prognoses. The glioma with the worst associated survival is Glioblastoma Multiforme (GBM), otherwise known as anaplastic astrocytoma grade IV. The median survival of patients diagnosed with GBM is just 12 to 15 months. After recurrence, only 9-15% of patients are alive and progression free at 6 months (APF6), with a median survival of 9 months.
Advances in surgical techniques and neuroimaging have proven important, but nonetheless have done little to improve survival. The standard treatment for newly diagnosed GBM remains an aggressive tripartite strategy of surgery, radiation therapy (RT), and chemotherapy with adjuvant and concurrent temozolomide (TMZ), and yet GBM almost inevitably recurs. TMZ was added to the standard of care after Stupp et al. published results in 2005 showing that TMZ extended survival by 2.5 months [1]. Other FDA approved treatments for GBM include the nitrosoureas lomustine and carmustine, as well as gliadel wafers that release carmustine and are placed during surgery. The use of these agents has been controversial and not standard, despite the fact that they have a similar effect on survival as TMZ. Upon recurrence, the treatment options for GBM are drastically diminished. Therapy is varied, and can include re-irradiation or surgery for some patients, and drug treatments. Only recently has the anti-angiogenic drug, bevacizumab, been added to the therapeutic regimen for recurrent tumors, although its impact on survival is debated [2]. NovoTTF, an electric current therapy, is also approved for use in recurrent GBM.
Current treatment for GBM is not without toxicity. None of the GBM treatments considerably extend survival or improve quality of life, and consequently the risk-benefit ratio in treating GBM is not greatly tipped towards beneficial. Indeed, individual prognostic factors of each patient, including 06-Methylguanine-DNA methyltransferase (MGMT) methylation status, presence of mutant epidermal growth factor variant III (EGFRvIII), baseline performance status, age, and extent of surgical resection, usually have a better correlation to survival than available treatments [3]. Younger age, MGMT methylation, IDH1 mutation, gross total surgical resection, and a higher performance status as measured by Karnofsky Performance Score (KPS) are positive predictors of survival [4-7].
The lack of effective treatments can be largely attributed to the biology of this glioma making it elusive to treatment. GBM is largely infiltrative of the surrounding brain tissue, so separation for surgical and radiation treatment is essentially impossible, thwarting efforts to prevent recurrence. Drugs may fail to impact GBM because of their inability to cross the blood-brain-barrier (BBB). Although it has been argued that the BBB becomes permeable due to a GBM, it is likely that many cancerous cells remain in areas with an intact BBB [8]. Additionally, the ubiquitous mutations and redundant biologic pathways in GBM allow the tumor to easily escape many therapies. Upon recurrence, GBM often mutates and takes on new genetic abnormalities, conferring resistance to treatment that previously achieved some success. Combination therapy approaches are likely the best solution to GBM’s escape and resistance mechanisms[9]. New therapies, possibly combined with older ones, are sorely needed to see remarkable advancements in the treatment of GBM. Only a handful of agents have been FDA approved for GBM in the last four decades, and these include: nitrosoureas, gliadel wafers, TMZ, bevacizumab, and Novo-TTF. As such, clinical trials remain as vital as ever.
Clinical trials of innovative treatments are the avenue for progress in GBM treatment, but serious obstacles plague trials and discourage advancements. Enrollment of patients and success of investigational agents is sub-par. Only 5% of adults with cancer enter clinical trials, and a mere 6% of the agents that go into trials are ultimately FDA approved.
A major barrier to developing new treatments has been the relative infrequency of GBM. The incidence of GBM is 11,000 diagnoses and a prevalence of 25,000 each year [10]. Although it gained some notoriety in the media when Senator Edward Kennedy passed away as a result of the disease in 2009, GBM is still seen as an orphan disease. Its rarity contributes to a paucity of funding, and makes innovative drug development through clinical trial research slow and frustrating as a result of low patient accrual. With just 3% of patients who receive standard of care surviving past 5 years, new clinical trials will shape the future of this diagnosis, but presently, a very small handful of GBM patients participate in clinical trials. The world of clinical trials is fraught with ethical debates, frustrating lack of standardization across trial parameters, and low funding. The efficacy of new treatments is obscured by poorly designed trials with insufficient stratification by individual prognostic factors or ill-chosen end-point analyses. However, as researchers continue to elucidate the molecular mechanisms of GBM, innovative, targeted treatments have gained promise as the new possible solution. These include immunotherapies, anti-angiogenic drugs, and therapies against target molecules like EGFR. Well-designed clinical trials involving these agents are necessary for finding progress for the low survival rate of GBM.
Although it has been debated whether or not clinical trial research should be conducted on terminally ill patients who may not reap a survival benefit, two recent studies have shown that clinical trials unequivocally help patients, irrespective of the trial’s occurrence before or after standard of care advances, including the addition of TMZ. Shahar et al [11] discovered a significant survival benefit for GBM patients who participated in clinical trials, regardless of their placement in the control or experimental arm, and independent of baseline performance scores or age. This important finding was corroborated by Field et al whose group showed that patients in clinical trials had improved outcomes, once again regardless of assigned trial arm, age, or performance status [12]. Clinical trials are valuable to academic and medical communities, and now it would appear, they can be to the patient. Patients in both arms of a trial could exhibit better outcomes because of the additional close surveillance by medical teams that offer psychological and physical support. The act of following a rigid protocol, placebo effect, and/or a change in the physician patient relationship as a result of both being observed may also suffice as explanations [12]. A disconcerting question is provoked from these results, if patients on the control arm do better than those who receive the standard of care, is it really the best standard of care?
Clinical trials have progressive phases of development, starting with pre-clinical laboratory research, followed by either a pre-clinical phase 0 or phase I trial, and then a succession of phase II, phase III, and usually a phase IV trial. Pre-clinical studies precede human trials, and involve bench research, such as human cell lines, followed by translation into animal models implanted with human xenografts or syngeneic rodent tumors in immune-competent mice for immunological studies.
A phase 0 trial, also known as a micro-dosing exploratory investigational new drug trial (IND), or early phase I trial, is the first translational step into human use, after an investigational agent has been thoroughly studied in animal models. In this phase, only a small amount of drug is used, and the data generated are preliminary without intended indications about safety or effectiveness. A small number of patients with advanced disease and without available treatment options participate, and once the experimental agent is deemed acceptable for human use, a phase I trial is initiated.
Phase I trials are meant to examine the dosing of a new drug, its safety, and pharmacokinetic properties. Classically, the goal is describe the maximum tolerated dose (MTD). Notably, efficacy is not evaluated at this phase [13]. Patients in phase I trials are monitored carefully for side effects. There are approximately 20 enrolled patients, who have advanced disease where no standard treatment exists. Phase I can last for months to a year or more, depending on accruement.
Phase II trials examine the efficacy and pharmacodynamics of the investigational treatment in under 100 patients. Healthy patients are excluded from participation in oncology trials because of the high toxicity associated with cancer treatments. Unfortunately, the efficacy and toxicity of cytotoxic drugs simultaneously increase [14]. In brain tumor patients, efficacy is typically measured by tumor changes, and these are characterized on a set spectrum from complete tumor response to progressive disease, with evaluation performed through radiographic imaging [13]. If a pre-determined level of efficacy is attained, the trial may advance to phase III, otherwise, the clinical trial process is halted. Phase I and II trials may be combined if a drug is already well known for another diagnosis, as there is some existing information on toxicities and dosing.
Phase III trials involve a larger cohort of patients, anywhere from hundreds to thousands of people, and last for years. The intent is to compare the investigational treatment to the standard of care and determine if it confers some advantage over the standard, in terms of efficacy, side effects, or other factors. This phase usually employs both randomization and blinded enrollment, which in combination with larger numbers of participating patients, helps to reduce bias of earlier phase trials. After the completion of phase III, if the study agent possesses benefit over the standard treatment, FDA approval is sought.
Phase IV trials are not always required, and simply serve to answer any lingering questions after the drug has FDA approval, such as side effects that have not been sufficiently explored. Phase IV trials enroll many more patients and may last a long time. Drug companies often sponsor phase IV studies to act as post-marketing surveillance trials (NCI).
The clinical trial process through all of the phases is not easy or rapid. It takes a median of 172 days to open any phase trial, and with three phases this adds up to an extra 1.5 years spent on the administrative process. Many factors play into this slow approval, including inadequate resources for frequent institutional review board (IRB) meetings and unavailability of staff that can be allocated to protocol development. Other barriers, like contracting, or increased litigation and bureaucracy at academic centers, also slow the process. Solutions such as a centralized IRB have been proposed, but not realized. A more efficient administrative path would mean opening trials faster, and consequently patients could obtain the benefits of new treatments sooner; this does not need to come at the expense of ensuring that patient safety and research integrity stay intact [15].
One more streamlined option for drugs entering clinical trials is to apply for accelerated approval (AA). The FDA designed AA so that drugs could be more quickly approved for life-threatening conditions. It is intended for drugs that fill an unmet need in the treatment of a serious condition. Two notable social movements, namely the AIDS and breast cancer movements, helped bring the concept of AA to fruition. Patients who were sick and dying were frustrated by their inability to access promising experimental drugs that still had years before FDA approval [16]. The advent of AA alleviated some of the regulatory sluggishness and hindrances. The results of these activist movements have trickled down to affect treatment of brain tumors; for example, both TMZ and bevacizumab have been granted AA for use in GBM.
AA is faster in part because it relies upon data from surrogate end-points, as opposed to regular approval, which is granted based off of data on real clinical benefit, designated to be either prolonged survival or improved quality of life. Surrogate end-points, such as progression free survival (PFS) or overall radiographic response (ORR), are supposed to reasonably predict an effect on actual clinical measures and give evidence of an acceptable risk-benefit ratio, while requiring less time to assess. Ideally, the surrogate end-point has been well validated in its relation to clinical benefit, as correlation with the clinical measure does not necessarily mean evidence of clinical improvement will follow suit. A prevalent example is the two drugs encainide and flecainide, which received AA in 1980 for their ability to suppress arrhythmias, a known risk factor in myocardial infarction. After AA, they were prescribed to almost half a million people; physicians even believed that it was unethical for control subjects in a randomized trial not to receive them. However, the completion of a randomized, post-marketing trial found that the drugs actually tripled the risk of death, and they were withdrawn from the market [17]. As shown by this example, simply correlating an end-point with a clinical benefit can be risky. Moreover, although phase II or III trials can provide the data for AA, regular approval is contingent upon the completion of required post-marketing trials that are conducted to demonstrate actual clinical benefit, or the drug may be withdrawn from the market.
Although the importance of post-marketing trials is unquestionable, it is apparent that these are not always conducted in a timely fashion for oncology drugs. The FDA granted AA to 47 new uses for 35 oncology drugs from 1992-2010, but by 2011, 21 had not been given regular approval because the clinical benefit had yet to be proven in a post-marketing trial. Monitoring from the FDA and penalties to companies that do not finish trials in a reasonable time will be necessary to preventing ineffective, or even harmful drugs from staying on the market and being prescribed. Confirming that a post-marketing trial is designed and ready for patient accrual at time that AA is granted would help ensure the drug company’s compliance [17, 18].
The FDA and other regulatory agencies are not solely responsible for a challenging clinical trial process. It can also partly be attributed to the complex ethics involved in cancer clinical trials. These ethical issues are important to recognize, and play a part in the physician, patient, and greater regulatory agencies’ attitudes towards clinical trial research.
Ethical issues for patients in brain tumor (as well as other oncology and terminal diagnoses) trials can be sorted into a series of fundamental questions. The first question is if terminally ill patients should be considered a vulnerable population? Although the GBM patients who participate in trials are often white, male, and educated, and therefore not classically categorized as vulnerable by society, their status as dying conveys a new vulnerability [19]. A vulnerable group is defined by an inability to protect their own interests or by having cognitive impairments that interfere with decision-making capacity. Physicians and others become concerned when a dying, desperate patient becomes willing to do anything, regardless of proposed risk or benefit, for the chance of an improved outcome. GBM patients undoubtedly suffer from varying degrees of cognitive impairment, and struggle physically and psychologically, so their resulting decision making capacity could very well be reduced. Conversely, these patients arguably make other equally important decisions, such as end-of-life wishes and estate wills.
The debate regarding vulnerability should not produce the conclusion that GBM patients need to be excluded from clinical trials; the very act of exclusion of dying patients can be unjust and harm the progress of medical care [20]. It is presumptive to assume that each patient prefers palliative care to the chance for involvement in research for future treatments, having an avenue to fight their diagnosis, or being valued in the medical research world. The notion that participation in clinical trials by desperate patients is similar to coercion is also incorrect, as being in a situation with inherently limited choices towards the end of life is distinct from coercion [19]. Avoiding the categorization of terminally ill patients participating in trials as exploitation can be achieved by ensuring that the research is essential to the future of the diagnosis, that another population could not replace dying patients, and that risk is minimized [20].
A second ethics issue is the patients understanding of the informed consent process mandatory to entering a trial. Consent is intended to explain the reasons for the trial and what can be expected to happen to a patient as a result of participation. For a phase I trial, the consent process would inform the patient that the study is meant for finding dosing and safety information. Despite this, patients involved in phase I trials often cite their desire for therapeutic benefit as the reason for participation, despite the fact that phase I trials do not anticipate efficacy for patients [14, 21]. A dichotomy between what the researcher, who searches for toxicity and pharmacological details, versus the patient, who wants to get better, hopes to gain is apparent [14]. The fact that patients use phase I trials as a last-ditch effort to fight their disease and to attain a response brings up the natural conclusion that the informed consent process is inadequate. If the consent process were sufficient, the patient would be aware that they very likely would not experience a response in their disease, and that the trial is simply for dosing and safety [21]. However, this gap in understanding is not as simple as inadequate consent. A vital line must be drawn between understanding and appreciation; a patient can comprehend that the chances of receiving a therapeutic benefit are incredibly slim, and that dosing is the end-point, but what they appreciate in this scenario may remain the possibility, however small, of a benefit. Indeed, although only a third of patients report the goal of a phase I trial is for dosing information, a full 92% report it is for safety. Furthermore, it is exceedingly difficult to grasp the psychological state of a person who is dealing with serious illness and fear, and thus inadequate to assume that healthy people fully understand the perspective that gives rise to a terminal patient’s decision to participate in a trial with an apparently skewed risk-benefit ratio [19]. Comprehension as a result of the informed consent process needs to be pursued and confirmed along with a realization that patients and researchers may continue to value different end goals. This will avoid exploitation and protect against the formation of false hope in patients.
The third ethics issue is the balance of the risk-benefit ratio, which is exceedingly important in ensuring that a clinical trial should be conducted. The risk-benefit ratio for terminally ill patients has is unique, as they may be more willing to accept risks in order to gain a benefit. For example, it has been historically believed that there has only been an overall response rate of 5%, and a complete response rate of 0.3-0.7%, in phase I anticancer trials. At first glance this seems quite low, and deciding whether or not conducting these trials is necessary also depends upon the associated risks. However, these numbers do not include newer targeted therapies, and additionally do not contain descriptions of less drastic responses. In fact, more than 60% actually showed at least one objective response (tumor shrinkage of more than 50%). The risk of death by phase I associated toxicities was 0.5% [19]. Horstmann et al. (2005) analyzed 460 oncology trials and found a 10.6% combined complete and partial response rate, and a 34.1% rate of less than partial response or stable disease, which are higher rates than previously recognized (deaths due to toxicity was 0.49%) [22]. It is possible that the benefits of phase I trials have been understated. Horstmann also points out that the retrospective analyses lacked separation by treatment type, which greatly affects toxicity and response. In addition to higher than believed biological response rates, an encouraging result is that psychological value has been discovered in phase I oncology trials. Although a large amount of time and energy must be dedicated by the patient, which is precious at the end of life, it is arguably balanced by the comfort of frequent physician contact and a chance to exert willpower in a powerless situation [19].
Another ethical dilemma in the oncology setting is how the physician-patient relationship is altered by clinical trial participation. This issue is key because physicians are the interface between patients and clinical trial research, and enrollment of patients into trials is heavily dependent upon physician referral. Phase I trials can be frustrating for physicians. A phase I trial is traditionally designed with the 3x3 model of Fibonacci escalation, meaning the first group of patients receives a low dose, the second a higher dose, and the third the highest dose, with dose escalation in each level until a reversible, toxic event occurs. In this design, the majority of patients will receive a sub-therapeutic dose, as disease responses are typically seen at 80-120% of the maximum dose [23]. This means 60-80% of patients in phase I trials receive an ineffective dose, along with any associated toxicities, a low overall response rate, and a historical disease remission rate of just 1%. It becomes understandable why physicians would not be enthusiastic about referring patients to phase I oncology trials. Physicians have no clinical authority over the care of their patient once they are enrolled in a trial, and it is hard to communicate to a patient that even if a benefit were to occur, the chances are not optimized for each patient in a phase I trial because this is fundamentally contrary to the Hippocratic oath [21]. New dosing methods have been suggested to reduce the amount of patients who receive sub-therapeutic doses and to quicken phase I trials. These can take the form of intra-patient escalation, a higher starting dose, fewer patients in each level, and accelerating the dose escalation process [23]. The Fibonacci scheme is no longer widely implemented, which eases some ethical tension for patients and physicians [16]. Changing dosing methods to increase the likelihood of patients benefitting is desirable, but it can blur the lines between research and therapeutics. It implies that phase I trials are for benefit, when they remain to be conducted for research on safety and dosing. With a scheme like intra-patient escalation, physicians may have a greater tendency to think that they are helping their patient, even though the end-point of the phase I trial remains unchanged. Standard medical care and clinical trial research are not one and the same, but physicians and patients alike often fail to see the boundaries [21]. This aside, decreasing the number of patients who are unnecessarily exposed to a drug by employing better dosing schemes is important.
Randomized phase III trials also present issues for the doctor-patient relationship. In order for a physician to send a patient to a clinical trial, they must not believe either arm of the clinical trial is superior; the Hippocratic oath would prevent the physician from accepting randomization in this case. Physicians are inclined to operate under concern for their present patient, not the future generations that will reap the results of a successful clinical trial [24]. However, randomization and blinded enrollment are significant. Trials that do not adequately conceal patient distribution have a greater tendency to find an advantage of the new treatment over the standard. Blinded assessment produces significantly lower and more consistent scores as compared to open assessment [25]. Dealing with ethical issues surrounding randomization is essential. Reluctance of physicians to refer patients to clinical trials is a major obstacle as it begets less effective and less powerful trials due to low patient accrual.
That being said, patient interaction with clinical trials is not wholly dependent upon a relationship with a physician. Patients do seek them out independently or find them as a result of patient advocacy and social movements, as seen with the AIDS and breast cancer activist movements. It would appear that the activist movements gained a victory for terminally ill patients who seek experimental drugs through AA. However, it is feasible that AA is monetarily helpful to pharmacology companies, who can profit once approval is granted, rather than being as advantageous as patients believe it to be. In the AIDS movement, the drugs that were granted AA were extremely expensive, while still being toxic and mediocre [16]. The FDA and congressional regulations are wary of drug companies taking advantage of patients through AA, which is why it is only granted for diseases with extreme need and why, in 1991, the FDA published specific regulations for AA in life-threatening conditions, including a post-marketing trial requirement [26]. The crux of the issue in patients versus approval mechanisms is the ethical argument between the right to take experimental drugs and the need to collect drug data.
In 1980, the United States Supreme Court ruled that patients do not have the right to obtain unapproved drugs (Rutherford vs. U.S.). Gonzales vs. Raich in 2005 resulted in the Supreme Court ruling, “dispensing of new drugs, even when doctors approve their use, must await federal approval” [26]. Recently, the Supreme Court denied the Abigail Alliance’s, a non-profit organization founded by a young girl’s father hoping to gain access to an experimental drug for his terminally ill daughter, requests to allow drugs to be approved and used after phase I trials, and to let companies financially profit before approval. The possibility of exploitation of sick and desperate patients by drug companies was too conceivable in this case. The facts remain that 66% of oncology drugs entering phase I trials fail to be approved [27]. Thus, accepting the Abigail Alliance’s desire for drug approval after phase I trials would be dangerous.
The right to early access to drugs through AA should not compromise further data collection. Once patients have access to a drug through AA, enrolling in the post-marketing trial is not appealing, yet the purpose of the trial is to ultimately understand the risk-benefit ratio, which is critical to patients and should not be undervalued [26]. Although AA is granted with the assumption that the agent will procure clinical benefit, this is not always the case. For example, if a drug receives AA after phase II, the reality is still that 45% of drugs fail phase III testing. Consequently, AA does need to be granted with caution and the assurance that more data will follow [28]. It is also necessary to understand that rare adverse events may only be illuminated in large randomized trials, and very rare ones may only be discovered after the drug is being taken by large numbers of the population. A possible solution for mitigating the risk of AA would be staggered approval, in which the drug is approved for use in a small subset of a disease, and as more data are collected the drugs’ use can be expanded [28]. A second option to reduce the risk associated with AA is expanded access for non-randomized open trials, so that more patients can enroll and receive a drug while data are generated. The National Coalition for Cancer Survivorship and the American Society for Clinical Oncology have advocated for expanded access [26].
The ethics of clinical trials do not have straightforward resolutions; the main point that must be adhered to through any of the ethical debates is protecting patients who have run out of medical options from exploitation or an unacceptably skewed risk-benefit ratio. The fact is that although clinical trials are complex to develop and run, their significance for GBM remains strong even in the midst of ethical and regulatory barriers.
Obstacles in brain tumor clinical trials will be discussed in order to illuminate why progress in the field continues to be a struggle. The issues covered will include: challenges to patient selection, trial end-point analyses, and the different trial parameters required for optimal assessment of recently developed targeted, experimental agents.
Patient accrual and selection in GBM clinical trials can be problematic, because without sufficient patient numbers or stratification, trials become ineffective. GBM is an orphan disease and consequently the number of patients who enter clinical trials is quite low. This problem is exacerbated by physician hesitance to refer patients to trials. As a result of low numbers, statistical power in clinical trials is diminished, which prevents detection of more subtle efficacies. For example, in a randomized clinical trial looking for a 50% increase in survival, 136 patients are needed per arm. To detect a 25% increase in survival, 411 patients must be in each arm. For this reason, in designing a clinical trial for a rare disease, the clinical outcome pre-determined as significant must be carefully considered [29]. By using the same standard for every disease, a drug might be inaccurately deemed ineffective and not worth studying.
Another element in patient selection for brain tumor trials is defining the appropriate control for a treatment comparison. The possibilities include: an untreated baseline from the same patient, an untreated patient in another arm, or historical controls. Historical controls are used to compare efficacy results of many phase I and II trials, but this is not an ideal measure. Historical controls can be derived from possibly flawed literature, and trials may have differed in significant ways, like eligibility criteria, lack of control for corticosteroids, types of imaging analysis, or unaccounted prognostic factors. There is little consistency across trials because of the absence of agreed upon standard care, with the exception of the Stupp protocol after 2005 [30]. With new, targeted therapies, the ideal control for a trial is to procure untreated and treated biological specimens, within the same patient over time. By the patient serving as his/her own control, the amount and function of a target can be easily and thoroughly compared. The issue in this approach lies in the feasibility and cost-effectiveness of multiple surgeries [31].
The GBM patient population is also heterogeneous in regards to individual prognostic factors. Principal prognostic factors described after a recursive partitioning analysis (RPA), performed by the Radiation Therapy Oncology Group, were the patient’s age, KPS, neurological function, mental status, and extent of surgery, which is related to survival after 89% of tumor volume resection [4, 32]. Another essential factor for prognosis is tumor location. If patients are not stratified and selected for, with consideration of prognostic factors, it may become impossible to assess whether or not treatment effects are truly due to treatment or individual differences. Understanding of these prognostic factors allows patient to be sorted into four main GBM risk classes, which can be accurately compared amongst one another [32]. Risk groups determined by RPA are important in phase II trials that compare data to historical controls to eliminate patient selection bias [5]. Age is an extremely important as a prognostic factor, followed by performance status for patients older than 50 years, and within that subset, mental status causes a significant split [4, 33].
Highlighting the vitality of prognostic factor description and separation in clinical trials was reported in a retrospective analysis by Perry et al. 1997 of the RTOG database. The group discovered that pre-treatment variables (i.e. prognostic factors) impacted survival more than actual treatment. The variables examined were the duration of symptoms, neurologic abnormalities, tumor grade, age at diagnosis, and post-operative performance status. In their examination of phase II studies, it became apparent that patient selection furnished sufficient explanation of survival differences. It is clear that patient stratification is imperative for accurate treatment analysis, even though it likely increases the required number of patients for trials as subgroups are created [34].
End point analysis has been a major point of contention and frustration in many GBM clinical trials. There is no single preferred end-point, making comparisons between trials complicated and doubts about a treatment’s efficacy hard to resolve. The importance of the end-point cannot be overstated, as an ill-chosen one can make a drug’s efficacy seem poorer or better than it actually is, which are both detrimental outcomes. The two main types of end-point analyses for efficacy in brain tumor clinical trials are tumor response (visible tumor effects along with rate and duration of response) and tumor control (PFS or OS). Tumor control is more optimal for targeted therapy effects because it takes into account cytostatic drugs that do not impact tumor burden, as compared to tumor response, which is more sensitive to cytotoxic drugs [34]. Both PFS and tumor response rely upon radiographic imaging analysis, yet this is plagued by unreliability and lack of standardization in brain tumor patients. Radiographic imaging needs meticulous and careful assessment.
Pseudoprogression is treatment caused changes in edema or contrast enhancement that radiographically mimics increasing tumor burden [35]. Up to 30% of patients have shown psuedoprogression after RT/TMZ, as well as after chemotherapy wafers, immunotoxins delivered with convection enhanced delivery, viral gene therapy, and immunotherapies [36]. A repeat scan must be performed 4-8 weeks later helps to rule out pseudoprogression [37] in order to prevent unnecessary therapy or accidental inclusion of patients in clinical trials for recurrence [35]. Alternatively, pseudoresponse is equally as problematic as it can give rise to the perception that a therapy has caused a response. The corticosteroids used by many patients considerably reduce tumor enhancement on MRI or CT imaging, giving the false appearance of a tumor response [34]. Further, agents that target vascularity alter vessel permeability, and in turn decrease perfusion and enhancement on imaging, without the underlying tumor being affected. One example is the anti-angiogenic agent bevacizumab, which can significantly decrease enhancement within 24 hours on MRI, although the solid tumor is static [38].
There are commonly used methods for assessing imaging in many trials, although no standard is globally applied. Before current methods were proposed, the Levin criteria and the WHO response criteria were used to assess brain tumor imaging. The Levin criteria called for analysis of MRI images to assess the extent of enhancement, edema, and mass effect as compared to a baseline scan. Tumor responses were either categorized as complete, partial, stable disease, or progressive disease [35, 39]. The WHO criteria evaluated contrast-enhanced computed topography (CT) by multiplying the greatest cross-sectional enhancing tumor diameters [35]. The Levin and WHO criteria were subsequently replaced by the Macdonald criteria in 1990 because they did not have adequately defined guidelines, and did not consider artificial enhancement created by factors besides the tumor.
The Macdonald criteria use MRI, contrast-enhancing imaging, which has become the imaging gold-standard method for measuring changes in GBM. There are two different types of MRI assessment. The first is to measure the largest diameter on any single axial section, which can be done using two distinct established criteria, and the second is volumetric measure of tumor size. The first diameter method is the Macdonald Criteria (two dimensional), outlined more than 20 years ago but still widely used, which analyzes the largest enhancing tumor diameter on a single axial gadolinium-enhanced T1-weighted section. This process also considers the greatest perpendicular diameter on that section. The product of the diameters is calculated, and each subsequent imaging study is summed with the previous diameters [40]. These results are then applied to classify the results as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). The Macdonald criteria defines complete response as the disappearance of all enhancing measureable and non-measurable disease for at least 4 weeks, with no new lesions, no corticosteroids, and stable or improved clinical status. A partial response requires greater than 50% decrease in all enhancing perpendicular diameters compared with the baseline, with no new lesions, stable or decreasing corticosteroid use, and stable or improved clinical status. Significant progressive disease is a 25% increase in the sum of the perpendicular diameter products in contrast-enhancing lesion, a new lesion, or clinical deterioration. Stable disease is defined as anything besides complete, partial, or stable response. Clinical status is measured with KPS or Eastern Cooperative Oncology Group (ECOG) performance status (explained below) [34,40]. The criteria take into account corticosteroid use and neurological status changes. Complete and partial responses are combined to comprise what is known as overall radiographic response (ORR), which is the indication of positive treatment efficacy. Radiographic response is used in clinical trials because changes in the size of the tumor are presumably a predictor of symptomatic and survival benefit. ORR can be evaluated in a single arm trial, and it is not convoluted by the history of the disease so it can more accurately predict therapeutic benefit. ORR also has advantage as an end-point because the Macdonald criteria are widely used and relatively objective, so they enable comparison between trials [35]. However, although radiographic response and survival are believed to be related, ORR has not been directly connected to therapeutic benefit, and the significance of a partial versus a complete response is not well characterized [30]. Furthermore, radiographic response is biased against cytostatic agents that produce stable disease as opposed to partial or complete radiographic responses [36].
There are also limitations associated with the Macdonald assessment method. Macdonald criteria do not specify directions for necrotic portions, are restricted in the ability measure irregularly shaped tumors, are subjective to the radiographic reviewer, offer no guidance for multifocal tumors, face challenges in measuring around cysts or surgical cavities, and fail to assess non-enhancing tumor [35, 40, 41]. Ignoring non-enhancing tumor while simply measuring contrast enhancement is insufficient because perfusion of enhancing agents across the BBB can be influenced by many factors, including corticosteroids, inflammation, surgery, ischemia, anti-angiogenic drugs, radiation, radiological methods, seizure, and post-surgical effects [36, 41].
In an effort to rectify these limitations, updates to the Macdonald criteria have been proposed by the Response-Assessment Neurooncology (RANO) working group. The updated criteria consider, without measuring, non-enhancing regions on T2-weighted and FLAIR MRI imaging to visualize response. Any enlargements in these areas are considered as progression, and to be defined as CR, PR, or SD, the non-enhancing regions must be stable or decreased. The definition of stable disease is expanded to be a greater than 25%, but less than 50%, decrease in enhancing disease, along with no new lesions, stable or decreasing corticosteroid use, and stable or increased clinical status. Pseudoprogression is clarified by stating that within the first 12 weeks after radiotherapy, progression can only be determined if all of the enhancement occurs outside the radiation field or is pathologically confirmed [35, 41].
The other diameter measuring method is the one-dimensional RECIST criteria, published in 2000, but not as widely utilized as the Macdonald criteria because it has not been validated in brain tumors [40, 41]. RECIST finds the longest linear enhancing diameter of a lesion in one axial plane, which is repeated on later imaging studies, regardless of changing section or orientation. Non-measurable lesions are less than 10mm, less than 2 times the imaging section thickness, and cannot be cystic foci, necrotic foci, or leptomeningeal lesions. If multiple lesions must be measured, they are done so separately and summed in final analysis [40]. RECIST does not consider steroid use or neurological status, and faces similar challenges as the Macdonald criteria in regards to the difficulty of radiographically measuring a heterogeneous tumor [35]. Macdonald and RECIST have been found to be concordant in other cancers, and recent evidence found that they gave similar responses for tumor response and progression in recurrent GBM treated with irinotecan and bevacizumab [35].
The final MRI method is computer-aided volumetric assessment, in which a computer delineates the border between enhancing and non-enhancing areas over every axial section with enhancement. Border review is conducted by a neuroradiologist to calculate the total enhancing volume. Volumetric measurements can better succeed in controlling measurement variation, and may be more sensitive to early progression and response rates [40]. Nevertheless, defining the borders for measurement is problematic in this heterogeneous tumor [40]. Although there are theoretical advantages, volumetric measurements are not recommended because they are not standardized and the technology is not yet widespread [42].
Newer imaging modalities are a promising solution for imaging confusion. Spectroscopy uses metabolites to better show events in the non-enhancing tumor regions and diffusion imaging uses water diffusion into the tumor to visualize a treatment’s efficacy and allow better imaging of the non-enhancing tumor. This helps distinguish between ischemia effects and recurrence. Perfusion imaging is sensitive to blood flow and permeability and therefore an ideal measure for anti-angiogenic therapy. PET scans can help distinguish recurrence versus necrosis post-radiation therapy [30, 36, 41]. T2-weighted or fluid attenuated inversion recovery (FLAIR) MRI imaging can give insight into non-enhancing tumor and the infiltrative tumor burden. These technologies have been used in some studies, although they remain to be standardized [3, 35].
In summary, tumor response on MRI is not infallibly reliable or objective, but PFS is still a common end-point. OS is another often used end-point, and does not rely on radiographic imaging. OS and PFS are explained below.
The FDA and the North American Brain Tumor Coalition (NABTC) have declared QOL a secondary end-point of interest, but it is notoriously resistant to standardized measurement and therefore it is challenging to validate QOL data to support drug approval [29, 30, 43]. A main problem in measuring QOL is that patients often do not fill out all questionnaires over time, due to symptomatic development, loss of motivation, or doctors and nurses failing to administer or explain questionnaires, so data remain incomplete. There are different questionnaires currently available to measure QOL, but none have become the standard. The MMSE is a questionnaire intended to give insight into QOL, but it is insensitive to mild cognitive impairments and is more appropriate for detecting dementia. QOL questionnaires have been developed by the Functional Assessment of Cancer Therapy (FACT) and the European Organization for the Research and Treatment of Cancer (EORTC) that incorporate information given by the patient and their proxy, although proxies often cannot accurately recapitulate the necessary data and may exaggerate HR-QOL issues while underestimating psychological problems [34, 46, 47]. The EORTC’s QLQ-C30 is a 30 item functional and symptomatic assessment for HR-QOL. A measurement specific for brain cancer developed by this group, the EORTC QLQ-BN20, has 20 items and assesses visual disorder, motor dysfunction, disease symptoms, treatment toxicity, and future uncertainty. The FACT-BR questionnaire is specific to brain cancer and examines physical, social, emotional, and functional measures and is more psychologically, than symptomatically focused [47]. Even if QOL cannot yet be used to support drug approval, it is an important measure in clinical trials of how a patient is coping with treatment, and a worsening QOL needs to be monitored and corrected.
The end-points in clinical trials for targeted therapies need to be re-evaluated. Targeted therapies frequently work in a cytostatic fashion, and judging their efficacy on imaging is often inappropriate. Because the biology of GBM is unimaginably complex, it is not likely that a single molecular agent will produce dramatic results on imaging. Instead, taking stock of biological markers before and after treatment will allow a better glimpse at if and how the drug is working. Other cancers have made use of biological markers, but this trend has not yet taken root in brain tumor clinical trials. The relationship between biological molecular changes and tumor response and clinical benefit requires comprehension before markers can be useful. Grasping how molecular markers respond to a treatment will help explain the ideal context for a drug. For example, identifying where it affects a biological pathway can shed light on combination therapy options. Preclinical evaluations in animal models will help define when molecular marker changes are significant in relation to survival or tumor burden. One biological marker in gliomas is phosphorylation of a target receptor in association with tyrosine kinase inhibitor drugs [31]. This measure is direct evaluation of the target, rather than upstream or downstream molecules, which provides a clear picture of the drug’s effect on the intended target. However, this does not take into consideration the target as part of a larger biological environment.
An ideal picture of biological events can be gleaned through analysis of surgical tumor samples. The most powerful scenario for efficacy appraisal using biomarkers is to administer the investigational drug before acquiring a tumor sample through biopsy or craniotomy, then give more investigational drug, and finally take another surgical tissue specimen after a specified amount of time has passed. In this model, the changes in biological pathways in direct relation to a drug can be carefully and thoroughly studied, but there are many disadvantages as well. The major obstacle is that not all surgeries are therapeutically necessary. Craniotomies are expensive and risky, while less invasive biopsies are a poor substitute as they may not be representative of the tumor [29, 31].
Moreover, some investigational drugs, namely anti-angiogenic agents, preclude surgery because they interfere with blood clotting, wound healing, and can complicate anesthesia. Immunotherapeutic drugs might also block necessary immune responses in unexpected ways after surgery [31, 34]. When the drug-surgery cycle is feasible, training must be in place for surgeons. In surgery, circumferential dissection yields more viable tissue than inside-out methods, thus standardization of how tissue is acquired is a key control step for clinical trial quality. In anticipation of this issue, surgeons who work with the NABTC have been taught the expected tissue acquisition methods.
Because the drug-surgery model is not always an option for patients, non-invasive marker development will be essential for these cases. Indeed, elucidating appropriate biomarkers and avoiding unnecessary surgery would be preferred in every possible situation. Non-invasive biomarkers were explored in clinical trials on the GBM drug cediranib. The trial utilized non-invasive biomarkers, including circulating progenitor cells (CPCs), circulating endothelial cells (CECs), and amounts of pro-angiogenic proteins in the plasma. These biomarkers were coupled with MRI for perfusion, permeability, and vessel size. Briefly, the study, which will be discussed more below, discovered that the biomarkers were useful to predicting certain tumor behaviors. Furthermore, it was revealed that the drug had a short-lived response, something that may have gone undetected without molecular markers [31]. Fully comprehending the drug’s effect is crucial, because subtle windows of efficacy such as this should not be missed or the drug will be mistakenly shelved as ineffective.
Incorporating molecular markers would merit re-vamping of phase 0, I, and II trials, hopefully into a more streamlined process. Trials that use molecular markers would preferably switch from calculating MTD to appropriate biological dose (ABD), instead. As stated previously, MTD works well for cytotoxic agents where a higher the dose equals a higher efficacy. However, ABD can occur well below MTD, and is a function of affecting the target as desired [31].
Phase 0 trials traditionally assess pharmacokinetic and pharmacodynamic properties in a small group of patients, followed by phase I revealing the MTD. An accelerated combined phase 0/I trial of a targeted molecular agent could simultaneously define ABD and gain a preliminary understanding of the drug’s action on its target. Actually binding the target with the drug would be a requirement for entering a phase II trial. The phase 0/I design is not meant to replace the dose escalation assessment in phase I or the efficacy analysis in phase II, but it would facilitate an efficient use of time and financial resources by combining dosing with initial target data [29]. Using molecular markers in a phase II trial to show that a molecular agent affects, not just binds the target as intended, would be crucial. Imaging and clinical data would remain helpful as an indirect end-point, especially in combination treatment trials; yet it is vital to keep in mind that a monotherapy clinical trial is unlikely to produce an obvious clinical benefit [31]. Currently, more phase II trials are arising that have surgical arms to facilitate analysis of molecular markers [8]. A phase II trial could go beyond its role for efficacy by identifying a relevant target population. This way, enrolling patients in clinical trials, who are not expected to benefit from it, could be avoided [29].
Comprehending if and how the drug works on the target will produce a knowledgeable foundation for future drug combinations, which is probably the most promising method for GBM treatment [31]. Although a drug may not produce obvious alterations to a clinical or radiographic end-point as monotherapy, its effectiveness could be augmented by adjuvant administration of other carefully selected drugs that simultaneously target relevant connected pathways. Tailoring combinations of targeted molecular agents based on the individual’s molecular profile is a future possibility, and trials may come to be designed for patients with different markers [48].
Ahead of many proposed clinical trial design changes, targeted molecular agents have begun to infiltrate clinical trials for GBM, some of which will be explored below. Certain clinical trial changes have taken place, but they are not uniform across the board. In addition to targeted therapies, immunotherapies and other therapies will be discussed, as they are prevalent in the clinical trial landscape and encompass similar trial designs and possible changes, such as use of biomarkers, as targeted molecular agents. The clinical trials discussed are intended to serve as practical examples of the changes, as well as established methods, that are actually taking place in trials, rather than theoretical propositions. Two important points of focus will be end-point analysis and choice of control in the clinical trials. The clinical trials examined below have either been recently completed, or are ongoing. They are organized into categories by the type of interventional agent, namely: anti-angiogenic/receptor tyrosine kinase (RTK) inhibitors, immunotherapies, and other therapy.
RTK’s are an enticing target in GBM because the RTK/ phosphoinositide 3-kinase (PI3K) / protein kinase b (AKT) pathway has mutations in over 80% of tumors [49]. RTKs, such as EGFR, bind and activate PI3Ks, which in turn activate AKT that has many downstream targets and causes apoptosis inhibition while stimulating growth and proliferation [50]. One important downstream target of AKT is hypoxia-inducible factor-1α (HIF-1α), a key player in angiogenesis [51]. EGFR is especially ubiquitous with a 40% alteration rate through mutation, rearrangement, or amplification [49, 52]. PI3K is not the only mediator in functional RTK signaling; in fact
Erraticism in RTK profiles from patient to patient and even within one tumor is precisely why combination therapy for RTK inhibitors would be necessary to demonstrate therapeutic success. Combinations might even be optimized if they are based on the individual’s specific RTK activation profile [52]. This will not be an easy undertaking, as the experience with some drugs’ efficacy, namely cediranib, not correlating with the target expression indicates. Targets are not biologically isolated, and their expression does not guarantee a targeted treatment will have results. Combination therapy comes with its own issues in teasing out toxicities and efficacy of different agents.
Ensuring that the RTK inhibitors, especially anti-angiogenic therapies, actually impact the tumor is paramount to understanding their influence on efficacy. Imaging issues have already been discussed; anti-angiogenic drugs can cause convoluted imaging read-outs with transient improvement in edema and mass effect. As such, biomarkers will be vital in clinical trials, as well as other imaging options, such as T2 and FLAIR MRI or PET with amino acid tracers [36, 37]. Finally, the side effects of RTKs are not negligible, and may affect future treatments, such as surgery due to inhibited wound healing [29]. Selecting the patient population that is most likely to benefit is essential for reducing unnecessary exposures to these drugs.
Bevacizumab is a humanized, monoclonal antibody that inhibits vascular endothelial growth factor (VEGFA), the ligand of the VEGF receptor, a receptor tyrosine kinase associated with angiogenesis. Angiogenesis is vital to embryogenesis in order to develop the vascular system from endothelial cells. When a tumor becomes too large (greater than 1-2mm) to rely on the host vasculature, it may transition from avascular to vascular prompted by hypoxia-induced activation of pro-angiogenic factors such as VEGF and transforming growth factor beta (TGF-β). VEGF is an important inducer of angiogenesis, and is over-expressed in GBM, as well as many other cancers [55]. Bevacizumab was granted FDA accelerated approved for the treatment of recurrent GBM on May 5th, 2009, based on the evidence for objective tumor response provided by two phase II studies. The process of bevacizumab through clinical trials is discussed.
This phase II trial was designed to study GBM in its first or second recurrence and give evidence for AA. The trial had two arms: bevacizumab as monotherapy and bevacizumab with Irinotecan, and was historically controlled. To be eligible, patients may have had prior surgery or biopsy, prior RT/TMZ, demonstrable radiographic evidence of progression after therapy, stable or decreasing corticosteroid use 5 days before the baseline MRI, and a KPS ≥ 70. The median age of the bevacizumab arm was 54 years, and KPS was stratified in groups of 70-80 and 90-100. There were 85 patients in the bevacizumab monotherapy arm; the irinotecan and bevacizumab arm were not analyzed for approval because the FDA stated that the efficacy of bevacizumab and irinotecan were inseparable. 6moPFS was the designated primary trial end-point. However, the primary end-point per the FDA was objective response rate, as 6moPFS needs a comparative control to show results. An independent review committee determined the objective response rate according to Macdonald response criteria, and the MRI readings were confirmed 4 weeks later. Secondary end-points were the duration of response and safety. Historical control data was from an analysis by Wong et al [56] of eight phase II trials at the M.D. Anderson Cancer Center, which included 225 GBM patients. In these studies, both CT and MRI imaging were used, scans were performed every 2 months, and criteria similar to Macdonald were used. In the AVF3708 trial, MRI imaging was conducted every six weeks with Macdonald criteria. The historical control objective response rates were assumed to be 5% for the bevacizumab monotherapy arm, and 15% for the 6moPFS. A significant 28.2% objective response rate with 1 CR and 23 PR, and a duration of 5.6 months was reported. The FDA reported a 25.9% response rate with 4.5 months duration. The discordance rate for objective response rate assessments between two assigned, independent review radiologists was 47.1% and a third radiologist failed to agree with the first two 14.3% of the time. The high frequency of disagreement highlights exactly why the FDA is hesitant about MRI usage in clinical trials, especially with anti-angiogenic therapies that are known to change MRI readings, as stated previously [38]. The 6moPFS reported by the trial sponsor (Genentech) was significant at 43.6%, the 6moPFS reported by the FDA was significant at 36%, and as reported by the investigator was significant at 42.6%. The discrepancy was purportedly due to the fact that Genentech used a 5.52 month cut-off, while the FDA adhered to 6 months. Although historical controls are not ideal due to possible population differences, tumor assessment frequency and criteria, along with type of follow-up, Genentech proposed that such a large change in 6moPFS is a reasonable predictor of clinical benefit.
AVF3708 suffered from lack of clarity over the end-point of choice, since the FDA disagreed with Genentech. The study also relied upon historical controls, which are never optimal, and due to poor planning was unable to use data from the bevacizumab and irinotecan arm. Finally, although the study used Macdonald criteria, the objective response rate was obviously a point of contention with disagreement between reviewers. Despite these issues, this data was used to support AA.
A second phase II trial examined the efficacy of bevacizumab in recurrent GBM, as compared to historical controls. It used the same tumor assessment criteria (Macdonald) with an independent review process, but collected MRI every 4 instead of 6 weeks. The median age of the patients (n=56) was 54 years, and KPS was stratified with a group scoring 70-80 and a group scoring 90-100. Patients had previously undergone surgery, radiation, and systemic chemotherapy. Once again, PFS was the determined end-point, but it was agreed that the data on objective response rate and the duration of the response would be used to support bevacizumab approval. A 19.6% response rate with a median duration of 3.9 months was reported. These data supported AA along with AVF3708.
After AA was granted based on these phase II trials, two post-marketing phase III clinical trials, as required by the FDA after AA, were initiated. They were intended to confirm the efficacy of bevacizumab, but this time in the primary tumor setting, and the trials have recently have reported results. The first trial, AVF4396g, was sponsored by the drug company Hoffman-La Roche and was a randomized, double-blind, placebo-controlled study of bevacizumab in combination with RT/TMZ for 921 newly diagnosed GBM patients. The median age in the treatment group was 57 years and in the placebo group it was 56 years. KPS was stratified with 32.6% and 30.3% having a score of 50-80 in the treatment and placebo groups, respectively, and 67.4% and 69.7% having a score of 90-100 in the treatment and placebo groups, respectively. Patients were also organized into RPA classes, with the majority being in class IV. The primary end-points were designated as OS and PFS, although the FDA declared OS as the principal regulatory end-point. Updated Macdonald criteria were used for imaging assessment. Patients were randomized with recursive partitioning analysis to receive RT/TMZ with or without bevacizumab (FDA 2009). The median PFS was significantly higher at 10.6 months in the bevacizumab arm versus 6.2 months in the placebo arm. OS was not significantly different in the experimental versus placebo groups, 72.4% and 66.3% at 1 year, and 33.9% and 30.1% at two years, respectively. No change was observed in QOL or neurocognitive function [57].
The second phase III trial was sponsored by the National Cancer Institute, and enrolled 978 patients, 637 of whom were eligible to undergo randomization to receive RT/TMZ with bevacizumab or a placebo. The median age was 58 years in the randomized group. There was a KPS of 60-80 in 40% and 39% of the treatment and placebo groups, respectively, and a KPS of 90-100 in 60% and 61% of the treatment and control groups, respectively. The majority of patients had total resection, although roughly a third had partial resection. RPA class stratification was used, with most patients being in class IV. There was no significant effect on OS, 15.7 months in the bevacizumab group and 16.1 months in the placebo arm. OS was similar to the AVF4396g study, but PFS differed, possibly due to a statistical difference in the pre-specified alpha level for progression (p<0.01). PFS was improved at 10.7 versus 7.3 months. This study reported that over time patients experienced worsened quality of life, a greater symptom burden, and a decline in neurocognitive function [58].
The phase III trials failed to show a direct clinical benefit for survival, which jeopardizes the continued usage of bevacizumab in GBM, at least in the upfront setting. Disturbingly, these two trials presented contrasting data on the impact on the quality of life for GBM patients. This was puzzling as both studies used the EORTC’s QLQ-30 and BN20 questionnaires for quality of life assessment. AVF4396g used updated Macdonald imaging criteria that took into account non-enhancing tumor, so the possibility of missing a progression in disease was reduced, which could have affected QOL [57]. The lessening of edema and subsequent reduced need for corticosteroids is the purported benefit to QOL seen in AVF4396g. Differences in statistics and imaging criteria between the post-marketing trials are not negligible, and point to the challenge of which results are to be most convincing.
Bevacizumab is a germane example of a drug that received AA, only to disappoint in confirmatory trials. If bevacizumab is indeed harmful to the quality of life, as suggested by the NCI’s phase III trial, its presence on the market is concerning, although the differences in primary vs recurrent setting may clarify that. It could be speculated that early studies and AA were flawed in their reliance on imaging dependent end-points as their initial primary considerations. Objective response and 6moPFS may not accurately predict clinical benefit. The issues with imaging in the trial are substantiated by the almost 50% frequency of disagreement in AVF3708 between radiological reviewers according to the FDA. AA is also based on much smaller trials, whereas the phase III trials combined looked at almost 2,000 patients, so statistical power is greatly improved. It remains to be seen how bevacizumab will be prescribed in the future, now that it is has a debatable effect on survival. It has not been removed from the market, and continues to be evaluated in clinical trials.
A receptor tyrosine kinase inhibitor that recently went through clinical trials is Cediranib (AZD2171), a pan-VEGFR inhibitor with some activity against related structures c-Kit andwhich acts against platelet-derived growth factor receptors (PDGFRA and B). A phase II trial involving 31 recurrent GBM patients receiving cediranib monotherapy, with the primary end-point being APF6, was conducted. The median age was 53 years and median KPS was 90 and patients were not stratified. Secondary end-points were radiographic response, median OS, and toxicity. Various imaging modalities were employed (assessment was changed to include 2D and volumetric measurements) and analysis of plasma and urinary biomarkers was undertaken. In summary, the median OS was 227 days and the APF6 was 25.8%. A radiographic partial response was detected in 17/30 (56.7%) patients with volumetric measurements, and with 8/30 (27%) using Macdonald criteria instead of volumetric analysis. This is a significant example of the differences that can arise between different imaging assessment methods. As compared to historical controls (Wong et al. analysis 1999), the results were deemed encouraging [59]. The baseline levels of different biomarkers were unable to be correlated with PFS or OS, but were postulated to be helpful for pharmacodynamics. However, some biomarkers did exhibit significant change, independent of PFS or OS, after treatment. A significant correlation was stated between some dynamic biomarkers and radiographic response and survival. This study demonstrated that the majority of patients reduced or stopped their corticosteroid dosages, but this was contingent upon continued treatment with cediranib. The study results were overall positive, and the vitality of combined therapy was re-iterated due to the belief that cediranib normalizes vessels to make other treatments more effective [60].
A phase III randomized, placebo controlled, partially blinded study was initiated after the promising phase II results. Phase III was a 3 arm study of 325 recurrent GBM patients investigating cediranib monotherapy, cediranib with lomustine (nitrosourea approved for use in GBM), and lomustine monotherapy. This phase took the important step of moving to combination therapy. The median age in each arm was 54 years. The patients were stratified according to KPS with 50%, 48%, and 36.2% having a score of 70-80 in each arm, respectively and 50, 51.2, and 62.5% having a KPS of 90-100 in the respective arms. Patients had previously been treated with RT/TMZ. The primary end-point was PFS, assessed by centralized, independent, blinded radiographic review, which used updated Macdonald criteria for T1, T2 and FLAIR MRI imaging. It should be noted that this evolved from the phase II trials that used volumetrics for imaging analysis and APF6. The soluble biomarkers VEGF, VEGFR2, and bFGF from plasma were measured in relation to baseline levels, but they were determined to be unrelated to predicting outcome in the trial. Biomarkers did not prove helpful in this trial, which was disappointing. The trial did not meet its PFS goal of significance, and did not impact OS. Since 136 patients received salvage therapy of bevacizumab monotherapy or combination therapy, survival could have been biased, yet salvage therapy was established to be similar in the different arms. Perhaps the disappointing results can be partially attributed to changes in imaging analysis methods over the course of the trial phases. There were secondary benefits of lengthened time to neurologic deterioration and reduced steroid dependence. The combination of cediranib and lomustine was not ideal, as cediranib heightened lomustine associated toxicities, although these were manageable. The idea that cediranib might be better in combination with RT, according to pre-clinical results, was proposed. Two phase II studies on cediranib and radiation are ongoing [2].
Immunotherapy has been gaining momentum as the next attractive treatment option for GBM. It promises fewer side effects, and greater efficacy because it uses the host’s own immune defense mechanisms to fight cancer while sparing normal tissue. Important immune cells to be activated are naïve and memory T cells, natural killer cells (NK), and natural killer T cells (NKT). Immunotherapies seem to show good evidence of impacting survival in clinical trials with relatively minimal toxicities [61].
Although immunotherapy is promising, there are inherent challenges and limitations. The BBB is often discussed in immunotherapy, but its role is a subject of debate. However, the BBB may not be as impenetrable as formerly proposed. Antigens from the CNS do end up in cervical and nasal lymph nodes. Also, lymphocytes are capable of crossing the BBB. In fact, activated T cells express certain molecules that enable them to penetrate the BBB [62]. Inflammatory chemokines stimulate lymphocyte arrest and binding of cell adhesion molecules to integrins, which is fundamental to immune cells entering the brain. Furthermore, lower numbers of immune molecules and cells, like CD4 and human leukocyte antigen (HLA) class I, have been correlated to worse prognosis and survival, which would not be expected if the brain was exclusive to the immune system [63].
In addition to the BBB, antigen identification is also challenging. While other cancers express tumor-specific antigens for obvious targeting, GBM has very few cancer specific antigens [63]. Even epidermal growth factor variant III (EGFRvIII), which is found solely on GBM cells, is expressed in just 20-30% of tumors. Also, because an antigen is tumor specific does not mean that it is immunogenic [64]. GBM cells do not adequately present antigens, limiting the activation of T cells [62]. A third formidable obstacle to immunotherapy is the profound immunosuppression of GBM patients, both in the tumor microenvironment and systemically. Immune suppression is typically profound and cannot be completely overcome, which is a disadvantage for immunotherapy efficacy but an advantage in avoiding a different risk of immunotherapy, that of accidentally inducing autoimmunity. The occurrence of an autoimmune reaction is a risk because tumor cells are technically host cells, so they have inherent tolerance systems put in place to avoid autoimmunity, and expression patterns similar to host cells [63].
Therapies that are effective despite immunosuppression issues can run into a major obstacle, which is tumoral immune editing. If a therapy effectively targets certain antigens, the tumor may subsequently change its reliance on these antigens [65]. This was illustrated by the loss of EGFRvIII expression in many recurrent tumors after administration of an EGFRvIII targeted vaccine, rindopepimut. Vaccines using whole tumor lysates or combination therapy are a possible solution to immune editing.
In addition to immune system obstacles, immunotherapy faces the same problems as other therapies with clinical trial design, imaging limitations, and end-point selection. Reliance on pre-clinical animal models is not optimal because the models have limits as surrogates, and translating the therapy’s effects into humans is complex. Moreover, obtaining an immune response does not necessarily bestow improved survival or longer time to progression [65]. Finally, immunotherapy trials are very expensive. The simplest phase III immunotherapy cancer trial with approximately 300 patients, easy immunotherapy manufacturing, and efficient clinical readouts, surgery, and imaging might cost about 20 million dollars. A larger trial that has personalized therapy and is more technology reliant could cost in the hundreds of millions [64].
Another popular and prevalent vaccine for GBM is Rindopepimut (CDX-110), an EGFRvIII specific 14-mer peptide. EGFRvIII is unique in that it is solely expressed on GBM cells. An in-frame deletion causes fusion of two parts of the molecule, ultimately leading to constitutive activation that is implicated in tumorigenicity, tumor cell migration, and resistance to chemotherapy and radiation [62].
A phase II clinical trial (ACT III) with intradermally administered rindopepimut plus GM-CSF and maintenance TMZ in 65 newly diagnosed EGFRvIII positive GBM patients reported a PFS of 12.3 months (compared to 6.3 historically) and an OS of 24.6 months (compared to 15.0 historically). Patients had to have undergone gross total resection and traditional TMZ/RT without progression. The median age was 56 years and the median KPS was 90 [62]. The historical control cohort consisted of 17 patients treated at the center at the same time and the populations were matched for positive EGFRvIII status, gross total resection, treatment with RT/TMZ, and no progression for 3 months post treatment [66]. The primary end-point was considered PFS. Methylation of MGMT resulted in a significantly increased PFS. After these positive results, new clinical trials were initiated.
The current investigations of rindopepimut are a phase III trial (ACT IV) for newly diagnosed GBM patients and a phase II trial (ReACT) of recurrent GBM patients. ACT IV aims to include 700 EGFRvIII positive patients who have had gross total and incomplete resection, in an effort to reduce bias towards grossly resected patients, and who have completed standard chemoradiation. Completion is expected in 2016 [62]. The trial is a 2 arm, randomized study, comparing rindopepimut to a TMZ control, with OS as the primary measure, and PFS and safety and tolerability as secondary measures. Results have not yet been released (Clinicaltrials.gov, NCT01480479). ReACT is studying the efficacy of rindopepimut in combination with bevacizumab for patients with relapsed EGFRvIII positive GBM. Patients are sorted into two groups: those who have received and are refractory to bevacizumab, and those who have not previously received bevacizumab. Within those two groups, patients will be randomly assigned to receive rindopepimut/GM-CSF or a placebo (KLH) while continuing, re-starting, or starting bevacizumab therapy. Group 1 is bevacizumb naïve and receives bevacizumab plus rindopepimut/GM-CSF. Group 2 is bevacizumab naïve and receives bevacizumab plus a KLH placebo. Group 2C is bevacizumab refractory and receives bevacizumab plus rindopepimut/GM-CSF. The primary end-point for Groups 1 and 2 is 6moPFS, and the secondary end-points are safety and tolerability, antitumor activity, and EGFRvIII specific immune responses. OS is notably absent as an end-point. The primary end-point in group 2C will be ORR. Imaging analyses are performed using RANO criteria. Patients must have had prior surgery and chemoradiation, be EGFRvIII positive, and be in their first or second relapse of primary GBM or first relapse of secondary GBM. Completion is anticipated for 2014 with 168 patients. Preliminary results were released in November 2013. The OS for Group 1 was 12.0 months versus 7.9 months in Group 2. The PFS was 3.7 months in group 1 as compared to 2.0 months in group 2. Interestingly, the occurrence of tumor response (>50% shrinkage) for group 1 was 37% per investigator review and was 32% per expert panel review. For group 2 it was 19% per investigator review and 25% per expert panel review. Once again, this demonstrates the objective nature of imaging analyses. The results also indicate that patients who are EGFRvIII positive do have a poorer prognosis. In Group 2C the OS was 5.6 months and the PFS was 1.9 months. In preliminary ReACT data it was suggested that the anti-EGFRvIII titer is predictive of patient outcome. The results for ReACT are continuing to be assessed, but show a trend towards efficacy (Clinicaltrials.gov, NCT01498328).
There are limitations in the analysis and use of rindopepimut. An obvious problem with rindopepimut is that only 20-30% of GBMs express EGFRvIII. Furthermore, upon recurrence it has been documented that between 82-91% of tumors lose EGFRvIII expression after recurrence [62, 67]. Importantly, EGFRvIII expression has not been significantly related to survival. Furthermore, trial design was not ideal in rindopepimut testing. The ACT III trial did not take into account certain prognostic factors, like mutation of isocitrate dehydrogenase one/two (IDH1/2), which is known to positively affect survival; patients in the trial also had various salvage therapies that may have influenced survival. The historical control population was also much smaller than the experimental group (n=17 vs. n=65). Despite matched eligibility criteria, discrepancies between the rindopepimut study population and the historical population used for comparison in ACT III are possible and would be problematic. Bias in the clinical trials of rindopepimut could also have arisen from the fact that KPS scores were quite high; in ACT III the median KPS was 90. KPS is a key prognostic factor and may indicate that patients in these trials had a better prognosis overall. Moreover, patients in these trials underwent gross total resection, which is not realistic to the greater GBM patient population, but ACTIV and ReAct do attempt to address this by including patients with less than gross total resection [62].
An intriguing non-drug option for GBM patients is the Novo-TTF system, approved by the FDA in 2011. NovoTTF is a portable device that is worn almost continuously, with the exception of short daily breaks for personal needs. It emits low intensity, intermediate frequency, alternating electronic fields that are non-invasive. Electronic fields disturb cell division by triggering microtubule misalignment necessary for the metaphase to anaphase transition. The fields also cause movement of intracellular macromolecules and organelles in telophase. Ultimately, the cytokinetic division of the cell is impossible after failed segregation and distribution of chromosomes, organelles, and microtubules, and cell death occurs [59]. Dividing cells have unique shapes and electric features, making rapidly multiplying cancer cells sensitive to electric field treatment.
NovoTTF was tested in 237 recurrent GBM patients in a phase III trial comparing NovoTTF monotherapy to any active chemotherapy, as determined by the physician’s judgment. The median age of patients was 54 years and the median KPS was 80. The primary end-point was OS and the secondary end-points were PFS, PFS6, radiological response, 1 year survival, QOL, and safety. A central review board did imaging analysis using the MacDonald criteria. Selected patients must have had radiation, with or without TMZ, and 80% had failed 2 or more chemotherapies and had more than one recurrence. The primary end-point of OS was not significant at 14% versus 9.6% in the active control arm. PFS6 was improved at 21% compared to 15%. The failure to produce improved survival might have been unavoidable in a patient population with more than one recurrence and failure of other treatments; other trials involving recurrent patients often enroll patients on their first recurrence. Despite not reaching survival significance, NovoTTF was approved. An important result contributing to approval was NovoTTF’s effect on QOL, assessed via QLQ-30 [59]. Enhanced QOL is attributable to the absence of serious chemotherapy related toxicities, such as nausea, anemia, fatigue, and serious infections, although, some patients treated with NovoTTF did have worsened neurologic events, including headaches and convulsion.
The FDA approval of NovoTTF was surprising in light of the FDA’s hesitance on relying unstandardized QOL measures. However, the decision to approve NovoTTF is understood through its contingency upon the dearth of treatments for recurrent GBM. Re-resection and re-irradiation are feasible in only a handful of recurrent patients, and chemotherapy has an extremely low response rate of less than 10%. Approval for an intervention that does not improve survival would is far more feasible in a disease like GBM that has such a poor prognosis. The vote for approval was very close (7 to 6) and can be classified as a “non-inferiority” approval, meaning NovoTTF is not better nor worse than other therapies, and it may improve QOL [59]. Here the risk-benefit ratio was tantamount to the drug succeeding in clinical trials. It is an example of how skewed the ratio is in a severe diagnosis such as GBM. The benefit did not have to be great because other approved agents have very low benefits in comparison to significant side effects.
The ideal design of clinical trials for GBM patients remains elusive. The conflict between OS, PFS, and ORR as primary end-points continues, with the FDA staying with OS. Radiographic imaging assessment remains an obstacle for PFS and ORR, which is evidenced by disagreement between radiographic reviewers (as seen in studies with bevacizumab). Although imaging criteria are being updated, the most likely progress will be through different imaging methods, like T2 MRI and FLAIR. Alternatively, biomarkers are becoming more important. They are already being used in trials, but there is still a gap in comprehension of how and when they are most useful. In RTK inhibitor clinical trials biomarkers were assessed, yet they did not always have predictive value or an expected relationship to an end-point. However, this does not mean that biomarkers are useless. Connecting tumoral and survival end-points to biomarkers will require further study, and they are indeed continuing to be analyzed in clinical trials.
Many investigational agents discussed above undergo changes to their end-points as the drug advances from phase to phase in the clinical trial. Rindopepimut is an example of the myriad end-points that may be used for assessing any one agent. Furthermore, as each investigational agent seems to use a different control cohort, there is especially variability in the historical cohorts chosen for comparative analyses, which are drawn from several literature sources. Lack of consistency across trials or even phases is detrimental because it creates confusion and complexity in analyzing investigational agents. Also, many drugs in clinical trials end up being disappointing despite promising early phase results. This phenomenon could be attributed to limitations in early phase clinical trials, such as small sample size, absence of a comparator arm, or bias in patient selection. Protecting drugs in early phases who have not demonstrated clear efficacy and safety from entering the market will continue to be an ethical and sometimes legal battle; collecting data is absolutely vital to the welfare of current and future patients and it cannot be compromised.
Another major issue is the tendency to focus on monotherapy (or monotherapy plus RT/TMZ). Monotherapy is helpful in determining how a drug works, but beyond this the therapeutic effects would be greatly augmented by creating relevant combination therapies. GBM evolves too quickly and frequently for any monotherapy to become a “cure”. Moreover, combination therapy in the form of novel drugs, in comparison to a new drug added to the RT/TMZ regimen, is not common and needs more focus. Combining novel drugs is admittedly tricky, yet it holds promise.
Clinical trials are the avenue for progress in GBM. The obstacles that inhibit the success of clinical trials are formidable, but not unsolvable. Greater patient participation, better standardization across and within clinical trials, and innovative end-points and combination therapy are the way forward.
The authors would like to thank the University of Colorado Department of Neurosurgery, The University of Colorado Cancer Center, the Cancer League of Colorado, and the National Institutes of Health RO1 # 11066485 for support.
Empyema is a common clinical problem to both pulmonary physicians and thoracic surgeons. It affected 65,000 patients annually in the US [1]. Thanks to the advent of antibiotics and continuous advancement of minimally invasive procedures, most acute empyema patients can now receive tube thoracostomy and/or video-assisted thoracoscopic surgeries (VATS) to alleviate the infection with good recovery [2]. Empyema, also known to be pleural empyema or thoracic empyema, is defined as infection in the pleural cavity. The most common scenario is that the patient has a prior or ongoing pneumonia which the infection has extended to the lung surface, causing a series of inflammation and infection response on the visceral pleura and therefore parietal pleura. The products of the infection then accumulate in the pleural space resulting in empyema. Some patients would develop pleuritic pain which they easily mistake it as muscle strains or sprains, so they tend to overlook the real problem and lead to delay diagnosis. There are also a lot of other reasons that can eventually cause empyema, such as trauma, invasive procedures (including thoracic operation), liver abscess, spinal abscess, mediastinitis (because in the vicinity of an infection source) or being transmitted through hematogenous route.
According to American Thoracic Society classification, empyema is divided into three stages (Table 1) [3, 4]. In the early stage of pleural cavity infection, some fibrin would develop in this avascular space along with some body fluid. It is often recognized as parapneumonic pleural effusion. At this exudative phase, most fluid in the pleural cavity can be drained by a chest tube. If the infectious process continues and the fluid accumulates, the fluid will become thicker with more fibrin deposition. This second stage is often characterized by loculated pleural effusion which makes it difficult to drain all effusion in different areas with a single chest tube. Patients with this true empyema stage often require surgical intervention to deloculate the effusion for complete drainage. Fibrinolytic agent is another option for non-surgical candidate. When the disease progresses, more and more fibrin pile up and the fluid becomes denser and denser. A thick peel will form to cover all contact surfaces, including lung, inner chest wall, diaphragm, and mediastinum. This final stage of empyema, organizing phase, will restrict lung expansion and hence reduce lung compliance. More aggressive treatment modalities should always be considered to avoid long-term lung function impairment.
Stage | Phase | Characteristics | Status of Lung Parenchyma | Treatment |
---|---|---|---|---|
I | Exudative (Acute) | Pleural membrane thickening Fibrin deposition Presence of exudative fluid | Compliant Reexpansion possible with evacuation of fluid | Thoracentesis Closed-tube thoracostomy |
II | Fibrinopurulent | Extensive fibrin deposition Pleural fluid becomes turbid or purulent Presence of loculated empyema | Partial compliance Lung entrapment due to fibrin deposition | Closed-tube thoracostomy with/ without fibrinolytics VATS Thoracotomy |
III | Organized (Chronic) | Fibroblast in growth Thickened pus Granulation tissue replacement of the pleural space | No compliance Lung completely entrapped by fibrous peel | VATS (decortication) Thoracotomy (decortication) Open window thoracostomy |
Since empyema equals to infected pleural cavity, the primary goal is to treat the infection. There are a few recognized treatment principles to such disease. First, sterilization of the pleural space. Second, adequate drainage. Third, optimizing lung expansion and reducing potential pleural space. These principles will be explained in detail below.
Just like treating other infectious disease, removal of pus or necrotic tissue and antibiotics therapy are the two key components to successful treatment. In empyema, sterilization targets not only the pleural space but also the original infection source, such as pneumonia or liver abscess. To select effective antibiotics, obtaining cultures are important so that adjustment can be made according to susceptibility test after empirical antibiotics. Other effective ways to lower the pathogen colonization in the pleural cavity are removal of the infectious debri and irrigation. These procedures, debridement and irrigation, are often carried out during the surgery, either through VATS or thoracotomy. Although some doctors believe irrigation may result in unstable hemodynamics as capillary permeability increases due to transient bacteremia, the author thinks it is reasonable to do so as it is easier and faster to achieve sterilization. If the patient’s blood pressure drops during the surgery, it is suggested to irrigate the pleural cavity with some diluted epinephrine with cautious monitoring. Since the patient’s capillary permeability may increase, it is possible that the patient would develop tachycardia and hypertension if the medication is well-absorbed by the pleura.
Unlike airway, pleural cavity is a closed space. The fluid should be drained adequately to avoid further or repeated infection. A chest tube is sufficient for simple parapneumonic pleural effusion (stage I empyema) while complicated pleural effusion (stage II empyema) or organizing empyema (stage III empyema) often requires surgical intervention and a chest tube(s) after the surgery for adequate drainage.
When the empyema reaches to its final stage --- organizing stage, the lung would become completely trapped and therefore poorly expanded. This not only leads to restrictive lung (impaired lung function), but also leaves a potential dead space in the pleural cavity. This space would possibly result in repeated infection. Therefore, the initial treatment goal of empyema should also include best pleural apposition to prevent chronicity. To achieve this, remove “peels” from the lung and other pleural surfaces. This surgical procedure is known as “Decortication.” As long as it is feasible, removing all debri and resuming patients’ optimal pulmonary function are always recommended. However, there could be exceptions that the lung fails to fill the pleural cavity. If this is the case, other measures should be taken to reduce the potential pleural space.
From a thoracic surgeon’s point of view towards managing empyema, it is always “the earlier the easier.” In an acute setting of empyema (stage I or II), most patients can be cured by tube thoracostomy or VATS [2]. This further emphasizes the fact that early diagnosis and early aggressive treatment to prevent chronicity are crucial. In addition, the choice of first intervention is important as well. According to the literature, failure of the first attempted procedure was an independent predictor of death [5]. As a result, operation is the most successful initial procedure in this study. More and more studies demonstrated good outcomes of early surgical intervention treating complex empyema [5, 6]. Furthermore, VATS decortication is found to be superior to open surgery in the management of primary empyema [7]. In the author’s hospital, empyema is a surgical disease. Once the diagnosis is made, almost all patients need surgical consult for further treatment planning. All surgeons tacitly agree that VATS is the gold standard procedure to treat acute empyema in the author’s institution.
There are still certain patients who will eventually continue to have the infection and enter to a chronic phase. Several causes of chronic empyema include delayed diagnosis, retained hematoma in the pleural cavity, bronchopleural fistula with continuous airway secretion spillage, a large potential pleural space (e.g. post lung resectional empyema) which is prone to have repeated infection, and the patient is too ill to receive definite treatment at the initial acute phase. Among all the causes, the author thinks that retained hematoma in the pleural cavity is the most preventable cause of chronic empyema. Blood clots are perfect culture medium for bacteria, so it is important to avoid too much oozing when one performs VATS debridement and decortication on empyema patients, especially those who have liver cirrhosis, end stage renal disease, or other bleeding tendency. Adequate hemostasis and diluted epinephrine irrigation are helpful to prevent retained hematoma. If retained hematoma still happens, at least it is detectable from the drainage fluid. The drained fluid would be bloody initially then turned to dark brown and remained in this color without turning to light yellow. As one recognizes the sign of retained hematoma in the pleural cavity, it is often required to do another operation to remove all the blood clots to prevent chronic empyema.
In this section, the focus will be solely on the treatment options of chronic empyema and to which treatment principles that each option fits in.
When dealing with empyema, following the above mentioned three treatment principles is the key to success. Although the principles are the same in different stages, treatment strategies may vary, especially in the chronic stage. Treating chronic empyema is more complicated, more unpredictable, and therefore more challenging. It may require staged operations, different surgical approaches, and there is no standardized option. Before establishing treatment plan for chronic empyema patients, comprehensive understanding between each option is necessary.
Decortication can be done either through VATS or thoracotomy. It is basically surgeon’s preference. During the same surgery, debridement is also done so that non-viable tissue and debri are removed to achieve “cleaning” in the pleural cavity. In stage III empyema, the lung is always restricted by thickened “cortex,” so freeing the lung by decortication can optimize lung expansion and reduce the potential pleural space. Choosing proper surgical instruments accelerates the procedure. In the author’s experience, Roberts artery forceps or long Kelly forceps are best tools to separate the lung from the overlying “cortex.” This separation process can be done sometimes with the operated lung ventilating so that the correct pleural plane is evident. If pleural apposition still cannot be achieved after decortication, make sure to check the lung surface again. There may be some remnant peel from the multi-layered peel that restricts lung expansion. Sometimes the peel is extremely thick and firm. Using a scalpel cautiously to slit through the peel will aid in removal.
*Fitting in the treatment principles sterilization of the pleural cavity and reducing potential pleural space by optimizing lung expansion.
To optimize lung expansion, there are several other ways, but none are as effective as decortication.
Some of these patients are ventilator dependent while others are not. If they still require ventilator support, it is acceptable to increase positive end-expiratory pressure (PEEP) a little, by 1 or 2 cmH2O, to further expand the lung. If patients can be weaned off from ventilator successfully after the operation, a strategical management option is to delay extubation time by 0.5 to 1 day. This may also allow the lung to further expand.
*Fitting in the treatment principle reducing potential pleural space by optimizing lung expansion.
Positive airway pressure expands the lung from internal while negative pleural pressure provides a tractive force externally. A suction pressure of −20 cmH2O is usually recommended with a traditional chest drainage system. Other modality that can create negative pressure in the pleural cavity is Vacuum-assisted closure (VAC) therapy. (see 4.4).
*Fitting in the treatment principles drainage and reducing potential pleural space by optimizing lung expansion.
OWT was first described by Robinson in 1916 and then revised by Leo Eloesser in 1935 which was also called Eloesser flap thoracostomy window [8]. However, the most adopted OWT is modified by Symbas and coworkers in 1971 as modified Eloesser flap [9].
This procedure, an open drainage method, is often saved as the last resort to treat chronic empyema, especially when the pleural infection is difficult to be managed by debridement and decortication. It is also a treatment option for critically ill patients who are too weak to receive decortication. As the name presents itself, OWT is to create a window through the patient’s chest so serial dressing changes are feasible to clean the infected pleural cavity and therefore alleviate the septic condition. The advantage of OWT is that it is proved to be safe and effective [10]. On the other hand, it affects the patient’s appearance and may cause chronic pain after chest wall resection. Some of the patients will need another surgery to close up the wound.
*Fitting in the treatment principles sterilization of the pleural cavity and drainage.
The most common use of OWT is modified Eloesser flap [11]. The window is usually created at the basal part of the hemithorax where most of the infected material accumulates (Figure 1). After confirming the chest CT image, an inverted U-shaped incision is made at this area. Electrocautery is used for dissection till the rib cage. In order to create a sufficient window, two or three ribs need to be resected. Then, the tongue-shaped muscular-cutaneous flap is folded inward and sutured to the diaphragm (Figure 2). The remaining wound edge is sutured to the pleura so that the window can be maintained for a period of time without spontaneous closure. It is also imperative that the window is large enough for the convenience of frequent wet packings. Another key point that must be mentioned is the timing of OWT creation. From the Massera et al. study [12], immediate OWT requires lesser time for the resolution of empyema comparing to the delayed OWT after prolonged chest tube drainage. As a result, the median OWT closure time (between performing and closing of OWT) of immediate OWT was 8 months shorter than that of delayed OWT. The timing of attempted closure should be carefully decided by the surgeon after a thorough evaluation of the empyema patient’s condition. This includes free from recurrent disease, good recovery of the pleural cavity with coverage by healthy granulation tissue, the patient’s general condition, and to a lesser degree by the normalization of inflammatory parameters [12, 13]. Methods of OWT closure please see 4.6.2 below.
OWT. An OWT on the patient’s left-side chest wall.
Coronal view of the Eloesser flap window. Demonstrating the supposition of the skin surface of the inferiorly based soft tissue flap to the diaphragmatic surface. (Adapted from Denlinger [
VAC is a negative pressure wound therapy that is widely used in acute and extended open wounds. The first case report of intrathoracic VAC therapy was published in 2006 [14]. Varker et al. managed a postlobectomy empyema patient with VAC device successfully after open debridement of the empyema cavity. In the next following decade, with the popularity of VAC therapy, it was proved that it is safe and efficient to fight against all kinds of intrathoracic infections [13, 15, 16, 17].
VAC device is able to create a negative pressure wound environment that promotes wound healing by reducing edema, promoting granulation tissue formation and perfusion, and removing exudate and infectious material. As to treating chronic empyema, it is a useful tool to apply on an open wound such as an OWT after debridement of the pleural cavity (Figure 3). In the setting of intrathoracic VAC usage, it may reduce the duration and frequency of dressing changes necessary for spontaneous chest closure or a space filling procedure, reducing patient’s discomfort, and resolving the infectious process faster [18]. When compared with conventional management of OWT, VAC therapy accelerates wound healing and helps re-expansion of residual lung parenchyma in patients with OWT [19]. In selected patients, applying Mini-VAC procedure can even avoid OWT by insertion of the ALEXIS (Applied Medical, Rancho Santa Margarita, CA, USA) wound retractor to create a similar window effect without resecting the ribs which preserves the chest wall integrity and avoids the consequences that OWT can cause (Figure 4) [20]. However, the biggest disadvantage of this device is that it is not suitable for everyone. VAC device should be used cautiously or be avoided on patients with bleeding tendency, presence of malignancy, or unstable hemodynamics. Because VAC creates a negative pressure environment, it may lead to continuous bleeding, promote cancer growth, or deteriorate hypotension. The reason why hypotension may develop is probably due to the negative pressure effect intrathoracically causing decreased cardiac output. Thus, intrathoracic application in older patients must be monitored closely and should be avoided on patients with poor cardiac function.
Intrathoracic VAC therapy. VAC therapy is applied through the patient’s OWT.
Mini-VAC procedure. VAC therapy is applied through the ALEXIS wound retractor which creates a similar window effect without resecting the ribs.
*Fitting in the treatment principles drainage and reducing potential pleural space by optimizing lung expansion.
VAC therapy is designed to be applied on open wounds. To treat chronic empyema with VAC, an open chest wound or an OWT must be created during the surgical intervention. Some authors advocate leaving the thoracotomy wound open directly after the operation [13, 14] while others create an OWT to make dressing changes easier [17, 18, 19]. It is reasonable to decide on an individual basis depending on the size and depth of the residual pleural space. A large and deep residual pleural space is preferred for OWT. The advantage of OWT is that the chest will stay open for a longer period because of the inverted skin flap compared to just leaving the thoracotomy wound open. OWT would avoid the skin from healing before complete eradication of the infected pleural cavity. It is contraindicated to apply VAC on a dirty wound with necrotic tissue that has yet to be debrided. After adequate debridement in the pleural cavity, VAC sponges (GranuFoam) are inserted in the residual pleural space to fill the entire cavity. Placing the sponges directly in contact with exposed blood vessels, anastomotic sites, organs, or nerves are prohibited, except for the lungs. According to the literature [13, 21] and the author’s personal experiences, VAC dressing can be safely applied directly on the visceral pleura or lung parenchyma without any complications. The negative pressure can be set at -50 mmHg from the start, and gradually increased to -125 mmHg if the patient does not have any discomfort. The dressing change should be done at least twice a week, and it can be performed at the bedside. During the VAC therapy period, the skin covered by the dressing should be well protected to prevent skin maceration problems. If negative pressure fails to be maintained due to significant air leak caused by bronchopleural fistula (BPF), combining a one-way valve may solve this issue [21].
When dealing with postpneumonectomy empyema (PPE), VAC therapy should be used carefully, especially for patients who develop the complication shortly after the initial surgery. This is because negative pressure would shift the mediastinum which may cause heart or great vessels herniation leading to obstructive shock or even cardiac arrest. On the contrary, if PPE is developed at a later stage, such events will not happen as the mediastinal shift has already completed and the patient’s body has compensated it well.
There are two scenarios where chronic empyema patients would need an empyema tube for long-term drainage. One is that the patient is too unstable and fragile to receive general anesthesia and adequate surgical intervention. To alleviate the septic condition, empyema tube (tube thoracostomy) can be placed to decrease the burden of infection until definite treatment can be initiated. Another scenario is that the chronic empyema is somehow localized in a small area without systemic infection. It is either a tube thoracostomy left after previous surgical intervention or a new chest tube inserted into this localized area for drainage if the patient is not a surgical candidate.
In the author’s opinion, this treatment option is only reserved for those who are not able to receive other definite treatment because of the low success rate, and not all infected materials can be drained adequately. However, if adequate drainage can be achieved, the tube may be slowly retracted over a period of weeks to months while the infected space heals behind it [3].
*Fitting in the treatment principle drainage.
Clagett procedure was first described by Clagett and Geraci in 1963 [22]. It is a method that obliterate the pleural cavity with antibiotic solution. As a precondition of the procedure, there must be no BPF and the pleural cavity should be sterilized by debridement and irrigation. In other words, if the patient has BPF and primary repair is impossible, Clagett procedure is not suitable for the patient. Nonetheless, this procedure has a good overall success rate in selected patients (no BPF at the time of the procedure), range from 81–100% [12, 23, 24, 25]. Those who fail from the procedure are mainly due to persistent or recurrent BPF.
*Fitting in the treatment principle reducing potential pleural space.
After confirming that there is no active BPF in the pleural cavity or it is firmly closed, antibiotic fluid can be instilled to fill the remaining pleural cavity after it is fully cleansed. DAB solution (gentamicin 80 mg/L, neomycin 500 mg/L, and polymyxin B 100 mg/L) is one of the antibiotic solution choices [23]. The combination of the fluid can be chosen according to the microbiological findings [26].
Tissue flap transposition technique is frequently used in chronic empyema patients for the purpose of either closure of the BPF or OWT, and/or obliteration of the residual pleural space. It can also be used for the prophylactic reinforcement of a bronchial stump after major lung resection to avoid BPF formation. Because the flap tissue is full of mesenchymal cells, it can promote granulation tissue growing under good circulation and secure the bronchial stump as a backup layer. A bulky muscle flap is extremely helpful to reduce the residual pleural space while a smaller residual space only requires a smaller tissue flap. However, not every patient is medically fit for long-hour flap surgery especially the critically ill. A successful flap reconstructive surgery is determined by a well-perfused flap which is highly dependent on patients’ stable hemodynamics.
*Fitting in the treatment principle reducing potential pleural space.
Tissue flaps commonly used in chronic empyema are latissimus dorsi (LD) muscle flap (Figure 5), serratus anterior (SA) muscle flap, pectoralis major (PM) muscle flap, intercostal muscle flap, pedicled omental flap, and other free flaps. LD is the largest muscle among all chest wall muscles. Therefore, it is an ideal option for pleural cavity obliteration. However, if the patient has received a standard posterolateral thoracotomy previously, this muscle may have been compromised and hence not suitable. PM flap is another good alternative for it is the second largest chest wall muscles. Because of its anatomy and orientation, PM flap is particularly useful to obliterate the apical residual pleural space [3, 27]. Although SA flap and intercostal muscle flap are relatively small compared to LD and PM flaps, they can be sufficient to help accelerate BPF healing as long as the pedicle is healthy. Omental flap is another option if no chest wall muscle is available [28]. However, entering the peritoneal cavity may potentially spread the infection and complicate the situation. Sometimes the remaining pleural space is too big that only by combining two flaps will fill the space [27]. Free flap may also be considered in highly selected patients.
LD muscle flap. Harvest of the LD muscle flap to reinforce the PPE BPF closure.
Thoracoplasty has a long history in the field of thoracic surgery. It was first described by Estlander in the late 19th century when tuberculosis was a troublesome pandemic without medical cure [29]. The original concept of this surgery is to collapse the chest wall to minimize the cavitary pleural space caused by mycobacterium. To achieve this goal, multiple ribs are resected resulting in loss of rigid chest wall configuration and therefore obliteration of the infected pleural space. Although it is an effective way to fill the potential pleural space, this procedure can cause significant morbidity, including chronic pain, chest wall deformity, thoracic spine scoliosis, limited ipsilateral shoulder range of motion, and finally resulting in poor quality of life.
*Fitting in the treatment principle reducing potential pleural space.
Thoracoplasty can be classified into three types, full, extended, and tailored thoracoplasty. Full thoracoplasty is defined as removing first 11 ribs to collapse the whole hemithorax. Extended thoracoplasty, on the other hand, is removing 7 to 9 ribs while tailored thoracoplasty is removing fewer than 5 ribs at certain area [30]. Resection of 7 ribs can lead to approximately 50% reduction of the pleural space, and resection of 5 ribs results in 25% reduction (Figure 6) [31]. The key to a successful thoracoplasty is complete resection of the targeted ribs which means from the transverse process of the thoracic spine posteriorly to the costosternal joint anteriorly. In the modern era, this procedure is seldom conducted alone. Combining with muscle flap transposition is an effective alternative so that chest wall deformity can be less significant [32, 33].
Thoracoplasty. Complete resection of the 4 right upper ribs. (Adapted from Lewis and Wolfe [
Managing chronic empyema is art. There is no standardized option. Knowing the different measures in depth and applying each principle with these measures will certainly increase the success rate of treatment. Making a customized treatment plan according to the patient’s physical condition, complications, and special requirements cannot be emphasized enough. There are special circumstances which will be introduced below for better understanding of how to put the different treatment options in use.
The main issue contributed by post-resectional empyema is that the residual pleural space is often large. The treatment strategy therefore should be emphasized on how to fill the space. If post-lobectomy empyema occurs in a delayed setting, the size of the residual pleural space would not be a concern because the pleural cavity should have been remodeled by diaphragm elevation, mediastinum shifting, and narrowing of the intercostal space over time. However, if post-resectional empyema happens in an acute phase when the remodeling has not been completed yet, different filling procedures should always be considered. For instance, if a patient who is medically fit for surgery develops a post-lobectomy empyema in a delayed phase, VATS or thoracotomy debridement and decortication are usually amenable to solving the problem.
Post-pneumonectomy empyema (PPE) is notorious for its high morbidity and mortality rate [12]. It is a challenging situation clinically, especially when BPF is present (Figure 7). According to the literature [12, 25, 30], approximately 65 to 84% PPE patients have BPF. Closure of the BPF is imperative or else spillage from the infected cavity into the airway can cause pneumonia or even acute respiratory distress syndrome (ARDS). On the other hand, the secretion from the airway would also leak into the pleural space continuously and contaminate the cavity. After closing the BPF, as per treatment of other empyema, sterilization of the cavity with debridement, irrigation, parenteral antibiotics, and adequate drainage, the most important is effective obliteration of the remaining pleural space. Since the BPF is often failed by primary suture alone, covering the stump with pedicled muscle flap ensures secondary healing as well and obliteration the pleural space at the same time. For example, if a debilitated patient suffers from severe sepsis caused by late onset right-sided PPE with BPF, it is reasonable to lay out a staged surgical plan. First, do a tube thoracostomy and forbid the patient to lie in a left decubitus position to protect the contralateral lung. This first stage is for drainage and lung protection. Second, perform simple debridement, OWT, and primary BPF repair added on a buttressed intercostal muscle flap. Instead of frequent dressing changes after OWT, VAC therapy can be initiated under the circumstance without any contraindication. VAC dressings can be changed at least twice a week. After a period of aggressive treatment plus appropriate nutritional support, successful BPF closure, a clean pleural cavity covered with healthy granulation tissue, and improved physical status of the patient can be expected. The second stage is for sterilization of the pleural space and open drainage. The third stage is purely for filling. Choose an appropriate procedure, such as Clagett procedure, to obliterate the pleural cavity.
PPE with BPFs. (A) from the thoracoscopic view of the BPFs (B) from the bronchoscopic view of the BPFs.
As mentioned in the last paragraph, BPF connects the bronchus to the pleural cavity leading to infection burden and possible respiratory distress. Life threatening events, such as ARDS or septic shock, must be managed as top priority. Successful closure of the BPF may prevent those critical situations from happening. As long as the patient’s physical condition is suitable for intervention, attempts to close the BPF should be carried out as early as possible.
There are several ways to manage BPF, either bronchoscopically or surgically. Treatment choices mainly depend on patients’ clinical status, duration before the development of BPF, and number and size of the BPF [30]. An algorithm for treatment of BPF at the European Oncologic Institute [34] (Figure 8) was created according to these principles. If the BPF occurs in an early setting (<14 days after surgery), surgical repair of the bronchial stump is always encouraged. In a delayed setting (>14 days after surgery), bronchoscopic application with sealants, fibrin glue, silver nitrate, coils, endobronchial stents, Endobronchial Watanabe Spigot, or atrial septal defect occluder device [35, 36, 37, 38] can be used for small BPF size <8 mm or for patients who are physically unfit for surgery. As for BPF size >8 mm, patients who are fit for surgery, patients who had failure from other treatment strategies, surgical intervention is unavoidable. In addition to primary closure of the bronchial stump, muscle flap transposition to cover the sutured stump provides a good environment for secondary healing which may increase the success rate of closure. If the BPF is deemed to be closed during the operation, Clagett procedure may be considered after thorough cleansing of the infected pleural cavity. Since continuous spillage from the BPF may occur, therefore OWT is often a treatment option to enable frequent dressing changes to eliminate the infection.
Management of PPE BPF: EOI algorithm. (Adapted from Mazzella et al. [
At times, malignant pleural effusion can be infected either through hematogenous or direct inoculation by invasive procedures. The treatment principles are essentially the same. Sterilization of the pleural cavity and adequate drainage are not difficult to achieve. Since the pleura tumor cells cannot be eradicated immediately by surgical procedures or medical treatment, it is almost impossible to fully expand the lung via decortication and therefore a possible residual pleural space which can cause repeated infection. Under this circumstance, a thorough decortication is not practical because tumor cells are prone to bleed and cause the underneath lung tissue to be more fragile. Too much “peeling” will lead to excessive bleeding resulting in hematoma retention and causing the lung to tear. To weigh the benefits and risks of surgical intervention is crucial since the patient’s life expectancy may be limited. From the author’s personal experience, debridement, irrigation, and limited decortication followed by a tube thoracostomy are sufficient to treat the infected pleural cavity.
Although some surgical measures for chronic empyema originated from treating tuberculous (TB) empyema [8, 29], such as Eloesser flap thoracostomy window and thoracoplasty, these intensive procedures are now rarely used to treat TB empyema. It is not that TB empyema patients do not need invasive procedures, but it is that most of these patients can be managed by tube thoracostomy or VATS debridement with decortication. When it comes to uncontrolled TB empyema with initial treatment attempt failure, more aggressive modalities should be considered which are the same as treating other bacterial chronic empyema.
Double lumen endotracheal tube intubation is frequently seen in thoracic surgery for lung isolation. It can be an adjunct to help with BPF treatment after pneumonectomy if the patient still requires ventilator support or to protect the remaining lung from fistular spillage. Application of this device would help ventilate the remaining side of the lung and leave the fistular side of the hemithorax unventilated to accelerate fistular healing. However, the diameter of the double lumen tube is certainly greater than the single lumen tube which would make the patient feel uncomfortable if not sedated. Another frequently encountered issue is that the left-sided tube tip would slide outward easily, and this malposition may cause failure of lung isolation. Although the whole diameter of the double lumen is greater than the single lumen tube, each individual double lumen tube diameter is smaller. This would make it difficult to clean the airway by suction as the suction tip may not always reach to the proper depth. As a result, airway hygiene may become a serious issue if the tube is placed in the bronchus for a long time.
With the development of modern medicine and minimally invasive technology, the role of both bronchoscopic and thoracoscopic (VATS) procedures have become increasingly important replacing some of the traditional surgeries in treating chronic empyema. More studies should focus on solving existing issues like, Mini-VAC replacing OWT completely, customized device to help repairing BPF, and 3D bioprinting assisting BPF closure. The author believes that chronic empyema management is still evolving, and look forward to less traumatic ways of approach with better outcome in the future.
Treating chronic empyema and BPF are certainly clinical challenges that thoracic surgeons would encounter from time to time. It is necessary to thoroughly comprehend each treatment option and some management key points of different situations. With the development of modern technology, more treatment modalities can be anticipated.
The author has nothing to declare.
If you are associated with any of the institutions in our list below, you can apply to receive OA publication funds by following the instructions provided in the links.
",metaTitle:"List of Institutions by Country",metaDescription:"If you are associated with any of the institutions in our list below, you can apply to receive OA publication funds by following the instructions provided in the links. However, if your research is financed through any of the below-mentioned funders, please consult their Open Access policies or grant ‘terms and conditions’ to explore ways to cover your publication costs (also accessible by clicking on the link in their title).",metaKeywords:null,canonicalURL:"open-access-funding-institutions-list",contentRaw:'[{"type":"htmlEditorComponent","content":"Book Chapters and Monographs
\\n\\nBook Chapters
\\n\\nMonographs Only
\\n\\n\\n\\nBook Chapters and Monographs
\\n\\nMonographs Only
\\n\\nBook Chapters and Monographs
\\n\\n\\n\\nBook Chapters and Monographs
\\n\\n\\n\\nCorresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\\n\\nCSIC affiliated authors can also take advantage of a central Open Access fund (amounting to 10,000 EUR) to cover up to 50% of the rest of the OAPF until it expires. Effective for chapters accepted from January 1, 2020.
\\n\\nCorresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\\n\\nCorresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\\n\\n\\n\\nCorresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\\n\\nBook Chapters and Monographs
\\n\\nBook Chapters and Monographs
\\n\\nBook Chapters and Monographs
\\n\\nBook Chapters and Monographs
\\n\\nThe Claremont Colleges are pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\\n\\nCorresponding authors will receive a 15% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
\\n\\nThe University of Massachusetts, Amherst is pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\\n\\nCorresponding authors will receive a 10% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
\\n\\nThe University of Surrey is pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\\n\\nCorresponding authors will receive a 10% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
\\n\\nMonographs Only
\\n\\n\\n\\nImportant: You must be a member or grantee of the above listed institutions in order to apply for their Open Access publication funds.
\\n"}]'},components:[{type:"htmlEditorComponent",content:'Book Chapters and Monographs
\n\n\n\nBook Chapters
\n\nMonographs Only
\n\n\n\nBook Chapters and Monographs
\n\nMonographs Only
\n\nBook Chapters and Monographs
\n\n\n\nBook Chapters and Monographs
\n\n\n\nCorresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\n\nCSIC affiliated authors can also take advantage of a central Open Access fund (amounting to 10,000 EUR) to cover up to 50% of the rest of the OAPF until it expires. Effective for chapters accepted from January 1, 2020.
\n\nCorresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\n\nCorresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\n\n\n\nCorresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\n\nBook Chapters and Monographs
\n\nBook Chapters and Monographs
\n\nBook Chapters and Monographs
\n\n\n\nBook Chapters and Monographs
\n\nThe Claremont Colleges are pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\n\nCorresponding authors will receive a 15% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
\n\nThe University of Massachusetts, Amherst is pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\n\nCorresponding authors will receive a 10% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
\n\nThe University of Surrey is pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\n\nCorresponding authors will receive a 10% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
\n\nMonographs Only
\n\n\n\nImportant: You must be a member or grantee of the above listed institutions in order to apply for their Open Access publication funds.
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{},profiles:[{id:"396",title:"Dr.",name:"Vedran",middleName:null,surname:"Kordic",slug:"vedran-kordic",fullName:"Vedran Kordic",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/396/images/7281_n.png",biography:"After obtaining his Master's degree in Mechanical Engineering he continued his education at the Vienna University of Technology where he obtained his PhD degree in 2004. He worked as a researcher at the Automation and Control Institute, Faculty of Electrical Engineering, Vienna University of Technology until 2008. His studies in robotics lead him not only to a PhD degree but also inspired him to co-found and build the International Journal of Advanced Robotic Systems - world's first Open Access journal in the field of robotics.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"441",title:"Ph.D.",name:"Jaekyu",middleName:null,surname:"Park",slug:"jaekyu-park",fullName:"Jaekyu Park",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/441/images/1881_n.jpg",biography:null,institutionString:null,institution:{name:"LG Corporation (South Korea)",country:{name:"Korea, South"}}},{id:"465",title:"Dr",name:"Christian",middleName:null,surname:"Martens",slug:"christian-martens",fullName:"Christian Martens",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"479",title:"Dr.",name:"Valentina",middleName:null,surname:"Colla",slug:"valentina-colla",fullName:"Valentina Colla",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/479/images/358_n.jpg",biography:null,institutionString:null,institution:{name:"Sant'Anna School of Advanced Studies",country:{name:"Italy"}}},{id:"494",title:"PhD",name:"Loris",middleName:null,surname:"Nanni",slug:"loris-nanni",fullName:"Loris Nanni",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/494/images/system/494.jpg",biography:"Loris Nanni received his Master Degree cum laude on June-2002 from the University of Bologna, and the April 26th 2006 he received his Ph.D. in Computer Engineering at DEIS, University of Bologna. On September, 29th 2006 he has won a post PhD fellowship from the university of Bologna (from October 2006 to October 2008), at the competitive examination he was ranked first in the industrial engineering area. He extensively served as referee for several international journals. He is author/coauthor of more than 100 research papers. He has been involved in some projects supported by MURST and European Community. His research interests include pattern recognition, bioinformatics, and biometric systems (fingerprint classification and recognition, signature verification, face recognition).",institutionString:null,institution:null},{id:"496",title:"Dr.",name:"Carlos",middleName:null,surname:"Leon",slug:"carlos-leon",fullName:"Carlos Leon",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Seville",country:{name:"Spain"}}},{id:"512",title:"Dr.",name:"Dayang",middleName:null,surname:"Jawawi",slug:"dayang-jawawi",fullName:"Dayang Jawawi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Technology Malaysia",country:{name:"Malaysia"}}},{id:"528",title:"Dr.",name:"Kresimir",middleName:null,surname:"Delac",slug:"kresimir-delac",fullName:"Kresimir Delac",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/528/images/system/528.jpg",biography:"K. Delac received his B.Sc.E.E. degree in 2003 and is currentlypursuing a Ph.D. degree at the University of Zagreb, Faculty of Electrical Engineering andComputing. His current research interests are digital image analysis, pattern recognition andbiometrics.",institutionString:null,institution:{name:"University of Zagreb",country:{name:"Croatia"}}},{id:"557",title:"Dr.",name:"Andon",middleName:"Venelinov",surname:"Topalov",slug:"andon-topalov",fullName:"Andon Topalov",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/557/images/1927_n.jpg",biography:"Dr. Andon V. Topalov received the MSc degree in Control Engineering from the Faculty of Information Systems, Technologies, and Automation at Moscow State University of Civil Engineering (MGGU) in 1979. He then received his PhD degree in Control Engineering from the Department of Automation and Remote Control at Moscow State Mining University (MGSU), Moscow, in 1984. From 1985 to 1986, he was a Research Fellow in the Research Institute for Electronic Equipment, ZZU AD, Plovdiv, Bulgaria. In 1986, he joined the Department of Control Systems, Technical University of Sofia at the Plovdiv campus, where he is presently a Full Professor. He has held long-term visiting Professor/Scholar positions at various institutions in South Korea, Turkey, Mexico, Greece, Belgium, UK, and Germany. And he has coauthored one book and authored or coauthored more than 80 research papers in conference proceedings and journals. His current research interests are in the fields of intelligent control and robotics.",institutionString:null,institution:{name:"Technical University of Sofia",country:{name:"Bulgaria"}}},{id:"585",title:"Prof.",name:"Munir",middleName:null,surname:"Merdan",slug:"munir-merdan",fullName:"Munir Merdan",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/585/images/system/585.jpg",biography:"Munir Merdan received the M.Sc. degree in mechanical engineering from the Technical University of Sarajevo, Bosnia and Herzegovina, in 2001, and the Ph.D. degree in electrical engineering from the Vienna University of Technology, Vienna, Austria, in 2009.Since 2005, he has been at the Automation and Control Institute, Vienna University of Technology, where he is currently a Senior Researcher. His research interests include the application of agent technology for achieving agile control in the manufacturing environment.",institutionString:null,institution:null},{id:"605",title:"Prof",name:"Dil",middleName:null,surname:"Hussain",slug:"dil-hussain",fullName:"Dil Hussain",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/605/images/system/605.jpg",biography:"Dr. Dil Muhammad Akbar Hussain is a professor of Electronics Engineering & Computer Science at the Department of Energy Technology, Aalborg University Denmark. Professor Akbar has a Master degree in Digital Electronics from Govt. College University, Lahore Pakistan and a P-hD degree in Control Engineering from the School of Engineering and Applied Sciences, University of Sussex United Kingdom. Aalborg University has Two Satellite Campuses, one in Copenhagen (Aalborg University Copenhagen) and the other in Esbjerg (Aalborg University Esbjerg).\n· He is a member of prestigious IEEE (Institute of Electrical and Electronics Engineers), and IAENG (International Association of Engineers) organizations. \n· He is the chief Editor of the Journal of Software Engineering.\n· He is the member of the Editorial Board of International Journal of Computer Science and Software Technology (IJCSST) and International Journal of Computer Engineering and Information Technology. \n· He is also the Editor of Communication in Computer and Information Science CCIS-20 by Springer.\n· Reviewer For Many Conferences\nHe is the lead person in making collaboration agreements between Aalborg University and many universities of Pakistan, for which the MOU’s (Memorandum of Understanding) have been signed.\nProfessor Akbar is working in Academia since 1990, he started his career as a Lab demonstrator/TA at the University of Sussex. After finishing his P. hD degree in 1992, he served in the Industry as a Scientific Officer and continued his academic career as a visiting scholar for a number of educational institutions. In 1996 he joined National University of Science & Technology Pakistan (NUST) as an Associate Professor; NUST is one of the top few universities in Pakistan. In 1999 he joined an International Company Lineo Inc, Canada as Manager Compiler Group, where he headed the group for developing Compiler Tool Chain and Porting of Operating Systems for the BLACKfin processor. The processor development was a joint venture by Intel and Analog Devices. In 2002 Lineo Inc., was taken over by another company, so he joined Aalborg University Denmark as an Assistant Professor.\nProfessor Akbar has truly a multi-disciplined career and he continued his legacy and making progress in many areas of his interests both in teaching and research. He has contributed in stochastic estimation of control area especially, in the Multiple Target Tracking and Interactive Multiple Model (IMM) research, Ball & Beam Control Problem, Robotics, Levitation Control. He has contributed in developing Algorithms for Fingerprint Matching, Computer Vision and Face Recognition. He has been supervising Pattern Recognition, Formal Languages and Distributed Processing projects for several years. He has reviewed many books on Management, Computer Science. Currently, he is an active and permanent reviewer for many international conferences and symposia and the program committee member for many international conferences.\nIn teaching he has taught the core computer science subjects like, Digital Design, Real Time Embedded System Programming, Operating Systems, Software Engineering, Data Structures, Databases, Compiler Construction. In the Engineering side, Digital Signal Processing, Computer Architecture, Electronics Devices, Digital Filtering and Engineering Management.\nApart from his Academic Interest and activities he loves sport especially, Cricket, Football, Snooker and Squash. He plays cricket for Esbjerg city in the second division team as an opener wicket keeper batsman. He is a very good player of squash but has not played squash since his arrival in Denmark.",institutionString:null,institution:null},{id:"611",title:"Prof.",name:"T",middleName:null,surname:"Nagarajan",slug:"t-nagarajan",fullName:"T Nagarajan",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universiti Teknologi Petronas",country:{name:"Malaysia"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:6581},{group:"region",caption:"Middle and South America",value:2,count:5888},{group:"region",caption:"Africa",value:3,count:2381},{group:"region",caption:"Asia",value:4,count:12507},{group:"region",caption:"Australia and Oceania",value:5,count:1006},{group:"region",caption:"Europe",value:6,count:17528}],offset:12,limit:12,total:132501},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{hasNoEditors:"0",sort:"-dateEndThirdStepPublish",src:"N-F-0-T2"},books:[{type:"book",id:"9985",title:"Geostatistics",subtitle:null,isOpenForSubmission:!0,hash:"423cb3896195a618c4acb493ce4fd23d",slug:null,bookSignature:"Prof. Jeffrey M. Yarus, Dr. Marko Maucec, Dr. Timothy C. Coburn and Associate Prof. Michael Pyrcz",coverURL:"https://cdn.intechopen.com/books/images_new/9985.jpg",editedByType:null,editors:[{id:"78011",title:"Prof.",name:"Jeffrey M.",surname:"Yarus",slug:"jeffrey-m.-yarus",fullName:"Jeffrey M. Yarus"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11872",title:"Peripheral Arterial Disease - The Challenges of Revascularization",subtitle:null,isOpenForSubmission:!0,hash:"80be3d16e4c8f89f3501ed408729f695",slug:null,bookSignature:"Prof. Ana Terezinha Guillaumon, Dr. Daniel Emilio Dalledone Siqueira and Dr. Martin Geiger",coverURL:"https://cdn.intechopen.com/books/images_new/11872.jpg",editedByType:null,editors:[{id:"251226",title:"Prof.",name:"Ana Terezinha",surname:"Guillaumon",slug:"ana-terezinha-guillaumon",fullName:"Ana Terezinha Guillaumon"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11533",title:"Advances in Green Electronics Technologies",subtitle:null,isOpenForSubmission:!0,hash:"209fb1d781e97e58e1b2098b8976e2c3",slug:null,bookSignature:"Dr. Albert Sabban",coverURL:"https://cdn.intechopen.com/books/images_new/11533.jpg",editedByType:null,editors:[{id:"16889",title:"Dr.",name:"Albert",surname:"Sabban",slug:"albert-sabban",fullName:"Albert Sabban"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11630",title:"Life in Extreme Environments - Diversity, Adaptability and Valuable Resources of Bioactive Molecules",subtitle:null,isOpenForSubmission:!0,hash:"9c39aa5fd22296ba53d87df6d761a5fc",slug:null,bookSignature:"Dr. Afef Najjari",coverURL:"https://cdn.intechopen.com/books/images_new/11630.jpg",editedByType:null,editors:[{id:"196823",title:"Dr.",name:"Afef",surname:"Najjari",slug:"afef-najjari",fullName:"Afef Najjari"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11433",title:"Human Migration in the Last Three Centuries",subtitle:null,isOpenForSubmission:!0,hash:"9836df9e82aa9f82e3852a60204909a8",slug:null,bookSignature:"Dr. Ingrid Muenstermann",coverURL:"https://cdn.intechopen.com/books/images_new/11433.jpg",editedByType:null,editors:[{id:"77112",title:"Dr.",name:"Ingrid",surname:"Muenstermann",slug:"ingrid-muenstermann",fullName:"Ingrid Muenstermann"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11842",title:"Altimetry - Theory, Applications and Recent Advances",subtitle:null,isOpenForSubmission:!0,hash:"b2b6e7b58333453ef7b73416d8fdfaf3",slug:null,bookSignature:"Prof. Tomislav Bašić",coverURL:"https://cdn.intechopen.com/books/images_new/11842.jpg",editedByType:null,editors:[{id:"343125",title:"Prof.",name:"Tomislav",surname:"Bašić",slug:"tomislav-basic",fullName:"Tomislav Bašić"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11804",title:"CRISPR Technology",subtitle:null,isOpenForSubmission:!0,hash:"4051570f538bd3315e051267180abe37",slug:null,bookSignature:"Dr. Yuan-Chuan Chen",coverURL:"https://cdn.intechopen.com/books/images_new/11804.jpg",editedByType:null,editors:[{id:"185559",title:"Dr.",name:"Yuan-Chuan",surname:"Chen",slug:"yuan-chuan-chen",fullName:"Yuan-Chuan Chen"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12104",title:"Viral Outbreaks - Global Trends and Perspectives",subtitle:null,isOpenForSubmission:!0,hash:"60828f26feed5832a47a13caac706c08",slug:null,bookSignature:"Prof. Shailendra K. Saxena",coverURL:"https://cdn.intechopen.com/books/images_new/12104.jpg",editedByType:null,editors:[{id:"158026",title:"Prof.",name:"Shailendra K.",surname:"Saxena",slug:"shailendra-k.-saxena",fullName:"Shailendra K. Saxena"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"12108",title:"Clinical Trials - Recent Advances",subtitle:null,isOpenForSubmission:!0,hash:"79472fc7310e9655a881c6d2ad7128b0",slug:null,bookSignature:"Dr. Xianli Lv",coverURL:"https://cdn.intechopen.com/books/images_new/12108.jpg",editedByType:null,editors:[{id:"153155",title:"Dr.",name:"Xianli",surname:"Lv",slug:"xianli-lv",fullName:"Xianli Lv"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11676",title:"Recent Advances in Homeostasis",subtitle:null,isOpenForSubmission:!0,hash:"63eb775115bf2d6d88530b234a1cc4c2",slug:null,bookSignature:"Dr. Gaffar Sarwar Zaman",coverURL:"https://cdn.intechopen.com/books/images_new/11676.jpg",editedByType:null,editors:[{id:"203015",title:"Dr.",name:"Gaffar",surname:"Zaman",slug:"gaffar-zaman",fullName:"Gaffar Zaman"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11733",title:"Injury and Sports Medicine",subtitle:null,isOpenForSubmission:!0,hash:"e2fdeca45129f6d5ba446f502c5a6373",slug:null,bookSignature:"M.D. Thomas Wojda and Dr. Stanislaw P. Stawicki",coverURL:"https://cdn.intechopen.com/books/images_new/11733.jpg",editedByType:null,editors:[{id:"415286",title:"M.D.",name:"Thomas",surname:"Wojda",slug:"thomas-wojda",fullName:"Thomas Wojda"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11831",title:"Novel Topics in the Diagnosis, Treatment, and Follow-Up of Nephritis, Nephrotic Syndrome, and Nephrosis",subtitle:null,isOpenForSubmission:!0,hash:"738f177168051e90f566ddc7c23b0862",slug:null,bookSignature:"Prof. Hulya Çiçek, Dr. Mustafa Yıldırım, Dr. Necat Yilmaz and Dr. Mehmet Solakhan",coverURL:"https://cdn.intechopen.com/books/images_new/11831.jpg",editedByType:null,editors:[{id:"466717",title:"Prof.",name:"Hulya",surname:"Çiçek",slug:"hulya-cicek",fullName:"Hulya Çiçek"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:41},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:11},{group:"topic",caption:"Business, Management and Economics",value:7,count:6},{group:"topic",caption:"Chemistry",value:8,count:20},{group:"topic",caption:"Computer and Information Science",value:9,count:20},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:15},{group:"topic",caption:"Engineering",value:11,count:59},{group:"topic",caption:"Environmental Sciences",value:12,count:8},{group:"topic",caption:"Immunology and Microbiology",value:13,count:9},{group:"topic",caption:"Materials Science",value:14,count:27},{group:"topic",caption:"Mathematics",value:15,count:9},{group:"topic",caption:"Medicine",value:16,count:122},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:9},{group:"topic",caption:"Neuroscience",value:18,count:3},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:6},{group:"topic",caption:"Physics",value:20,count:11},{group:"topic",caption:"Psychology",value:21,count:10},{group:"topic",caption:"Robotics",value:22,count:4},{group:"topic",caption:"Social Sciences",value:23,count:9},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:4}],offset:12,limit:12,total:405},popularBooks:{featuredBooks:[{type:"book",id:"10584",title:"Engineered Wood Products for Construction",subtitle:null,isOpenForSubmission:!1,hash:"421757c56a3735986055250821275a51",slug:"engineered-wood-products-for-construction",bookSignature:"Meng Gong",coverURL:"https://cdn.intechopen.com/books/images_new/10584.jpg",editors:[{id:"274242",title:"Dr.",name:"Meng",middleName:null,surname:"Gong",slug:"meng-gong",fullName:"Meng Gong"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10222",title:"Demyelination Disorders",subtitle:null,isOpenForSubmission:!1,hash:"b6c26ceccacdde70c41c587361bd5558",slug:"demyelination-disorders",bookSignature:"Stavros J. Baloyannis, Fabian H. Rossi and Welwin Liu",coverURL:"https://cdn.intechopen.com/books/images_new/10222.jpg",editors:[{id:"156098",title:"Emeritus Prof.",name:"Stavros J.",middleName:"J.",surname:"Baloyannis",slug:"stavros-j.-baloyannis",fullName:"Stavros J. Baloyannis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9544",title:"Global Trade in the Emerging Business Environment",subtitle:null,isOpenForSubmission:!1,hash:"fb8cb09b9599246add78d508a98273d5",slug:"global-trade-in-the-emerging-business-environment",bookSignature:"Muhammad Mohiuddin, Jingbin Wang , Md. Samim Al Azad and Selim Ahmed",coverURL:"https://cdn.intechopen.com/books/images_new/9544.jpg",editors:[{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10979",title:"Parenting",subtitle:"Challenges of Child Rearing in a Changing Society",isOpenForSubmission:!1,hash:"6f345ebcf4fd61e73643c69063a12c7b",slug:"parenting-challenges-of-child-rearing-in-a-changing-society",bookSignature:"Sayyed Ali Samadi",coverURL:"https://cdn.intechopen.com/books/images_new/10979.jpg",editors:[{id:"52145",title:"Dr.",name:"Sayyed Ali",middleName:null,surname:"Samadi",slug:"sayyed-ali-samadi",fullName:"Sayyed Ali Samadi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9808",title:"Contemporary Topics in Patient Safety",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"fb6371607c2c6c02c6a2af8892765aba",slug:"contemporary-topics-in-patient-safety-volume-1",bookSignature:"Stanislaw P. Stawicki and Michael S. Firstenberg",coverURL:"https://cdn.intechopen.com/books/images_new/9808.jpg",editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10681",title:"Biodegradation Technology of Organic and Inorganic Pollutants",subtitle:null,isOpenForSubmission:!1,hash:"9a6e10e02788092872fd249436898e97",slug:"biodegradation-technology-of-organic-and-inorganic-pollutants",bookSignature:"Kassio Ferreira Mendes, Rodrigo Nogueira de Sousa and Kamila Cabral Mielke",coverURL:"https://cdn.intechopen.com/books/images_new/10681.jpg",editors:[{id:"197720",title:"Ph.D.",name:"Kassio",middleName:null,surname:"Ferreira Mendes",slug:"kassio-ferreira-mendes",fullName:"Kassio Ferreira Mendes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10764",title:"Antenna Systems",subtitle:null,isOpenForSubmission:!1,hash:"2fbf1c7a5d92723f08198fc9b526a8ad",slug:"antenna-systems",bookSignature:"Hussain Al-Rizzo and Said Abushamleh",coverURL:"https://cdn.intechopen.com/books/images_new/10764.jpg",editors:[{id:"153384",title:"Prof.",name:"Hussain",middleName:null,surname:"Al-Rizzo",slug:"hussain-al-rizzo",fullName:"Hussain Al-Rizzo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10668",title:"Sustainability of Concrete With Synthetic and Recycled Aggregates",subtitle:null,isOpenForSubmission:!1,hash:"55856c6a8bc3a5b21dae5a1af09a56b6",slug:"sustainability-of-concrete-with-synthetic-and-recycled-aggregates",bookSignature:"Hosam M. Saleh",coverURL:"https://cdn.intechopen.com/books/images_new/10668.jpg",editors:[{id:"144691",title:"Prof.",name:"Hosam",middleName:null,surname:"Saleh",slug:"hosam-saleh",fullName:"Hosam Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10803",title:"Reactive Oxygen Species",subtitle:null,isOpenForSubmission:!1,hash:"176adcf090fdd1f93cb8ce3146e79ca1",slug:"reactive-oxygen-species",bookSignature:"Rizwan Ahmad",coverURL:"https://cdn.intechopen.com/books/images_new/10803.jpg",editors:[{id:"40482",title:null,name:"Rizwan",middleName:null,surname:"Ahmad",slug:"rizwan-ahmad",fullName:"Rizwan Ahmad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9032",title:"Corporate Social Responsibility",subtitle:null,isOpenForSubmission:!1,hash:"f609bf3251d7cc7bae0099a4374adfc3",slug:"corporate-social-responsibility",bookSignature:"Beatrice Orlando",coverURL:"https://cdn.intechopen.com/books/images_new/9032.jpg",editors:[{id:"232969",title:"Prof.",name:"Beatrice",middleName:null,surname:"Orlando",slug:"beatrice-orlando",fullName:"Beatrice Orlando"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10351",title:"Enhanced Liposuction",subtitle:"New Perspectives and Techniques",isOpenForSubmission:!1,hash:"f08ed6de16da357614586c5b58ed4dfa",slug:"enhanced-liposuction-new-perspectives-and-techniques",bookSignature:"Diane Irvine Duncan",coverURL:"https://cdn.intechopen.com/books/images_new/10351.jpg",editors:[{id:"279869",title:"Dr.",name:"Diane Irvine",middleName:null,surname:"Duncan",slug:"diane-irvine-duncan",fullName:"Diane Irvine Duncan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10779",title:"21st Century Nanostructured Materials",subtitle:"Physics, Chemistry, Classification, and Emerging Applications in Industry, Biomedicine, and Agriculture",isOpenForSubmission:!1,hash:"72c67f97f9bef68200df115b5fd79884",slug:"21st-century-nanostructured-materials-physics-chemistry-classification-and-emerging-applications-in-industry-biomedicine-and-agriculture",bookSignature:"Phuong V. Pham",coverURL:"https://cdn.intechopen.com/books/images_new/10779.jpg",editors:[{id:"236073",title:"Dr.",name:"Phuong",middleName:"Viet",surname:"Pham",slug:"phuong-pham",fullName:"Phuong Pham"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:4386},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"10584",title:"Engineered Wood Products for Construction",subtitle:null,isOpenForSubmission:!1,hash:"421757c56a3735986055250821275a51",slug:"engineered-wood-products-for-construction",bookSignature:"Meng Gong",coverURL:"https://cdn.intechopen.com/books/images_new/10584.jpg",publishedDate:"April 28th 2022",numberOfDownloads:3665,editors:[{id:"274242",title:"Dr.",name:"Meng",middleName:null,surname:"Gong",slug:"meng-gong",fullName:"Meng Gong"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10222",title:"Demyelination Disorders",subtitle:null,isOpenForSubmission:!1,hash:"b6c26ceccacdde70c41c587361bd5558",slug:"demyelination-disorders",bookSignature:"Stavros J. Baloyannis, Fabian H. Rossi and Welwin Liu",coverURL:"https://cdn.intechopen.com/books/images_new/10222.jpg",publishedDate:"May 4th 2022",numberOfDownloads:1713,editors:[{id:"156098",title:"Emeritus Prof.",name:"Stavros J.",middleName:"J.",surname:"Baloyannis",slug:"stavros-j.-baloyannis",fullName:"Stavros J. Baloyannis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9544",title:"Global Trade in the Emerging Business Environment",subtitle:null,isOpenForSubmission:!1,hash:"fb8cb09b9599246add78d508a98273d5",slug:"global-trade-in-the-emerging-business-environment",bookSignature:"Muhammad Mohiuddin, Jingbin Wang , Md. Samim Al Azad and Selim Ahmed",coverURL:"https://cdn.intechopen.com/books/images_new/9544.jpg",publishedDate:"April 28th 2022",numberOfDownloads:2481,editors:[{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10979",title:"Parenting",subtitle:"Challenges of Child Rearing in a Changing Society",isOpenForSubmission:!1,hash:"6f345ebcf4fd61e73643c69063a12c7b",slug:"parenting-challenges-of-child-rearing-in-a-changing-society",bookSignature:"Sayyed Ali Samadi",coverURL:"https://cdn.intechopen.com/books/images_new/10979.jpg",publishedDate:"May 4th 2022",numberOfDownloads:1107,editors:[{id:"52145",title:"Dr.",name:"Sayyed Ali",middleName:null,surname:"Samadi",slug:"sayyed-ali-samadi",fullName:"Sayyed Ali Samadi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9808",title:"Contemporary Topics in Patient Safety",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"fb6371607c2c6c02c6a2af8892765aba",slug:"contemporary-topics-in-patient-safety-volume-1",bookSignature:"Stanislaw P. Stawicki and Michael S. Firstenberg",coverURL:"https://cdn.intechopen.com/books/images_new/9808.jpg",publishedDate:"April 20th 2022",numberOfDownloads:3307,editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10681",title:"Biodegradation Technology of Organic and Inorganic Pollutants",subtitle:null,isOpenForSubmission:!1,hash:"9a6e10e02788092872fd249436898e97",slug:"biodegradation-technology-of-organic-and-inorganic-pollutants",bookSignature:"Kassio Ferreira Mendes, Rodrigo Nogueira de Sousa and Kamila Cabral Mielke",coverURL:"https://cdn.intechopen.com/books/images_new/10681.jpg",publishedDate:"April 20th 2022",numberOfDownloads:3266,editors:[{id:"197720",title:"Ph.D.",name:"Kassio",middleName:null,surname:"Ferreira Mendes",slug:"kassio-ferreira-mendes",fullName:"Kassio Ferreira Mendes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10764",title:"Antenna Systems",subtitle:null,isOpenForSubmission:!1,hash:"2fbf1c7a5d92723f08198fc9b526a8ad",slug:"antenna-systems",bookSignature:"Hussain Al-Rizzo and Said Abushamleh",coverURL:"https://cdn.intechopen.com/books/images_new/10764.jpg",publishedDate:"April 28th 2022",numberOfDownloads:1868,editors:[{id:"153384",title:"Prof.",name:"Hussain",middleName:null,surname:"Al-Rizzo",slug:"hussain-al-rizzo",fullName:"Hussain Al-Rizzo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10668",title:"Sustainability of Concrete With Synthetic and Recycled Aggregates",subtitle:null,isOpenForSubmission:!1,hash:"55856c6a8bc3a5b21dae5a1af09a56b6",slug:"sustainability-of-concrete-with-synthetic-and-recycled-aggregates",bookSignature:"Hosam M. Saleh",coverURL:"https://cdn.intechopen.com/books/images_new/10668.jpg",publishedDate:"May 4th 2022",numberOfDownloads:856,editors:[{id:"144691",title:"Prof.",name:"Hosam",middleName:null,surname:"Saleh",slug:"hosam-saleh",fullName:"Hosam Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10803",title:"Reactive Oxygen Species",subtitle:null,isOpenForSubmission:!1,hash:"176adcf090fdd1f93cb8ce3146e79ca1",slug:"reactive-oxygen-species",bookSignature:"Rizwan Ahmad",coverURL:"https://cdn.intechopen.com/books/images_new/10803.jpg",publishedDate:"April 28th 2022",numberOfDownloads:1704,editors:[{id:"40482",title:null,name:"Rizwan",middleName:null,surname:"Ahmad",slug:"rizwan-ahmad",fullName:"Rizwan Ahmad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9032",title:"Corporate Social Responsibility",subtitle:null,isOpenForSubmission:!1,hash:"f609bf3251d7cc7bae0099a4374adfc3",slug:"corporate-social-responsibility",bookSignature:"Beatrice Orlando",coverURL:"https://cdn.intechopen.com/books/images_new/9032.jpg",publishedDate:"March 16th 2022",numberOfDownloads:7489,editors:[{id:"232969",title:"Prof.",name:"Beatrice",middleName:null,surname:"Orlando",slug:"beatrice-orlando",fullName:"Beatrice Orlando"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"8737",title:"Rabies Virus at the Beginning of 21st Century",subtitle:null,isOpenForSubmission:!1,hash:"49cce3f548da548c718c865feb343509",slug:"rabies-virus-at-the-beginning-of-21st-century",bookSignature:"Sergey Tkachev",coverURL:"https://cdn.intechopen.com/books/images_new/8737.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"61139",title:"Dr.",name:"Sergey",middleName:null,surname:"Tkachev",slug:"sergey-tkachev",fullName:"Sergey Tkachev"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10861",title:"Furan Derivatives",subtitle:"Recent Advances and Applications",isOpenForSubmission:!1,hash:"fdfc39cecd82f91b0effac994f75c877",slug:"furan-derivatives-recent-advances-and-applications",bookSignature:"Anish Khan, Mohammed Muzibur Rahman, M. Ramesh, Salman Ahmad Khan and Abdullah Mohammed Ahmed Asiri",coverURL:"https://cdn.intechopen.com/books/images_new/10861.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"293058",title:"Dr.",name:"Anish",middleName:null,surname:"Khan",slug:"anish-khan",fullName:"Anish Khan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10356",title:"Natural Medicinal Plants",subtitle:null,isOpenForSubmission:!1,hash:"943e56ccaaf19ff696d25aa638ae37d6",slug:"natural-medicinal-plants",bookSignature:"Hany A. El-Shemy",coverURL:"https://cdn.intechopen.com/books/images_new/10356.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"54719",title:"Prof.",name:"Hany",middleName:null,surname:"El-Shemy",slug:"hany-el-shemy",fullName:"Hany El-Shemy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10870",title:"Ultrasound Imaging",subtitle:"Current Topics",isOpenForSubmission:!1,hash:"2f0bc3733ab226d67fa73759ef0e12ad",slug:"ultrasound-imaging-current-topics",bookSignature:"Felix Okechukwu Erondu",coverURL:"https://cdn.intechopen.com/books/images_new/10870.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"68312",title:"Prof.",name:"Felix",middleName:null,surname:"Okechukwu Erondu",slug:"felix-okechukwu-erondu",fullName:"Felix Okechukwu Erondu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11392",title:"Leadership in a Changing World",subtitle:"A Multidimensional Perspective",isOpenForSubmission:!1,hash:"86a6d33cf601587e591064ce92effc02",slug:"leadership-in-a-changing-world-a-multidimensional-perspective",bookSignature:"Muhammad Mohiuddin, Bilal Khalid, Md. Samim Al Azad and Slimane Ed-dafali",coverURL:"https://cdn.intechopen.com/books/images_new/11392.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10400",title:"The Application of Ant Colony Optimization",subtitle:null,isOpenForSubmission:!1,hash:"f4fdfd07ee1ab99fb7c740d6d0c144c6",slug:"the-application-of-ant-colony-optimization",bookSignature:"Ali Soofastaei",coverURL:"https://cdn.intechopen.com/books/images_new/10400.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"257455",title:"Dr.",name:"Ali",middleName:null,surname:"Soofastaei",slug:"ali-soofastaei",fullName:"Ali Soofastaei"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10915",title:"Leadership",subtitle:"New Insights",isOpenForSubmission:!1,hash:"0d72e79892f2a020cee66a52d09de5a4",slug:"leadership-new-insights",bookSignature:"Mário Franco",coverURL:"https://cdn.intechopen.com/books/images_new/10915.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"105529",title:"Dr.",name:"Mário",middleName:null,surname:"Franco",slug:"mario-franco",fullName:"Mário Franco"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10683",title:"Technological Innovations and Advances in Hydropower Engineering",subtitle:null,isOpenForSubmission:!1,hash:"7ce7ad8768bd2cad155470fe1fd883f4",slug:"technological-innovations-and-advances-in-hydropower-engineering",bookSignature:"Yizi Shang, Ling Shang and Xiaofei Li",coverURL:"https://cdn.intechopen.com/books/images_new/10683.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"349630",title:"Dr.",name:"Yizi",middleName:null,surname:"Shang",slug:"yizi-shang",fullName:"Yizi Shang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7102",title:"Pneumonia",subtitle:null,isOpenForSubmission:!1,hash:"9fd70142814192dcec58a176749f1b60",slug:"pneumonia",bookSignature:"Nima Rezaei",coverURL:"https://cdn.intechopen.com/books/images_new/7102.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"116250",title:"Dr.",name:"Nima",middleName:null,surname:"Rezaei",slug:"nima-rezaei",fullName:"Nima Rezaei"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9670",title:"Current Trends in Wheat Research",subtitle:null,isOpenForSubmission:!1,hash:"89d795987f1747a76eee532700d2093d",slug:"current-trends-in-wheat-research",bookSignature:"Mahmood-ur-Rahman Ansari",coverURL:"https://cdn.intechopen.com/books/images_new/9670.jpg",editedByType:"Edited by",publishedDate:"May 11th 2022",editors:[{id:"185476",title:"Dr.",name:"Mahmood-ur-Rahman",middleName:null,surname:"Ansari",slug:"mahmood-ur-rahman-ansari",fullName:"Mahmood-ur-Rahman Ansari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"290",title:"Information and Communication",slug:"information-and-communication",parent:{id:"24",title:"Technology",slug:"technology"},numberOfBooks:20,numberOfSeries:0,numberOfAuthorsAndEditors:332,numberOfWosCitations:571,numberOfCrossrefCitations:518,numberOfDimensionsCitations:938,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicId:"290",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"6940",title:"e-Services",subtitle:null,isOpenForSubmission:!1,hash:"0dd6e0f6c0a6d3be53af40ae99a1529d",slug:"e-services",bookSignature:"Sam Goundar",coverURL:"https://cdn.intechopen.com/books/images_new/6940.jpg",editedByType:"Edited by",editors:[{id:"280395",title:"Dr.",name:"Sam",middleName:null,surname:"Goundar",slug:"sam-goundar",fullName:"Sam Goundar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7654",title:"Wearable Devices",subtitle:"the Big Wave of Innovation",isOpenForSubmission:!1,hash:"46b13f25dc9a1576e355717c903d81bc",slug:"wearable-devices-the-big-wave-of-innovation",bookSignature:"Noushin Nasiri",coverURL:"https://cdn.intechopen.com/books/images_new/7654.jpg",editedByType:"Edited by",editors:[{id:"234150",title:"Dr.",name:"Noushin",middleName:null,surname:"Nasiri",slug:"noushin-nasiri",fullName:"Noushin Nasiri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8723",title:"Telecommunication Systems",subtitle:"Principles and Applications of Wireless-Optical Technologies",isOpenForSubmission:!1,hash:"8bf1ec49936ab44fcdfc9fea042e73d7",slug:"telecommunication-systems-principles-and-applications-of-wireless-optical-technologies",bookSignature:"Isiaka A. Alimi, Paulo P. Monteiro and António L. Teixeira",coverURL:"https://cdn.intechopen.com/books/images_new/8723.jpg",editedByType:"Edited by",editors:[{id:"208236",title:"Dr.",name:"Isiaka",middleName:"Ajewale",surname:"Alimi",slug:"isiaka-alimi",fullName:"Isiaka Alimi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8383",title:"Multiplexing",subtitle:null,isOpenForSubmission:!1,hash:"57b7f473289c825517f17b8e18d893fc",slug:"multiplexing",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/8383.jpg",editedByType:"Edited by",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7401",title:"Telecommunication Networks",subtitle:"Trends and Developments",isOpenForSubmission:!1,hash:"bbaf96f832d3a8b509e18bf1bdaacc87",slug:"telecommunication-networks-trends-and-developments",bookSignature:"Mohammad Abdul Matin",coverURL:"https://cdn.intechopen.com/books/images_new/7401.jpg",editedByType:"Edited by",editors:[{id:"12623",title:"Prof.",name:"Mohammad Abdul",middleName:"A",surname:"Matin",slug:"mohammad-abdul-matin",fullName:"Mohammad Abdul Matin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7291",title:"Cognitive Radio in 4G/5G Wireless Communication Systems",subtitle:null,isOpenForSubmission:!1,hash:"15cb591deb13165af8e0286da414c1bd",slug:"cognitive-radio-in-4g-5g-wireless-communication-systems",bookSignature:"Shahriar Shirvani Moghaddam",coverURL:"https://cdn.intechopen.com/books/images_new/7291.jpg",editedByType:"Edited by",editors:[{id:"185038",title:"Dr.",name:"Shahriar",middleName:null,surname:"Shirvani Moghaddam",slug:"shahriar-shirvani-moghaddam",fullName:"Shahriar Shirvani Moghaddam"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6321",title:"Broadband Communications Networks",subtitle:"Recent Advances and Lessons from Practice",isOpenForSubmission:!1,hash:"6e29995cd9dd6193bd198112d9549f32",slug:"broadband-communications-networks-recent-advances-and-lessons-from-practice",bookSignature:"Abdelfatteh Haidine and Abdelhak Aqqal",coverURL:"https://cdn.intechopen.com/books/images_new/6321.jpg",editedByType:"Edited by",editors:[{id:"187242",title:"Dr.",name:"Abdelfatteh",middleName:null,surname:"Haidine",slug:"abdelfatteh-haidine",fullName:"Abdelfatteh Haidine"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5740",title:"Smartphones from an Applied Research Perspective",subtitle:null,isOpenForSubmission:!1,hash:"10f605202aae0cd293bfc2b4e5027e5c",slug:"smartphones-from-an-applied-research-perspective",bookSignature:"Nawaz Mohamudally",coverURL:"https://cdn.intechopen.com/books/images_new/5740.jpg",editedByType:"Edited by",editors:[{id:"119486",title:"Dr.",name:"Nawaz",middleName:null,surname:"Mohamudally",slug:"nawaz-mohamudally",fullName:"Nawaz Mohamudally"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4646",title:"Cutting Edge Research in Technologies",subtitle:null,isOpenForSubmission:!1,hash:"a0c6cc73cb98936693e6e4845a19dfcf",slug:"cutting-edge-research-in-technologies",bookSignature:"Constantin Volosencu",coverURL:"https://cdn.intechopen.com/books/images_new/4646.jpg",editedByType:"Edited by",editors:[{id:"1063",title:"Prof.",name:"Constantin",middleName:null,surname:"Volosencu",slug:"constantin-volosencu",fullName:"Constantin Volosencu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1892",title:"Technological Change",subtitle:null,isOpenForSubmission:!1,hash:"3cf7980708feb75306ac4e7fdc678d5c",slug:"technological-change",bookSignature:"Aurora A.C. Teixeira",coverURL:"https://cdn.intechopen.com/books/images_new/1892.jpg",editedByType:"Edited by",editors:[{id:"112335",title:"Dr.",name:"Aurora",middleName:"A.C.",surname:"Teixeira",slug:"aurora-teixeira",fullName:"Aurora Teixeira"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"577",title:"Assistive Technologies",subtitle:null,isOpenForSubmission:!1,hash:"a96647e24e8f72a97a6df1368e625ebc",slug:"assistive-technologies",bookSignature:"Fernando A. Auat Cheein",coverURL:"https://cdn.intechopen.com/books/images_new/577.jpg",editedByType:"Edited by",editors:[{id:"78273",title:"Dr.",name:"Fernando",middleName:null,surname:"Auat Cheein",slug:"fernando-auat-cheein",fullName:"Fernando Auat Cheein"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1914",title:"Fuzzy Logic",subtitle:"Emerging Technologies and Applications",isOpenForSubmission:!1,hash:"8587a78f376ef175e1a26fb4f61f79e2",slug:"fuzzy-logic-emerging-technologies-and-applications",bookSignature:"Elmer P. Dadios",coverURL:"https://cdn.intechopen.com/books/images_new/1914.jpg",editedByType:"Edited by",editors:[{id:"111683",title:"Prof.",name:"Elmer",middleName:"P.",surname:"Dadios",slug:"elmer-dadios",fullName:"Elmer Dadios"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:20,seriesByTopicCollection:[],seriesByTopicTotal:0,mostCitedChapters:[{id:"31905",doi:"10.5772/38302",title:"Touch Screens for the Older User",slug:"touch-screens-for-the-older-user",totalDownloads:5103,totalCrossrefCites:51,totalDimensionsCites:80,abstract:null,book:{id:"577",slug:"assistive-technologies",title:"Assistive Technologies",fullTitle:"Assistive Technologies"},signatures:"Niamh Caprani, Noel E. O’Connor and Cathal Gurrin",authors:[{id:"1479",title:"Dr.",name:"Cathal",middleName:null,surname:"Gurrin",slug:"cathal-gurrin",fullName:"Cathal Gurrin"},{id:"116543",title:"Ms.",name:"Niamh",middleName:null,surname:"Caprani",slug:"niamh-caprani",fullName:"Niamh Caprani"},{id:"116548",title:"Prof.",name:"Noel",middleName:null,surname:"E. O'Connor",slug:"noel-e.-o'connor",fullName:"Noel E. O'Connor"}]},{id:"12285",doi:"10.5772/10432",title:"Capabilities and Performances of the Selective Laser Melting Process",slug:"capabilities-and-performances-of-the-selective-laser-melting-process",totalDownloads:6313,totalCrossrefCites:8,totalDimensionsCites:65,abstract:null,book:{id:"3720",slug:"new-trends-in-technologies--devices--computer--communication-and-industrial-systems",title:"New Trends in Technologies",fullTitle:"New Trends in Technologies: Devices, Computer, Communication and Industrial Systems"},signatures:"Sabina Luisa Campanelli, Nicola Contuzzi, Andrea Angelastro and Antonio Domenico Ludovico",authors:null},{id:"56113",doi:"10.5772/intechopen.69734",title:"Smartphone: The Ultimate IoT and IoE Device",slug:"smartphone-the-ultimate-iot-and-ioe-device",totalDownloads:2847,totalCrossrefCites:23,totalDimensionsCites:35,abstract:"Internet of Things (IoT) and Internet of Everything (IoE) are emerging communication concepts that will interconnect a variety of devices (including smartphones, home appliances, sensors, and other network devices), people, data, and processes and allow them to communicate with each other seamlessly. These new concepts can be applied in many application domains such as healthcare, transportation, and supply chain management (SCM), to name a few, and allow users to get real-time information such as location-based services, disease management, and tracking. The smartphone-enabling technologies such as built-in sensors, Bluetooth, radio-frequency identification (RFID) tracking, and near-field communications (NFC) allow it to be an integral part of IoT and IoE world and the mostly used device in these environments. However, its use imposes severe security and privacy threats, because the smartphone usually contains and communicates sensitive private data. In this chapter, we provide a comprehensive survey on IoT and IoE technologies, their application domains, IoT structure and architecture, the use of smartphones in IoT and IoE, and the difference between IoT networks and mobile cellular networks. We also provide a concise overview of future opportunities and challenges in IoT and IoE environments and focus more on the security and privacy threats of using the smartphone in IoT and IoE networks with a suggestion of some countermeasures.",book:{id:"5740",slug:"smartphones-from-an-applied-research-perspective",title:"Smartphones from an Applied Research Perspective",fullTitle:"Smartphones from an Applied Research Perspective"},signatures:"Mehdia Ajana El Khaddar and Mohammed Boulmalf",authors:[{id:"26677",title:"Dr.",name:"Mehdia",middleName:null,surname:"Ajana El Khaddar",slug:"mehdia-ajana-el-khaddar",fullName:"Mehdia Ajana El Khaddar"},{id:"209424",title:"Dr.",name:"Mohammed",middleName:null,surname:"Boulmalf",slug:"mohammed-boulmalf",fullName:"Mohammed Boulmalf"}]},{id:"12298",doi:"10.5772/10420",title:"Intelligent Technologies in Modeling and Control of Turbojet Engines",slug:"intelligent-technologies-in-modeling-and-control-of-turbojet-engines",totalDownloads:2829,totalCrossrefCites:23,totalDimensionsCites:29,abstract:null,book:{id:"3684",slug:"new-trends-in-technologies--control--management--computational-intelligence-and-network-systems",title:"New Trends in Technologies",fullTitle:"New Trends in Technologies: Control, Management, Computational Intelligence and Network Systems"},signatures:"Ladislav Madarász, Rudolf Andoga and Ladislav Fozo",authors:null},{id:"9410",doi:"10.5772/7297",title:"Competence-based Curriculum Development in Higher Education: a Globalised Concept?",slug:"competence-based-curriculum-development-in-higher-education-a-globalised-concept-",totalDownloads:10079,totalCrossrefCites:9,totalDimensionsCites:24,abstract:null,book:{id:"3611",slug:"technology-education-and-development",title:"Technology",fullTitle:"Technology, Education and Development"},signatures:"Wim Kouwenhoven",authors:null}],mostDownloadedChaptersLast30Days:[{id:"66828",title:"Breathing Monitoring and Pattern Recognition with Wearable Sensors",slug:"breathing-monitoring-and-pattern-recognition-with-wearable-sensors",totalDownloads:3012,totalCrossrefCites:10,totalDimensionsCites:13,abstract:"This chapter introduces the anatomy and physiology of the respiratory system, and the reasons for measuring breathing events, particularly, using wearable sensors. Respiratory monitoring is vital including detection of sleep apnea and measurement of respiratory rate. The automatic detection of breathing patterns is equally important in other respiratory rehabilitation therapies, for example, magnetic resonance exams for respiratory triggered imaging, and synchronized functional electrical stimulation. In this context, the goal of many research groups is to create wearable devices able to monitor breathing activity continuously, under natural physiological conditions in different environments. Therefore, wearable sensors that have been used recently as well as the main signal processing methods for breathing analysis are discussed. The following sensor technologies are presented: acoustic, resistive, inductive, humidity, acceleration, pressure, electromyography, impedance, and infrared. New technologies open the door to future methods of noninvasive breathing analysis using wearable sensors associated with machine learning techniques for pattern detection.",book:{id:"7654",slug:"wearable-devices-the-big-wave-of-innovation",title:"Wearable Devices",fullTitle:"Wearable Devices - the Big Wave of Innovation"},signatures:"Taisa Daiana da Costa, Maria de Fatima Fernandes Vara, Camila Santos Cristino, Tyene Zoraski Zanella, Guilherme Nunes Nogueira Neto and Percy Nohama",authors:[{id:"192464",title:"Ph.D.",name:"Percy",middleName:null,surname:"Nohama",slug:"percy-nohama",fullName:"Percy Nohama"},{id:"285706",title:"MSc.",name:"Taísa Daiana",middleName:null,surname:"Da Costa",slug:"taisa-daiana-da-costa",fullName:"Taísa Daiana Da Costa"},{id:"285707",title:"MSc.",name:"Maria de Fatima Fernandes",middleName:null,surname:"Vara",slug:"maria-de-fatima-fernandes-vara",fullName:"Maria de Fatima Fernandes Vara"},{id:"285708",title:"BSc.",name:"Camila Santos",middleName:null,surname:"Cristino",slug:"camila-santos-cristino",fullName:"Camila Santos Cristino"},{id:"285709",title:"Prof.",name:"Guilherme Nunes",middleName:null,surname:"Nogueira Neto",slug:"guilherme-nunes-nogueira-neto",fullName:"Guilherme Nunes Nogueira Neto"},{id:"293109",title:"BSc.",name:"Tyene",middleName:null,surname:"Zoraski Zanella",slug:"tyene-zoraski-zanella",fullName:"Tyene Zoraski Zanella"}]},{id:"59149",title:"Evolution of Broadband Communication Networks: Architecture and Applications",slug:"evolution-of-broadband-communication-networks-architecture-and-applications",totalDownloads:1566,totalCrossrefCites:0,totalDimensionsCites:0,abstract:"With the rapid increase in users’ demand for flexibility and scalability of communication services, broadband communication networks are facing an ongoing challenge of providing various broadband services using a single communication architecture. This leads to the evolution of a challenging field of multiservice broadband network architectures. This chapter discusses the basic concepts associated with broadband communication network architectures with emphasis on provision of multiservice, and it also focuses on the evolution of broadband communication networks from the traditional architecture to the incorporation of virtualization services, that is, cloud computing. Another important aspect, which relates to the multiservice broadband network, is the “applications” which, as this chapter highlights, are a key-driving factor for the evolution of broadband communication networks. Moreover, this chapter also includes a discussion on New Zealand’s government initiatives to provide improved network coverage within the country.",book:{id:"6321",slug:"broadband-communications-networks-recent-advances-and-lessons-from-practice",title:"Broadband Communications Networks",fullTitle:"Broadband Communications Networks - Recent Advances and Lessons from Practice"},signatures:"Sonia Gul and Jairo Gutierrez",authors:[{id:"214670",title:"Dr.",name:"Sonia",middleName:null,surname:"Gul",slug:"sonia-gul",fullName:"Sonia Gul"},{id:"215559",title:"Prof.",name:"Jairo",middleName:null,surname:"Gutierrez",slug:"jairo-gutierrez",fullName:"Jairo Gutierrez"}]},{id:"9429",title:"ICT Use in VET: The Virtual Training Centre for Shoe Design as a Model",slug:"ict-use-in-vet-the-virtual-training-centre-for-shoe-design-as-a-model",totalDownloads:8126,totalCrossrefCites:0,totalDimensionsCites:0,abstract:null,book:{id:"3611",slug:"technology-education-and-development",title:"Technology",fullTitle:"Technology, Education and Development"},signatures:"Aura Mihai and Mehmet Sahin",authors:null},{id:"67713",title:"Multiplexing",slug:"multiplexing",totalDownloads:1876,totalCrossrefCites:1,totalDimensionsCites:1,abstract:"In any communication system that is either digital or analog, we need a communication channel for transmission. This channel can be a wired or a wireless link. It is not practical to allocate individual channels for each user. Therefore a group of signals are combined together and sent over a common channel. For this we use multiplexers. A multiplexer is a device that allows digital information from several sources to be routed onto a single line for transmission to a single destination. A demultiplexer does the reverse operation of multiplexing. It takes digital information from a single line and distributes it to a given number of output lines.",book:{id:"8383",slug:"multiplexing",title:"Multiplexing",fullTitle:"Multiplexing"},signatures:"Vijayakumar Nandalal and M.S. Sumalatha",authors:[{id:"285973",title:"Dr.",name:"Nandalal",middleName:null,surname:"Vijayakumar",slug:"nandalal-vijayakumar",fullName:"Nandalal Vijayakumar"},{id:"297986",title:"Mrs.",name:"Sumalatha",middleName:null,surname:"M S",slug:"sumalatha-m-s",fullName:"Sumalatha M S"}]},{id:"62142",title:"5G Backhaul: Requirements, Challenges, and Emerging Technologies",slug:"5g-backhaul-requirements-challenges-and-emerging-technologies",totalDownloads:3153,totalCrossrefCites:11,totalDimensionsCites:22,abstract:"5G is the next generation cellular networks which is expected to quench the ever-ending thirst of data rates and interconnect billions of smart devices to support not only human centric traffic, but also machine centric traffic. Recent research and standardization work have been addressing requirements and challenges from radio perspective (e.g., new spectrum allocation, network densification, massive multiple-input-multiple-output antenna, carrier aggregation, inter-cell interference mitigation techniques, and coordinated multi-point processing). In addition, a new network bottleneck has emerged: the backhaul network which will allow to interconnect and support billions of devices from the core network. Up to 4G cellular networks, the major challenges to meet the backhaul requirements were capacity, availability, deployment cost, and long-distance reach. However, as 5G network capabilities and services added to 4G cellular networks, the backhaul network would face two additional challenges that include ultralow latency (i.e., 1 ms) requirements and ultradense nature of the network. Due to the dense small cell deployment and heavy traffic cells in 5G, 5G backhaul network will need to support hundreds of gigabits of traffic from the core network and today’s cellular backhaul networks are infeasible to meet these requirements in terms of capacity, availability, latency, energy, and cost efficiency. This book chapter first introduce the mobile backhaul network perspective for 2G, 3G, and 4G networks. Then, outlines the backhaul requirements of 5G networks, and describes the impact on current mobile backhaul networks.",book:{id:"6321",slug:"broadband-communications-networks-recent-advances-and-lessons-from-practice",title:"Broadband Communications Networks",fullTitle:"Broadband Communications Networks - Recent Advances and Lessons from Practice"},signatures:"Md Maruf Ahamed and Saleh Faruque",authors:[{id:"215861",title:"Ph.D. Student",name:"Md Maruf",middleName:null,surname:"Ahamed",slug:"md-maruf-ahamed",fullName:"Md Maruf Ahamed"},{id:"216864",title:"Prof.",name:"Saleh",middleName:null,surname:"Faruque",slug:"saleh-faruque",fullName:"Saleh Faruque"}]}],onlineFirstChaptersFilter:{topicId:"290",limit:6,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},subscriptionForm:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[],offset:8,limit:8,total:0},allSeries:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:8,numberOfPublishedChapters:87,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:98,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:27,numberOfPublishedChapters:286,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:9,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:11,numberOfPublishedChapters:139,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:8,numberOfPublishedChapters:129,numberOfOpenTopics:0,numberOfUpcomingTopics:2,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!1},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:105,numberOfOpenTopics:3,numberOfUpcomingTopics:1,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:9,numberOfPublishedChapters:101,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:11,numberOfOpenTopics:2,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:0,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!1},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:0,numberOfPublishedChapters:9,numberOfOpenTopics:4,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],testimonialsList:[{id:"6",text:"It is great to work with the IntechOpen to produce a worthwhile collection of research that also becomes a great educational resource and guide for future research endeavors.",author:{id:"259298",name:"Edward",surname:"Narayan",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/259298/images/system/259298.jpeg",slug:"edward-narayan",institution:{id:"3",name:"University of Queensland",country:{id:null,name:"Australia"}}}},{id:"13",text:"The collaboration with and support of the technical staff of IntechOpen is fantastic. The whole process of submitting an article and editing of the submitted article goes extremely smooth and fast, the number of reads and downloads of chapters is high, and the contributions are also frequently cited.",author:{id:"55578",name:"Antonio",surname:"Jurado-Navas",institutionString:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRisIQAS/Profile_Picture_1626166543950",slug:"antonio-jurado-navas",institution:{id:"720",name:"University of Malaga",country:{id:null,name:"Spain"}}}}]},series:{item:{id:"11",title:"Biochemistry",doi:"10.5772/intechopen.72877",issn:"2632-0983",scope:"Biochemistry, the study of chemical transformations occurring within living organisms, impacts all areas of life sciences, from molecular crystallography and genetics to ecology, medicine, and population biology. Biochemistry examines macromolecules - proteins, nucleic acids, carbohydrates, and lipids – and their building blocks, structures, functions, and interactions. Much of biochemistry is devoted to enzymes, proteins that catalyze chemical reactions, enzyme structures, mechanisms of action and their roles within cells. Biochemistry also studies small signaling molecules, coenzymes, inhibitors, vitamins, and hormones, which play roles in life processes. Biochemical experimentation, besides coopting classical chemistry methods, e.g., chromatography, adopted new techniques, e.g., X-ray diffraction, electron microscopy, NMR, radioisotopes, and developed sophisticated microbial genetic tools, e.g., auxotroph mutants and their revertants, fermentation, etc. More recently, biochemistry embraced the ‘big data’ omics systems. Initial biochemical studies have been exclusively analytic: dissecting, purifying, and examining individual components of a biological system; in the apt words of Efraim Racker (1913 –1991), “Don’t waste clean thinking on dirty enzymes.” Today, however, biochemistry is becoming more agglomerative and comprehensive, setting out to integrate and describe entirely particular biological systems. The ‘big data’ metabolomics can define the complement of small molecules, e.g., in a soil or biofilm sample; proteomics can distinguish all the comprising proteins, e.g., serum; metagenomics can identify all the genes in a complex environment, e.g., the bovine rumen. This Biochemistry Series will address the current research on biomolecules and the emerging trends with great promise.",coverUrl:"https://cdn.intechopen.com/series/covers/11.jpg",latestPublicationDate:"May 15th, 2022",hasOnlineFirst:!0,numberOfPublishedBooks:27,editor:{id:"31610",title:"Dr.",name:"Miroslav",middleName:null,surname:"Blumenberg",slug:"miroslav-blumenberg",fullName:"Miroslav Blumenberg",profilePictureURL:"https://mts.intechopen.com/storage/users/31610/images/system/31610.jpg",biography:"Miroslav Blumenberg, Ph.D., was born in Subotica and received his BSc in Belgrade, Yugoslavia. He completed his Ph.D. at MIT in Organic Chemistry; he followed up his Ph.D. with two postdoctoral study periods at Stanford University. Since 1983, he has been a faculty member of the RO Perelman Department of Dermatology, NYU School of Medicine, where he is codirector of a training grant in cutaneous biology. Dr. Blumenberg’s research is focused on the epidermis, expression of keratin genes, transcription profiling, keratinocyte differentiation, inflammatory diseases and cancers, and most recently the effects of the microbiome on the skin. He has published more than 100 peer-reviewed research articles and graduated numerous Ph.D. and postdoctoral students.",institutionString:null,institution:{name:"New York University Langone Medical Center",institutionURL:null,country:{name:"United States of America"}}},editorTwo:null,editorThree:null},subseries:{paginationCount:4,paginationItems:[{id:"14",title:"Cell and Molecular Biology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/14.jpg",isOpenForSubmission:!0,editor:{id:"165627",title:"Dr.",name:"Rosa María",middleName:null,surname:"Martínez-Espinosa",slug:"rosa-maria-martinez-espinosa",fullName:"Rosa María Martínez-Espinosa",profilePictureURL:"https://mts.intechopen.com/storage/users/165627/images/system/165627.jpeg",biography:"Dr. Rosa María Martínez-Espinosa has been a Spanish Full Professor since 2020 (Biochemistry and Molecular Biology) and is currently Vice-President of International Relations and Cooperation development and leader of the research group 'Applied Biochemistry” (University of Alicante, Spain). Other positions she has held at the university include Vice-Dean of Master Programs, Vice-Dean of the Degree in Biology and Vice-Dean for Mobility and Enterprise and Engagement at the Faculty of Science (University of Alicante). She received her Bachelor in Biology in 1998 (University of Alicante) and her PhD in 2003 (Biochemistry, University of Alicante). She undertook post-doctoral research at the University of East Anglia (Norwich, U.K. 2004-2005; 2007-2008).\nHer multidisciplinary research focuses on investigating archaea and their potential applications in biotechnology. She has an H-index of 21. She has authored one patent and has published more than 70 indexed papers and around 60 book chapters.\nShe has contributed to more than 150 national and international meetings during the last 15 years. Her research interests include archaea metabolism, enzymes purification and characterization, gene regulation, carotenoids and bioplastics production, antioxidant\ncompounds, waste water treatments, and brines bioremediation.\nRosa María’s other roles include editorial board member for several journals related\nto biochemistry, reviewer for more than 60 journals (biochemistry, molecular biology, biotechnology, chemistry and microbiology) and president of several organizing committees in international meetings related to the N-cycle or respiratory processes.",institutionString:null,institution:{name:"University of Alicante",institutionURL:null,country:{name:"Spain"}}},editorTwo:null,editorThree:null},{id:"15",title:"Chemical Biology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/15.jpg",isOpenForSubmission:!0,editor:{id:"441442",title:"Dr.",name:"Şükrü",middleName:null,surname:"Beydemir",slug:"sukru-beydemir",fullName:"Şükrü Beydemir",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y00003GsUoIQAV/Profile_Picture_1634557147521",biography:"Dr. Şükrü Beydemir obtained a BSc in Chemistry in 1995 from Yüzüncü Yıl University, MSc in Biochemistry in 1998, and PhD in Biochemistry in 2002 from Atatürk University, Turkey. He performed post-doctoral studies at Max-Planck Institute, Germany, and University of Florence, Italy in addition to making several scientific visits abroad. He currently works as a Full Professor of Biochemistry in the Faculty of Pharmacy, Anadolu University, Turkey. Dr. Beydemir has published over a hundred scientific papers spanning protein biochemistry, enzymology and medicinal chemistry, reviews, book chapters and presented several conferences to scientists worldwide. He has received numerous publication awards from various international scientific councils. He serves in the Editorial Board of several international journals. Dr. Beydemir is also Rector of Bilecik Şeyh Edebali University, Turkey.",institutionString:null,institution:{name:"Anadolu University",institutionURL:null,country:{name:"Turkey"}}},editorTwo:{id:"13652",title:"Prof.",name:"Deniz",middleName:null,surname:"Ekinci",slug:"deniz-ekinci",fullName:"Deniz Ekinci",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYLT1QAO/Profile_Picture_1634557223079",biography:"Dr. Deniz Ekinci obtained a BSc in Chemistry in 2004, MSc in Biochemistry in 2006, and PhD in Biochemistry in 2009 from Atatürk University, Turkey. He studied at Stetson University, USA, in 2007-2008 and at the Max Planck Institute of Molecular Cell Biology and Genetics, Germany, in 2009-2010. Dr. Ekinci currently works as a Full Professor of Biochemistry in the Faculty of Agriculture and is the Head of the Enzyme and Microbial Biotechnology Division, Ondokuz Mayıs University, Turkey. He is a member of the Turkish Biochemical Society, American Chemical Society, and German Genetics society. Dr. Ekinci published around ninety scientific papers, reviews and book chapters, and presented several conferences to scientists. He has received numerous publication awards from several scientific councils. Dr. Ekinci serves as the Editor in Chief of four international books and is involved in the Editorial Board of several international journals.",institutionString:null,institution:{name:"Ondokuz Mayıs University",institutionURL:null,country:{name:"Turkey"}}},editorThree:null},{id:"17",title:"Metabolism",coverUrl:"https://cdn.intechopen.com/series_topics/covers/17.jpg",isOpenForSubmission:!0,editor:{id:"138626",title:"Dr.",name:"Yannis",middleName:null,surname:"Karamanos",slug:"yannis-karamanos",fullName:"Yannis Karamanos",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002g6Jv2QAE/Profile_Picture_1629356660984",biography:"Yannis Karamanos, born in Greece in 1953, completed his pre-graduate studies at the Université Pierre et Marie Curie, Paris, then his Masters and Doctoral degree at the Université de Lille (1983). He was associate professor at the University of Limoges (1987) before becoming full professor of biochemistry at the Université d’Artois (1996). He worked on the structure-function relationships of glycoconjugates and his main project was the investigations on the biological roles of the de-N-glycosylation enzymes (Endo-N-acetyl-β-D-glucosaminidase and peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidase). From 2002 he contributes to the understanding of the Blood-brain barrier functioning using proteomics approaches. He has published more than 70 papers. His teaching areas are energy metabolism and regulation, integration and organ specialization and metabolic adaptation.",institutionString:null,institution:{name:"Artois University",institutionURL:null,country:{name:"France"}}},editorTwo:null,editorThree:null},{id:"18",title:"Proteomics",coverUrl:"https://cdn.intechopen.com/series_topics/covers/18.jpg",isOpenForSubmission:!0,editor:{id:"200689",title:"Prof.",name:"Paolo",middleName:null,surname:"Iadarola",slug:"paolo-iadarola",fullName:"Paolo Iadarola",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bSCl8QAG/Profile_Picture_1623568118342",biography:"Paolo Iadarola graduated with a degree in Chemistry from the University of Pavia (Italy) in July 1972. He then worked as an Assistant Professor at the Faculty of Science of the same University until 1984. In 1985, Prof. Iadarola became Associate Professor at the Department of Biology and Biotechnologies of the University of Pavia and retired in October 2017. Since then, he has been working as an Adjunct Professor in the same Department at the University of Pavia. His research activity during the first years was primarily focused on the purification and structural characterization of enzymes from animal and plant sources. During this period, Prof. Iadarola familiarized himself with the conventional techniques used in column chromatography, spectrophotometry, manual Edman degradation, and electrophoresis). Since 1995, he has been working on: i) the determination in biological fluids (serum, urine, bronchoalveolar lavage, sputum) of proteolytic activities involved in the degradation processes of connective tissue matrix, and ii) on the identification of biological markers of lung diseases. In this context, he has developed and validated new methodologies (e.g., Capillary Electrophoresis coupled to Laser-Induced Fluorescence, CE-LIF) whose application enabled him to determine both the amounts of biochemical markers (Desmosines) in urine/serum of patients affected by Chronic Obstructive Pulmonary Disease (COPD) and the activity of proteolytic enzymes (Human Neutrophil Elastase, Cathepsin G, Pseudomonas aeruginosa elastase) in sputa of these patients. More recently, Prof. Iadarola was involved in developing techniques such as two-dimensional electrophoresis coupled to liquid chromatography/mass spectrometry (2DE-LC/MS) for the proteomic analysis of biological fluids aimed at the identification of potential biomarkers of different lung diseases. He is the author of about 150 publications (According to Scopus: H-Index: 23; Total citations: 1568- According to WOS: H-Index: 20; Total Citations: 1296) of peer-reviewed international journals. He is a Consultant Reviewer for several journals, including the Journal of Chromatography A, Journal of Chromatography B, Plos ONE, Proteomes, International Journal of Molecular Science, Biotech, Electrophoresis, and others. He is also Associate Editor of Biotech.",institutionString:null,institution:{name:"University of Pavia",institutionURL:null,country:{name:"Italy"}}},editorTwo:{id:"201414",title:"Dr.",name:"Simona",middleName:null,surname:"Viglio",slug:"simona-viglio",fullName:"Simona Viglio",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRKDHQA4/Profile_Picture_1630402531487",biography:"Simona Viglio is an Associate Professor of Biochemistry at the Department of Molecular Medicine at the University of Pavia. She has been working since 1995 on the determination of proteolytic enzymes involved in the degradation process of connective tissue matrix and on the identification of biological markers of lung diseases. She gained considerable experience in developing and validating new methodologies whose applications allowed her to determine both the amount of biomarkers (Desmosine and Isodesmosine) in the urine of patients affected by COPD, and the activity of proteolytic enzymes (HNE, Cathepsin G, Pseudomonas aeruginosa elastase) in the sputa of these patients. Simona Viglio was also involved in research dealing with the supplementation of amino acids in patients with brain injury and chronic heart failure. She is presently engaged in the development of 2-DE and LC-MS techniques for the study of proteomics in biological fluids. The aim of this research is the identification of potential biomarkers of lung diseases. She is an author of about 90 publications (According to Scopus: H-Index: 23; According to WOS: H-Index: 20) on peer-reviewed journals, a member of the “Società Italiana di Biochimica e Biologia Molecolare,“ and a Consultant Reviewer for International Journal of Molecular Science, Journal of Chromatography A, COPD, Plos ONE and Nutritional Neuroscience.",institutionString:null,institution:{name:"University of Pavia",institutionURL:null,country:{name:"Italy"}}},editorThree:null}]},overviewPageOFChapters:{paginationCount:48,paginationItems:[{id:"81799",title:"Cross Talk of Purinergic and Immune Signaling: Implication in Inflammatory and Pathogenic Diseases",doi:"10.5772/intechopen.104978",signatures:"Richa Rai",slug:"cross-talk-of-purinergic-and-immune-signaling-implication-in-inflammatory-and-pathogenic-diseases",totalDownloads:1,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81764",title:"Involvement of the Purinergic System in Cell Death in Models of Retinopathies",doi:"10.5772/intechopen.103935",signatures:"Douglas Penaforte Cruz, Marinna Garcia Repossi and Lucianne Fragel Madeira",slug:"involvement-of-the-purinergic-system-in-cell-death-in-models-of-retinopathies",totalDownloads:2,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}},{id:"81756",title:"Alteration of Cytokines Level and Oxidative Stress Parameters in COVID-19",doi:"10.5772/intechopen.104950",signatures:"Marija Petrusevska, Emilija Atanasovska, Dragica Zendelovska, Aleksandar Eftimov and Katerina Spasovska",slug:"alteration-of-cytokines-level-and-oxidative-stress-parameters-in-covid-19",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Chemokines Updates",coverURL:"https://cdn.intechopen.com/books/images_new/11672.jpg",subseries:{id:"18",title:"Proteomics"}}},{id:"81681",title:"Immunomodulatory Effects of a M2-Conditioned Medium (PRS® CK STORM): Theory on the Possible Complex Mechanism of Action through Anti-Inflammatory Modulation of the TLR System and the Purinergic System",doi:"10.5772/intechopen.104486",signatures:"Juan Pedro Lapuente",slug:"immunomodulatory-effects-of-a-m2-conditioned-medium-prs-ck-storm-theory-on-the-possible-complex-mech",totalDownloads:5,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Purinergic System",coverURL:"https://cdn.intechopen.com/books/images_new/10801.jpg",subseries:{id:"17",title:"Metabolism"}}}]},overviewPagePublishedBooks:{paginationCount:27,paginationItems:[{type:"book",id:"7006",title:"Biochemistry and Health Benefits of Fatty Acids",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7006.jpg",slug:"biochemistry-and-health-benefits-of-fatty-acids",publishedDate:"December 19th 2018",editedByType:"Edited by",bookSignature:"Viduranga Waisundara",hash:"c93a00abd68b5eba67e5e719f67fd20b",volumeInSeries:1,fullTitle:"Biochemistry and Health Benefits of Fatty Acids",editors:[{id:"194281",title:"Dr.",name:"Viduranga Y.",middleName:null,surname:"Waisundara",slug:"viduranga-y.-waisundara",fullName:"Viduranga Y. Waisundara",profilePictureURL:"https://mts.intechopen.com/storage/users/194281/images/system/194281.jpg",biography:"Dr. Viduranga Waisundara obtained her Ph.D. in Food Science and Technology from the Department of Chemistry, National University of Singapore, in 2010. She was a lecturer at Temasek Polytechnic, Singapore from July 2009 to March 2013. She relocated to her motherland of Sri Lanka and spearheaded the Functional Food Product Development Project at the National Institute of Fundamental Studies from April 2013 to October 2016. She was a senior lecturer on a temporary basis at the Department of Food Technology, Faculty of Technology, Rajarata University of Sri Lanka. She is currently Deputy Principal of the Australian College of Business and Technology – Kandy Campus, Sri Lanka. She is also the Global Harmonization Initiative (GHI) Ambassador to Sri Lanka.",institutionString:"Australian College of Business & Technology",institution:null}]},{type:"book",id:"6820",title:"Keratin",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/6820.jpg",slug:"keratin",publishedDate:"December 19th 2018",editedByType:"Edited by",bookSignature:"Miroslav Blumenberg",hash:"6def75cd4b6b5324a02b6dc0359896d0",volumeInSeries:2,fullTitle:"Keratin",editors:[{id:"31610",title:"Dr.",name:"Miroslav",middleName:null,surname:"Blumenberg",slug:"miroslav-blumenberg",fullName:"Miroslav Blumenberg",profilePictureURL:"https://mts.intechopen.com/storage/users/31610/images/system/31610.jpg",biography:"Miroslav Blumenberg, Ph.D., was born in Subotica and received his BSc in Belgrade, Yugoslavia. He completed his Ph.D. at MIT in Organic Chemistry; he followed up his Ph.D. with two postdoctoral study periods at Stanford University. Since 1983, he has been a faculty member of the RO Perelman Department of Dermatology, NYU School of Medicine, where he is codirector of a training grant in cutaneous biology. Dr. Blumenberg’s research is focused on the epidermis, expression of keratin genes, transcription profiling, keratinocyte differentiation, inflammatory diseases and cancers, and most recently the effects of the microbiome on the skin. He has published more than 100 peer-reviewed research articles and graduated numerous Ph.D. and postdoctoral students.",institutionString:null,institution:{name:"New York University Langone Medical Center",institutionURL:null,country:{name:"United States of America"}}}]},{type:"book",id:"7978",title:"Vitamin A",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7978.jpg",slug:"vitamin-a",publishedDate:"May 15th 2019",editedByType:"Edited by",bookSignature:"Leila Queiroz Zepka, Veridiana Vera de Rosso and Eduardo Jacob-Lopes",hash:"dad04a658ab9e3d851d23705980a688b",volumeInSeries:3,fullTitle:"Vitamin A",editors:[{id:"261969",title:"Dr.",name:"Leila",middleName:null,surname:"Queiroz Zepka",slug:"leila-queiroz-zepka",fullName:"Leila Queiroz Zepka",profilePictureURL:"https://mts.intechopen.com/storage/users/261969/images/system/261969.png",biography:"Prof. Dr. Leila Queiroz Zepka is currently an associate professor in the Department of Food Technology and Science, Federal University of Santa Maria, Brazil. She has more than fifteen years of teaching and research experience. She has published more than 550 scientific publications/communications, including 15 books, 50 book chapters, 100 original research papers, 380 research communications in national and international conferences, and 12 patents. She is a member of the editorial board of five journals and acts as a reviewer for several national and international journals. Her research interests include microalgal biotechnology with an emphasis on microalgae-based products.",institutionString:"Universidade Federal de Santa Maria",institution:{name:"Universidade Federal de Santa Maria",institutionURL:null,country:{name:"Brazil"}}}]},{type:"book",id:"7953",title:"Bioluminescence",subtitle:"Analytical Applications and Basic Biology",coverURL:"https://cdn.intechopen.com/books/images_new/7953.jpg",slug:"bioluminescence-analytical-applications-and-basic-biology",publishedDate:"September 25th 2019",editedByType:"Edited by",bookSignature:"Hirobumi Suzuki",hash:"3a8efa00b71abea11bf01973dc589979",volumeInSeries:4,fullTitle:"Bioluminescence - Analytical Applications and Basic Biology",editors:[{id:"185746",title:"Dr.",name:"Hirobumi",middleName:null,surname:"Suzuki",slug:"hirobumi-suzuki",fullName:"Hirobumi Suzuki",profilePictureURL:"https://mts.intechopen.com/storage/users/185746/images/system/185746.png",biography:"Dr. Hirobumi Suzuki received his Ph.D. in 1997 from Tokyo Metropolitan University, Japan, where he studied firefly phylogeny and the evolution of mating systems. He is especially interested in the genetic differentiation pattern and speciation process that correlate to the flashing pattern and mating behavior of some fireflies in Japan. He then worked for Olympus Corporation, a Japanese manufacturer of optics and imaging products, where he was involved in the development of luminescence technology and produced a bioluminescence microscope that is currently being used for gene expression analysis in chronobiology, neurobiology, and developmental biology. Dr. Suzuki currently serves as a visiting researcher at Kogakuin University, Japan, and also a vice president of the Japan Firefly Society.",institutionString:"Kogakuin University",institution:null}]}]},openForSubmissionBooks:{paginationCount:3,paginationItems:[{id:"11675",title:"Advances in Skeletal Muscle Health and Disease",coverURL:"https://cdn.intechopen.com/books/images_new/11675.jpg",hash:"e1d9662c334dd78ab35bfb57c3bf106e",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"April 19th 2022",isOpenForSubmission:!0,editors:[{id:"281317",title:"Dr.",name:"Fabio",surname:"Iannotti",slug:"fabio-iannotti",fullName:"Fabio Iannotti"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11677",title:"New Insights in Mammalian Endocrinology",coverURL:"https://cdn.intechopen.com/books/images_new/11677.jpg",hash:"c59dd0f87bbf829ca091c485f4cc4e68",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"May 5th 2022",isOpenForSubmission:!0,editors:[{id:"321396",title:"Prof.",name:"Muhammad Subhan",surname:"Qureshi",slug:"muhammad-subhan-qureshi",fullName:"Muhammad Subhan Qureshi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11676",title:"Recent Advances in Homeostasis",coverURL:"https://cdn.intechopen.com/books/images_new/11676.jpg",hash:"63eb775115bf2d6d88530b234a1cc4c2",secondStepPassed:!1,currentStepOfPublishingProcess:2,submissionDeadline:"June 10th 2022",isOpenForSubmission:!0,editors:[{id:"203015",title:"Dr.",name:"Gaffar",surname:"Zaman",slug:"gaffar-zaman",fullName:"Gaffar Zaman"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},onlineFirstChapters:{paginationCount:25,paginationItems:[{id:"81793",title:"Canine parvovirus-2: An Emerging Threat to Young Pets",doi:"10.5772/intechopen.104846",signatures:"Mithilesh Singh, Rajendran Manikandan, Ujjwal Kumar De, Vishal Chander, Babul Rudra Paul, Saravanan Ramakrishnan and Darshini Maramreddy",slug:"canine-parvovirus-2-an-emerging-threat-to-young-pets",totalDownloads:0,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Recent Advances in Canine Medicine",coverURL:"https://cdn.intechopen.com/books/images_new/11580.jpg",subseries:{id:"19",title:"Animal Science"}}},{id:"81271",title:"The Diversity of Parvovirus Telomeres",doi:"10.5772/intechopen.102684",signatures:"Marianne Laugel, Emilie Lecomte, Eduard Ayuso, Oumeya Adjali, Mathieu Mével and Magalie Penaud-Budloo",slug:"the-diversity-of-parvovirus-telomeres",totalDownloads:22,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Recent Advances in Canine Medicine",coverURL:"https://cdn.intechopen.com/books/images_new/11580.jpg",subseries:{id:"19",title:"Animal Science"}}},{id:"80187",title:"Potential Utilization of Insect Meal as Livestock Feed",doi:"10.5772/intechopen.101766",signatures:"Sipho Moyo and Busani Moyo",slug:"potential-utilization-of-insect-meal-as-livestock-feed",totalDownloads:100,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Animal Feed Science and Nutrition - Production, Health and Environment",coverURL:"https://cdn.intechopen.com/books/images_new/10830.jpg",subseries:{id:"20",title:"Animal Nutrition"}}},{id:"79909",title:"Cryopreservation Methods and Frontiers in the Art of Freezing Life in Animal Models",doi:"10.5772/intechopen.101750",signatures:"Feda S. Aljaser",slug:"cryopreservation-methods-and-frontiers-in-the-art-of-freezing-life-in-animal-models",totalDownloads:159,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Animal Reproduction",coverURL:"https://cdn.intechopen.com/books/images_new/10664.jpg",subseries:{id:"28",title:"Animal Reproductive Biology and Technology"}}},{id:"79866",title:"Ruminal Microbiome Manipulation to Improve Fermentation Efficiency in Ruminants",doi:"10.5772/intechopen.101582",signatures:"Yosra Ahmed Soltan and Amlan Kumar Patra",slug:"ruminal-microbiome-manipulation-to-improve-fermentation-efficiency-in-ruminants",totalDownloads:215,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Animal Feed Science and Nutrition - Production, Health and Environment",coverURL:"https://cdn.intechopen.com/books/images_new/10830.jpg",subseries:{id:"20",title:"Animal Nutrition"}}},{id:"79782",title:"Avian Reproduction",doi:"10.5772/intechopen.101185",signatures:"Kingsley Omogiade Idahor",slug:"avian-reproduction",totalDownloads:149,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Kingsley O.",surname:"Idahor"}],book:{title:"Animal Reproduction",coverURL:"https://cdn.intechopen.com/books/images_new/10664.jpg",subseries:{id:"28",title:"Animal Reproductive Biology and Technology"}}},{id:"78802",title:"Intraovarian Gestation in Viviparous Teleosts: Unique Type of Gestation among Vertebrates",doi:"10.5772/intechopen.100267",signatures:"Mari-Carmen Uribe, Gabino De la Rosa-Cruz, Adriana García-Alarcón and Juan Carlos Campuzano-Caballero",slug:"intraovarian-gestation-in-viviparous-teleosts-unique-type-of-gestation-among-vertebrates",totalDownloads:183,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Animal Reproduction",coverURL:"https://cdn.intechopen.com/books/images_new/10664.jpg",subseries:{id:"28",title:"Animal Reproductive Biology and Technology"}}},{id:"79209",title:"Virtual Physiology: A Tool for the 21st Century",doi:"10.5772/intechopen.99671",signatures:"Carmen Nóbrega, Maria Aires Pereira, Catarina Coelho, Isabel Brás, Ana Cristina Mega, Carla Santos, Fernando Esteves, Rita Cruz, Ana I. Faustino-Rocha, Paula A. Oliveira, João Mesquita and Helena Vala",slug:"virtual-physiology-a-tool-for-the-21st-century",totalDownloads:135,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Updates on Veterinary Anatomy and Physiology",coverURL:"https://cdn.intechopen.com/books/images_new/10665.jpg",subseries:{id:"19",title:"Animal Science"}}},{id:"78849",title:"Application of Vermicompost Fertilizer in Aquaculture Nutrition: Review",doi:"10.5772/intechopen.100326",signatures:"Sonnia Nzilani Musyoka and Rita Nairuti",slug:"application-of-vermicompost-fertilizer-in-aquaculture-nutrition-review",totalDownloads:67,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Animal Nutrition - Annual Volume 2022",coverURL:"https://cdn.intechopen.com/books/images_new/11416.jpg",subseries:{id:"20",title:"Animal Nutrition"}}},{id:"78998",title:"Effect of Various Feed Additives on the Methane Emissions from Beef Cattle Based on an Ammoniated Palm Frond Feeds",doi:"10.5772/intechopen.100142",signatures:"Mardiati Zain, Rusmana Wijaya Setia Ningrat, Heni Suryani and Novirman Jamarun",slug:"effect-of-various-feed-additives-on-the-methane-emissions-from-beef-cattle-based-on-an-ammoniated-pa",totalDownloads:142,totalCrossrefCites:0,totalDimensionsCites:1,authors:null,book:{title:"Animal Feed Science and Nutrition - Production, Health and Environment",coverURL:"https://cdn.intechopen.com/books/images_new/10830.jpg",subseries:{id:"20",title:"Animal Nutrition"}}}]},subseriesFiltersForOFChapters:[{caption:"Animal Nutrition",value:20,count:7,group:"subseries"},{caption:"Animal Reproductive Biology and Technology",value:28,count:7,group:"subseries"},{caption:"Animal Science",value:19,count:11,group:"subseries"}],publishedBooks:{paginationCount:8,paginationItems:[{type:"book",id:"10859",title:"Data Mining",subtitle:"Concepts and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/10859.jpg",slug:"data-mining-concepts-and-applications",publishedDate:"March 30th 2022",editedByType:"Edited by",bookSignature:"Ciza Thomas",hash:"63a4e514e537d3962cf53ef1c6b9d5eb",volumeInSeries:8,fullTitle:"Data Mining - Concepts and Applications",editors:[{id:"43680",title:"Prof.",name:"Ciza",middleName:null,surname:"Thomas",slug:"ciza-thomas",fullName:"Ciza Thomas",profilePictureURL:"https://mts.intechopen.com/storage/users/43680/images/system/43680.jpeg",institutionString:null,institution:{name:"Government of Kerala",institutionURL:null,country:{name:"India"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10651",title:"Machine Learning",subtitle:"Algorithms, Models and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/10651.jpg",slug:"machine-learning-algorithms-models-and-applications",publishedDate:"December 22nd 2021",editedByType:"Edited by",bookSignature:"Jaydip Sen",hash:"6208156401c496e0a4ca5ff4265324cc",volumeInSeries:7,fullTitle:"Machine Learning - Algorithms, Models and Applications",editors:[{id:"4519",title:"Prof.",name:"Jaydip",middleName:null,surname:"Sen",slug:"jaydip-sen",fullName:"Jaydip Sen",profilePictureURL:"https://mts.intechopen.com/storage/users/4519/images/system/4519.jpeg",institutionString:"Praxis Business School",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9869",title:"Self-Driving Vehicles and Enabling Technologies",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9869.jpg",slug:"self-driving-vehicles-and-enabling-technologies",publishedDate:"September 22nd 2021",editedByType:"Edited by",bookSignature:"Marian Găiceanu",hash:"fd451ca2e4785ef098e04b7d695a18d9",volumeInSeries:6,fullTitle:"Self-Driving Vehicles and Enabling Technologies",editors:[{id:"169608",title:"Prof.",name:"Marian",middleName:null,surname:"Găiceanu",slug:"marian-gaiceanu",fullName:"Marian Găiceanu",profilePictureURL:"https://mts.intechopen.com/storage/users/169608/images/system/169608.png",institutionString:'"Dunarea de Jos" University of Galati',institution:{name:'"Dunarea de Jos" University of Galati',institutionURL:null,country:{name:"Romania"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9958",title:"Artificial Intelligence",subtitle:"Latest Advances, New Paradigms and Novel Applications",coverURL:"https://cdn.intechopen.com/books/images_new/9958.jpg",slug:"artificial-intelligence-latest-advances-new-paradigms-and-novel-applications",publishedDate:"September 1st 2021",editedByType:"Edited by",bookSignature:"Eneko Osaba, Esther Villar, Jesús L. Lobo and Ibai Laña",hash:"39648fbfdaa11385097d62b1f13aad54",volumeInSeries:5,fullTitle:"Artificial Intelligence - Latest Advances, New Paradigms and Novel Applications",editors:[{id:"221364",title:"Dr.",name:"Eneko",middleName:null,surname:"Osaba",slug:"eneko-osaba",fullName:"Eneko Osaba",profilePictureURL:"https://mts.intechopen.com/storage/users/221364/images/system/221364.jpg",institutionString:"TECNALIA Research & Innovation",institution:{name:"Tecnalia",institutionURL:null,country:{name:"Spain"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9963",title:"Advances and Applications in Deep Learning",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9963.jpg",slug:"advances-and-applications-in-deep-learning",publishedDate:"December 9th 2020",editedByType:"Edited by",bookSignature:"Marco Antonio Aceves-Fernandez",hash:"0d51ba46f22e55cb89140f60d86a071e",volumeInSeries:4,fullTitle:"Advances and Applications in Deep Learning",editors:[{id:"24555",title:"Dr.",name:"Marco Antonio",middleName:null,surname:"Aceves Fernandez",slug:"marco-antonio-aceves-fernandez",fullName:"Marco Antonio Aceves Fernandez",profilePictureURL:"https://mts.intechopen.com/storage/users/24555/images/system/24555.jpg",institutionString:null,institution:{name:"Autonomous University of Queretaro",institutionURL:null,country:{name:"Mexico"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7656",title:"Fuzzy Logic",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7656.jpg",slug:"fuzzy-logic",publishedDate:"February 5th 2020",editedByType:"Edited by",bookSignature:"Constantin Volosencu",hash:"54f092d4ffe0abf5e4172a80025019bc",volumeInSeries:3,fullTitle:"Fuzzy Logic",editors:[{id:"1063",title:"Prof.",name:"Constantin",middleName:null,surname:"Volosencu",slug:"constantin-volosencu",fullName:"Constantin Volosencu",profilePictureURL:"https://mts.intechopen.com/storage/users/1063/images/system/1063.png",institutionString:"Polytechnic University of Timişoara",institution:{name:"Polytechnic University of Timişoara",institutionURL:null,country:{name:"Romania"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7726",title:"Swarm Intelligence",subtitle:"Recent Advances, New Perspectives and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/7726.jpg",slug:"swarm-intelligence-recent-advances-new-perspectives-and-applications",publishedDate:"December 4th 2019",editedByType:"Edited by",bookSignature:"Javier Del Ser, Esther Villar and Eneko Osaba",hash:"e7ea7e74ce7a7a8e5359629e07c68d31",volumeInSeries:2,fullTitle:"Swarm Intelligence - Recent Advances, New Perspectives and Applications",editors:[{id:"49813",title:"Dr.",name:"Javier",middleName:null,surname:"Del Ser",slug:"javier-del-ser",fullName:"Javier Del Ser",profilePictureURL:"https://mts.intechopen.com/storage/users/49813/images/system/49813.png",institutionString:"Tecnalia Research & Innovation",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7723",title:"Artificial Intelligence",subtitle:"Applications in Medicine and Biology",coverURL:"https://cdn.intechopen.com/books/images_new/7723.jpg",slug:"artificial-intelligence-applications-in-medicine-and-biology",publishedDate:"July 31st 2019",editedByType:"Edited by",bookSignature:"Marco Antonio Aceves-Fernandez",hash:"a3852659e727f95c98c740ed98146011",volumeInSeries:1,fullTitle:"Artificial Intelligence - Applications in Medicine and Biology",editors:[{id:"24555",title:"Dr.",name:"Marco Antonio",middleName:null,surname:"Aceves Fernandez",slug:"marco-antonio-aceves-fernandez",fullName:"Marco Antonio Aceves Fernandez",profilePictureURL:"https://mts.intechopen.com/storage/users/24555/images/system/24555.jpg",institutionString:null,institution:{name:"Autonomous University of Queretaro",institutionURL:null,country:{name:"Mexico"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},subseriesFiltersForPublishedBooks:[{group:"subseries",caption:"Evolutionary Computation",value:25,count:1},{group:"subseries",caption:"Machine Learning and Data Mining",value:26,count:3},{group:"subseries",caption:"Applied Intelligence",value:22,count:4}],publicationYearFilters:[{group:"publicationYear",caption:"2022",value:2022,count:1},{group:"publicationYear",caption:"2021",value:2021,count:3},{group:"publicationYear",caption:"2020",value:2020,count:2},{group:"publicationYear",caption:"2019",value:2019,count:2}],authors:{paginationCount:249,paginationItems:[{id:"274452",title:"Dr.",name:"Yousif",middleName:"Mohamed",surname:"Abdallah",slug:"yousif-abdallah",fullName:"Yousif Abdallah",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/274452/images/8324_n.jpg",biography:"I certainly enjoyed my experience in Radiotherapy and Nuclear Medicine, particularly it has been in different institutions and hospitals with different Medical Cultures and allocated resources. Radiotherapy and Nuclear Medicine Technology has always been my aspiration and my life. As years passed I accumulated a tremendous amount of skills and knowledge in Radiotherapy and Nuclear Medicine, Conventional Radiology, Radiation Protection, Bioinformatics Technology, PACS, Image processing, clinically and lecturing that will enable me to provide a valuable service to the community as a Researcher and Consultant in this field. My method of translating this into day to day in clinical practice is non-exhaustible and my habit of exchanging knowledge and expertise with others in those fields is the code and secret of success.",institutionString:null,institution:{name:"Majmaah University",country:{name:"Saudi Arabia"}}},{id:"313277",title:"Dr.",name:"Bartłomiej",middleName:null,surname:"Płaczek",slug:"bartlomiej-placzek",fullName:"Bartłomiej Płaczek",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/313277/images/system/313277.jpg",biography:"Bartłomiej Płaczek, MSc (2002), Ph.D. (2005), Habilitation (2016), is a professor at the University of Silesia, Institute of Computer Science, Poland, and an expert from the National Centre for Research and Development. His research interests include sensor networks, smart sensors, intelligent systems, and image processing with applications in healthcare and medicine. He is the author or co-author of more than seventy papers in peer-reviewed journals and conferences as well as the co-author of several books. He serves as a reviewer for many scientific journals, international conferences, and research foundations. Since 2010, Dr. Placzek has been a reviewer of grants and projects (including EU projects) in the field of information technologies.",institutionString:"University of Silesia",institution:{name:"University of Silesia",country:{name:"Poland"}}},{id:"35000",title:"Prof.",name:"Ulrich H.P",middleName:"H.P.",surname:"Fischer",slug:"ulrich-h.p-fischer",fullName:"Ulrich H.P Fischer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/35000/images/3052_n.jpg",biography:"Academic and Professional Background\nUlrich H. P. has Diploma and PhD degrees in Physics from the Free University Berlin, Germany. He has been working on research positions in the Heinrich-Hertz-Institute in Germany. Several international research projects has been performed with European partners from France, Netherlands, Norway and the UK. He is currently Professor of Communications Systems at the Harz University of Applied Sciences, Germany.\n\nPublications and Publishing\nHe has edited one book, a special interest book about ‘Optoelectronic Packaging’ (VDE, Berlin, Germany), and has published over 100 papers and is owner of several international patents for WDM over POF key elements.\n\nKey Research and Consulting Interests\nUlrich’s research activity has always been related to Spectroscopy and Optical Communications Technology. Specific current interests include the validation of complex instruments, and the application of VR technology to the development and testing of measurement systems. He has been reviewer for several publications of the Optical Society of America\\'s including Photonics Technology Letters and Applied Optics.\n\nPersonal Interests\nThese include motor cycling in a very relaxed manner and performing martial arts.",institutionString:null,institution:{name:"Charité",country:{name:"Germany"}}},{id:"341622",title:"Ph.D.",name:"Eduardo",middleName:null,surname:"Rojas Alvarez",slug:"eduardo-rojas-alvarez",fullName:"Eduardo Rojas Alvarez",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/341622/images/15892_n.jpg",biography:null,institutionString:null,institution:{name:"University of Cuenca",country:{name:"Ecuador"}}},{id:"215610",title:"Prof.",name:"Muhammad",middleName:null,surname:"Sarfraz",slug:"muhammad-sarfraz",fullName:"Muhammad Sarfraz",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/215610/images/system/215610.jpeg",biography:"Muhammad Sarfraz is a professor in the Department of Information Science, Kuwait University, Kuwait. His research interests include optimization, computer graphics, computer vision, image processing, machine learning, pattern recognition, soft computing, data science, and intelligent systems. Prof. Sarfraz has been a keynote/invited speaker at various platforms around the globe. He has advised/supervised more than 110 students for their MSc and Ph.D. theses. He has published more than 400 publications as books, journal articles, and conference papers. He has authored and/or edited around seventy books. Prof. Sarfraz is a member of various professional societies. He is a chair and member of international advisory committees and organizing committees of numerous international conferences. He is also an editor and editor in chief for various international journals.",institutionString:"Kuwait University",institution:{name:"Kuwait University",country:{name:"Kuwait"}}},{id:"32650",title:"Prof.",name:"Lukas",middleName:"Willem",surname:"Snyman",slug:"lukas-snyman",fullName:"Lukas Snyman",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/32650/images/4136_n.jpg",biography:"Lukas Willem Snyman received his basic education at primary and high schools in South Africa, Eastern Cape. He enrolled at today's Nelson Metropolitan University and graduated from this university with a BSc in Physics and Mathematics, B.Sc Honors in Physics, MSc in Semiconductor Physics, and a Ph.D. in Semiconductor Physics in 1987. After his studies, he chose an academic career and devoted his energy to the teaching of physics to first, second, and third-year students. After positions as a lecturer at the University of Port Elizabeth, he accepted a position as Associate Professor at the University of Pretoria, South Africa.\r\n\r\nIn 1992, he motivates the concept of 'television and computer-based education” as means to reach large student numbers with only the best of teaching expertise and publishes an article on the concept in the SA Journal of Higher Education of 1993 (and later in 2003). The University of Pretoria subsequently approved a series of test projects on the concept with outreach to Mamelodi and Eerste Rust in 1993. In 1994, the University established a 'Unit for Telematic Education ' as a support section for multiple faculties at the University of Pretoria. In subsequent years, the concept of 'telematic education” subsequently becomes well established in academic circles in South Africa, grew in popularity, and is adopted by many universities and colleges throughout South Africa as a medium of enhancing education and training, as a method to reaching out to far out communities, and as a means to enhance study from the home environment.\r\n\r\nProfessor Snyman in subsequent years pursued research in semiconductor physics, semiconductor devices, microelectronics, and optoelectronics.\r\n\r\nIn 2000 he joined the TUT as a full professor. Here served for a period as head of the Department of Electronic Engineering. Here he makes contributions to solar energy development, microwave and optoelectronic device development, silicon photonics, as well as contributions to new mobile telecommunication systems and network planning in SA.\r\n\r\nCurrently, he teaches electronics and telecommunications at the TUT to audiences ranging from first-year students to Ph.D. level.\r\n\r\nFor his research in the field of 'Silicon Photonics” since 1990, he has published (as author and co-author) about thirty internationally reviewed articles in scientific journals, contributed to more than forty international conferences, about 25 South African provisional patents (as inventor and co-inventor), 8 PCT international patent applications until now. Of these, two USA patents applications, two European Patents, two Korean patents, and ten SA patents have been granted. A further 4 USA patents, 5 European patents, 3 Korean patents, 3 Chinese patents, and 3 Japanese patents are currently under consideration.\r\n\r\nRecently he has also published an extensive scholarly chapter in an internet open access book on 'Integrating Microphotonic Systems and MOEMS into standard Silicon CMOS Integrated circuitry”.\r\n\r\nFurthermore, Professor Snyman recently steered a new initiative at the TUT by introducing a 'Laboratory for Innovative Electronic Systems ' at the Department of Electrical Engineering. The model of this laboratory or center is to primarily combine outputs as achieved by high-level research with lower-level system development and entrepreneurship in a technical university environment. Students are allocated to projects at different levels with PhDs and Master students allocated to the generation of new knowledge and new technologies, while students at the diploma and Baccalaureus level are allocated to electronic systems development with a direct and a near application for application in industry or the commercial and public sectors in South Africa.\r\n\r\nProfessor Snyman received the WIRSAM Award of 1983 and the WIRSAM Award in 1985 in South Africa for best research papers by a young scientist at two international conferences on electron microscopy in South Africa. He subsequently received the SA Microelectronics Award for the best dissertation emanating from studies executed at a South African university in the field of Physics and Microelectronics in South Africa in 1987. In October of 2011, Professor Snyman received the prestigious Institutional Award for 'Innovator of the Year” for 2010 at the Tshwane University of Technology, South Africa. This award was based on the number of patents recognized and granted by local and international institutions as well as for his contributions concerning innovation at the TUT.",institutionString:null,institution:{name:"University of South Africa",country:{name:"South Africa"}}},{id:"317279",title:"Mr.",name:"Ali",middleName:"Usama",surname:"Syed",slug:"ali-syed",fullName:"Ali Syed",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/317279/images/16024_n.png",biography:"A creative, talented, and innovative young professional who is dedicated, well organized, and capable research fellow with two years of experience in graduate-level research, published in engineering journals and book, with related expertise in Bio-robotics, equally passionate about the aesthetics of the mechanical and electronic system, obtained expertise in the use of MS Office, MATLAB, SolidWorks, LabVIEW, Proteus, Fusion 360, having a grasp on python, C++ and assembly language, possess proven ability in acquiring research grants, previous appointments with social and educational societies with experience in administration, current affiliations with IEEE and Web of Science, a confident presenter at conferences and teacher in classrooms, able to explain complex information to audiences of all levels.",institutionString:null,institution:{name:"Air University",country:{name:"Pakistan"}}},{id:"75526",title:"Ph.D.",name:"Zihni Onur",middleName:null,surname:"Uygun",slug:"zihni-onur-uygun",fullName:"Zihni Onur Uygun",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/75526/images/12_n.jpg",biography:"My undergraduate education and my Master of Science educations at Ege University and at Çanakkale Onsekiz Mart University have given me a firm foundation in Biochemistry, Analytical Chemistry, Biosensors, Bioelectronics, Physical Chemistry and Medicine. After obtaining my degree as a MSc in analytical chemistry, I started working as a research assistant in Ege University Medical Faculty in 2014. In parallel, I enrolled to the MSc program at the Department of Medical Biochemistry at Ege University to gain deeper knowledge on medical and biochemical sciences as well as clinical chemistry in 2014. In my PhD I deeply researched on biosensors and bioelectronics and finished in 2020. Now I have eleven SCI-Expanded Index published papers, 6 international book chapters, referee assignments for different SCIE journals, one international patent pending, several international awards, projects and bursaries. In parallel to my research assistant position at Ege University Medical Faculty, Department of Medical Biochemistry, in April 2016, I also founded a Start-Up Company (Denosens Biotechnology LTD) by the support of The Scientific and Technological Research Council of Turkey. Currently, I am also working as a CEO in Denosens Biotechnology. The main purposes of the company, which carries out R&D as a research center, are to develop new generation biosensors and sensors for both point-of-care diagnostics; such as glucose, lactate, cholesterol and cancer biomarker detections. My specific experimental and instrumental skills are Biochemistry, Biosensor, Analytical Chemistry, Electrochemistry, Mobile phone based point-of-care diagnostic device, POCTs and Patient interface designs, HPLC, Tandem Mass Spectrometry, Spectrophotometry, ELISA.",institutionString:null,institution:{name:"Ege University",country:{name:"Turkey"}}},{id:"246502",title:"Dr.",name:"Jaya T.",middleName:"T",surname:"Varkey",slug:"jaya-t.-varkey",fullName:"Jaya T. Varkey",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/246502/images/11160_n.jpg",biography:"Jaya T. Varkey, PhD, graduated with a degree in Chemistry from Cochin University of Science and Technology, Kerala, India. She obtained a PhD in Chemistry from the School of Chemical Sciences, Mahatma Gandhi University, Kerala, India, and completed a post-doctoral fellowship at the University of Minnesota, USA. She is a research guide at Mahatma Gandhi University and Associate Professor in Chemistry, St. Teresa’s College, Kochi, Kerala, India.\nDr. Varkey received a National Young Scientist award from the Indian Science Congress (1995), a UGC Research award (2016–2018), an Indian National Science Academy (INSA) Visiting Scientist award (2018–2019), and a Best Innovative Faculty award from the All India Association for Christian Higher Education (AIACHE) (2019). She Hashas received the Sr. Mary Cecil prize for best research paper three times. She was also awarded a start-up to develop a tea bag water filter. \nDr. Varkey has published two international books and twenty-seven international journal publications. She is an editorial board member for five international journals.",institutionString:"St. Teresa’s College",institution:null},{id:"250668",title:"Dr.",name:"Ali",middleName:null,surname:"Nabipour Chakoli",slug:"ali-nabipour-chakoli",fullName:"Ali Nabipour Chakoli",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/250668/images/system/250668.jpg",biography:"Academic Qualification:\r\n•\tPhD in Materials Physics and Chemistry, From: Sep. 2006, to: Sep. 2010, School of Materials Science and Engineering, Harbin Institute of Technology, Thesis: Structure and Shape Memory Effect of Functionalized MWCNTs/poly (L-lactide-co-ε-caprolactone) Nanocomposites. Supervisor: Prof. Wei Cai,\r\n•\tM.Sc in Applied Physics, From: 1996, to: 1998, Faculty of Physics & Nuclear Science, Amirkabir Uni. of Technology, Tehran, Iran, Thesis: Determination of Boron in Micro alloy Steels with solid state nuclear track detectors by neutron induced auto radiography, Supervisors: Dr. M. Hosseini Ashrafi and Dr. A. Hosseini.\r\n•\tB.Sc. in Applied Physics, From: 1991, to: 1996, Faculty of Physics & Nuclear Science, Amirkabir Uni. of Technology, Tehran, Iran, Thesis: Design of shielding for Am-Be neutron sources for In Vivo neutron activation analysis, Supervisor: Dr. M. Hosseini Ashrafi.\r\n\r\nResearch Experiences:\r\n1.\tNanomaterials, Carbon Nanotubes, Graphene: Synthesis, Functionalization and Characterization,\r\n2.\tMWCNTs/Polymer Composites: Fabrication and Characterization, \r\n3.\tShape Memory Polymers, Biodegradable Polymers, ORC, Collagen,\r\n4.\tMaterials Analysis and Characterizations: TEM, SEM, XPS, FT-IR, Raman, DSC, DMA, TGA, XRD, GPC, Fluoroscopy, \r\n5.\tInteraction of Radiation with Mater, Nuclear Safety and Security, NDT(RT),\r\n6.\tRadiation Detectors, Calibration (SSDL),\r\n7.\tCompleted IAEA e-learning Courses:\r\nNuclear Security (15 Modules),\r\nNuclear Safety:\r\nTSA 2: Regulatory Protection in Occupational Exposure,\r\nTips & Tricks: Radiation Protection in Radiography,\r\nSafety and Quality in Radiotherapy,\r\nCourse on Sealed Radioactive Sources,\r\nCourse on Fundamentals of Environmental Remediation,\r\nCourse on Planning for Environmental Remediation,\r\nKnowledge Management Orientation Course,\r\nFood Irradiation - Technology, Applications and Good Practices,\r\nEmployment:\r\nFrom 2010 to now: Academic staff, Nuclear Science and Technology Research Institute, Kargar Shomali, Tehran, Iran, P.O. Box: 14395-836.\r\nFrom 1997 to 2006: Expert of Materials Analysis and Characterization. Research Center of Agriculture and Medicine. Rajaeeshahr, Karaj, Iran, P. O. Box: 31585-498.",institutionString:"Atomic Energy Organization of Iran",institution:{name:"Atomic Energy Organization of Iran",country:{name:"Iran"}}},{id:"248279",title:"Dr.",name:"Monika",middleName:"Elzbieta",surname:"Machoy",slug:"monika-machoy",fullName:"Monika Machoy",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/248279/images/system/248279.jpeg",biography:"Monika Elżbieta Machoy, MD, graduated with distinction from the Faculty of Medicine and Dentistry at the Pomeranian Medical University in 2009, defended her PhD thesis with summa cum laude in 2016 and is currently employed as a researcher at the Department of Orthodontics of the Pomeranian Medical University. She expanded her professional knowledge during a one-year scholarship program at the Ernst Moritz Arndt University in Greifswald, Germany and during a three-year internship at the Technical University in Dresden, Germany. She has been a speaker at numerous orthodontic conferences, among others, American Association of Orthodontics, European Orthodontic Symposium and numerous conferences of the Polish Orthodontic Society. She conducts research focusing on the effect of orthodontic treatment on dental and periodontal tissues and the causes of pain in orthodontic patients.",institutionString:"Pomeranian Medical University",institution:{name:"Pomeranian Medical University",country:{name:"Poland"}}},{id:"252743",title:"Prof.",name:"Aswini",middleName:"Kumar",surname:"Kar",slug:"aswini-kar",fullName:"Aswini Kar",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/252743/images/10381_n.jpg",biography:"uploaded in cv",institutionString:null,institution:{name:"KIIT University",country:{name:"India"}}},{id:"204256",title:"Dr.",name:"Anil",middleName:"Kumar",surname:"Kumar Sahu",slug:"anil-kumar-sahu",fullName:"Anil Kumar Sahu",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/204256/images/14201_n.jpg",biography:"I have nearly 11 years of research and teaching experience. I have done my master degree from University Institute of Pharmacy, Pt. Ravi Shankar Shukla University, Raipur, Chhattisgarh India. I have published 16 review and research articles in international and national journals and published 4 chapters in IntechOpen, the world’s leading publisher of Open access books. I have presented many papers at national and international conferences. I have received research award from Indian Drug Manufacturers Association in year 2015. My research interest extends from novel lymphatic drug delivery systems, oral delivery system for herbal bioactive to formulation optimization.",institutionString:null,institution:{name:"Chhattisgarh Swami Vivekanand Technical University",country:{name:"India"}}},{id:"253468",title:"Dr.",name:"Mariusz",middleName:null,surname:"Marzec",slug:"mariusz-marzec",fullName:"Mariusz Marzec",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/253468/images/system/253468.png",biography:"An assistant professor at Department of Biomedical Computer Systems, at Institute of Computer Science, Silesian University in Katowice. Scientific interests: computer analysis and processing of images, biomedical images, databases and programming languages. He is an author and co-author of scientific publications covering analysis and processing of biomedical images and development of database systems.",institutionString:"University of Silesia",institution:null},{id:"212432",title:"Prof.",name:"Hadi",middleName:null,surname:"Mohammadi",slug:"hadi-mohammadi",fullName:"Hadi Mohammadi",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/212432/images/system/212432.jpeg",biography:"Dr. Hadi Mohammadi is a biomedical engineer with hands-on experience in the design and development of many engineering structures and medical devices through various projects that he has been involved in over the past twenty years. Dr. Mohammadi received his BSc. and MSc. degrees in Mechanical Engineering from Sharif University of Technology, Tehran, Iran, and his PhD. degree in Biomedical Engineering (biomaterials) from the University of Western Ontario. He was a postdoctoral trainee for almost four years at University of Calgary and Harvard Medical School. He is an industry innovator having created the technology to produce lifelike synthetic platforms that can be used for the simulation of almost all cardiovascular reconstructive surgeries. He’s been heavily involved in the design and development of cardiovascular devices and technology for the past 10 years. He is currently an Assistant Professor with the University of British Colombia, Canada.",institutionString:"University of British Columbia",institution:{name:"University of British Columbia",country:{name:"Canada"}}},{id:"254463",title:"Prof.",name:"Haisheng",middleName:null,surname:"Yang",slug:"haisheng-yang",fullName:"Haisheng Yang",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/254463/images/system/254463.jpeg",biography:"Haisheng Yang, Ph.D., Professor and Director of the Department of Biomedical Engineering, College of Life Science and Bioengineering, Beijing University of Technology. He received his Ph.D. degree in Mechanics/Biomechanics from Harbin Institute of Technology (jointly with University of California, Berkeley). Afterwards, he worked as a Postdoctoral Research Associate in the Purdue Musculoskeletal Biology and Mechanics Lab at the Department of Basic Medical Sciences, Purdue University, USA. He also conducted research in the Research Centre of Shriners Hospitals for Children-Canada at McGill University, Canada. Dr. Yang has over 10 years research experience in orthopaedic biomechanics and mechanobiology of bone adaptation and regeneration. He earned an award from Beijing Overseas Talents Aggregation program in 2017 and serves as Beijing Distinguished Professor.",institutionString:"Beijing University of Technology",institution:null},{id:"255757",title:"Dr.",name:"Igor",middleName:"Victorovich",surname:"Lakhno",slug:"igor-lakhno",fullName:"Igor Lakhno",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/255757/images/system/255757.jpg",biography:"Lakhno Igor Victorovich was born in 1971 in Kharkiv (Ukraine). \nMD – 1994, Kharkiv National Medical Univesity.\nOb&Gyn; – 1997, master courses in Kharkiv Medical Academy of Postgraduate Education.\nPhD – 1999, Kharkiv National Medical Univesity.\nDSc – 2019, PL Shupik National Academy of Postgraduate Education \nLakhno Igor has been graduated from an international training courses on reproductive medicine and family planning held in Debrecen University (Hungary) in 1997. Since 1998 Lakhno Igor has worked as an associate professor of the department of obstetrics and gynecology of VN Karazin National University and an associate professor of the perinatology, obstetrics and gynecology department of Kharkiv Medical Academy of Postgraduate Education. Since June 2019 he’s a professor of the department of obstetrics and gynecology of VN Karazin National University and a professor of the perinatology, obstetrics and gynecology department of Kharkiv Medical Academy of Postgraduate Education . He’s an author of about 200 printed works and there are 17 of them in Scopus or Web of Science databases. Lakhno Igor is a rewiever of Journal of Obstetrics and Gynaecology (Taylor and Francis), Informatics in Medicine Unlocked (Elsevier), The Journal of Obstetrics and Gynecology Research (Wiley), Endocrine, Metabolic & Immune Disorders-Drug Targets (Bentham Open), The Open Biomedical Engineering Journal (Bentham Open), etc. He’s defended a dissertation for DSc degree \\'Pre-eclampsia: prediction, prevention and treatment”. Lakhno Igor has participated as a speaker in several international conferences and congresses (International Conference on Biological Oscillations April 10th-14th 2016, Lancaster, UK, The 9th conference of the European Study Group on Cardiovascular Oscillations). His main scientific interests: obstetrics, women’s health, fetal medicine, cardiovascular medicine.",institutionString:"V.N. Karazin Kharkiv National University",institution:{name:"Kharkiv Medical Academy of Postgraduate Education",country:{name:"Ukraine"}}},{id:"89721",title:"Dr.",name:"Mehmet",middleName:"Cuneyt",surname:"Ozmen",slug:"mehmet-ozmen",fullName:"Mehmet Ozmen",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/89721/images/7289_n.jpg",biography:null,institutionString:null,institution:{name:"Gazi University",country:{name:"Turkey"}}},{id:"243698",title:"M.D.",name:"Xiaogang",middleName:null,surname:"Wang",slug:"xiaogang-wang",fullName:"Xiaogang Wang",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/243698/images/system/243698.png",biography:"Dr. Xiaogang Wang, a faculty member of Shanxi Eye Hospital specializing in the treatment of cataract and retinal disease and a tutor for postgraduate students of Shanxi Medical University, worked in the COOL Lab as an international visiting scholar under the supervision of Dr. David Huang and Yali Jia from October 2012 through November 2013. Dr. Wang earned an MD from Shanxi Medical University and a Ph.D. from Shanghai Jiao Tong University. Dr. Wang was awarded two research project grants focused on multimodal optical coherence tomography imaging and deep learning in cataract and retinal disease, from the National Natural Science Foundation of China. He has published around 30 peer-reviewed journal papers and four book chapters and co-edited one book.",institutionString:"Shanxi Eye Hospital",institution:{name:"Shanxi Eye Hospital",country:{name:"China"}}},{id:"242893",title:"Ph.D. Student",name:"Joaquim",middleName:null,surname:"De Moura",slug:"joaquim-de-moura",fullName:"Joaquim De Moura",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/242893/images/7133_n.jpg",biography:"Joaquim de Moura received his degree in Computer Engineering in 2014 from the University of A Coruña (Spain). In 2016, he received his M.Sc degree in Computer Engineering from the same university. He is currently pursuing his Ph.D degree in Computer Science in a collaborative project between ophthalmology centers in Galicia and the University of A Coruña. His research interests include computer vision, machine learning algorithms and analysis and medical imaging processing of various kinds.",institutionString:null,institution:{name:"University of A Coruña",country:{name:"Spain"}}},{id:"267434",title:"Dr.",name:"Rohit",middleName:null,surname:"Raja",slug:"rohit-raja",fullName:"Rohit Raja",position:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRZkkQAG/Profile_Picture_2022-05-09T12:55:18.jpg",biography:null,institutionString:null,institution:null},{id:"294334",title:"B.Sc.",name:"Marc",middleName:null,surname:"Bruggeman",slug:"marc-bruggeman",fullName:"Marc Bruggeman",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/294334/images/8242_n.jpg",biography:"Chemical engineer graduate, with a passion for material science and specific interest in polymers - their near infinite applications intrigue me. \n\nI plan to continue my scientific career in the field of polymeric biomaterials as I am fascinated by intelligent, bioactive and biomimetic materials for use in both consumer and medical applications.",institutionString:null,institution:null},{id:"244950",title:"Dr.",name:"Salvatore",middleName:null,surname:"Di Lauro",slug:"salvatore-di-lauro",fullName:"Salvatore Di Lauro",position:null,profilePictureURL:"https://intech-files.s3.amazonaws.com/0030O00002bSF1HQAW/ProfilePicture%202021-12-20%2014%3A54%3A14.482",biography:"Name:\n\tSALVATORE DI LAURO\nAddress:\n\tHospital Clínico Universitario Valladolid\nAvda Ramón y Cajal 3\n47005, Valladolid\nSpain\nPhone number: \nFax\nE-mail:\n\t+34 983420000 ext 292\n+34 983420084\nsadilauro@live.it\nDate and place of Birth:\nID Number\nMedical Licence \nLanguages\t09-05-1985. Villaricca (Italy)\n\nY1281863H\n474707061\nItalian (native language)\nSpanish (read, written, spoken)\nEnglish (read, written, spoken)\nPortuguese (read, spoken)\nFrench (read)\n\t\t\nCurrent position (title and company)\tDate (Year)\nVitreo-Retinal consultant in ophthalmology. Hospital Clinico Universitario Valladolid. Sacyl. National Health System.\nVitreo-Retinal consultant in ophthalmology. Instituto Oftalmologico Recoletas. Red Hospitalaria Recoletas. Private practise.\t2017-today\n\n2019-today\n\t\n\t\nEducation (High school, university and postgraduate training > 3 months)\tDate (Year)\nDegree in Medicine and Surgery. University of Neaples 'Federico II”\nResident in Opthalmology. Hospital Clinico Universitario Valladolid\nMaster in Vitreo-Retina. IOBA. University of Valladolid\nFellow of the European Board of Ophthalmology. Paris\nMaster in Research in Ophthalmology. University of Valladolid\t2003-2009\n2012-2016\n2016-2017\n2016\n2012-2013\n\t\nEmployments (company and positions)\tDate (Year)\nResident in Ophthalmology. Hospital Clinico Universitario Valladolid. Sacyl.\nFellow in Vitreo-Retina. IOBA. University of Valladolid\nVitreo-Retinal consultant in ophthalmology. Hospital Clinico Universitario Valladolid. Sacyl. National Health System.\nVitreo-Retinal consultant in ophthalmology. Instituto Oftalmologico Recoletas. Red Hospitalaria Recoletas. \n\t2012-2016\n2016-2017\n2017-today\n\n2019-Today\n\n\n\t\nClinical Research Experience (tasks and role)\tDate (Year)\nAssociated investigator\n\n' FIS PI20/00740: DESARROLLO DE UNA CALCULADORA DE RIESGO DE\nAPARICION DE RETINOPATIA DIABETICA BASADA EN TECNICAS DE IMAGEN MULTIMODAL EN PACIENTES DIABETICOS TIPO 1. Grant by: Ministerio de Ciencia e Innovacion \n\n' (BIO/VA23/14) Estudio clínico multicéntrico y prospectivo para validar dos\nbiomarcadores ubicados en los genes p53 y MDM2 en la predicción de los resultados funcionales de la cirugía del desprendimiento de retina regmatógeno. Grant by: Gerencia Regional de Salud de la Junta de Castilla y León.\n' Estudio multicéntrico, aleatorizado, con enmascaramiento doble, en 2 grupos\nparalelos y de 52 semanas de duración para comparar la eficacia, seguridad e inmunogenicidad de SOK583A1 respecto a Eylea® en pacientes con degeneración macular neovascular asociada a la edad' (CSOK583A12301; N.EUDRA: 2019-004838-41; FASE III). Grant by Hexal AG\n\n' Estudio de fase III, aleatorizado, doble ciego, con grupos paralelos, multicéntrico para comparar la eficacia y la seguridad de QL1205 frente a Lucentis® en pacientes con degeneración macular neovascular asociada a la edad. (EUDRACT: 2018-004486-13). Grant by Qilu Pharmaceutical Co\n\n' Estudio NEUTON: Ensayo clinico en fase IV para evaluar la eficacia de aflibercept en pacientes Naive con Edema MacUlar secundario a Oclusion de Vena CenTral de la Retina (OVCR) en regimen de tratamientO iNdividualizado Treat and Extend (TAE)”, (2014-000975-21). Grant by Fundacion Retinaplus\n\n' Evaluación de la seguridad y bioactividad de anillos de tensión capsular en conejo. Proyecto Procusens. Grant by AJL, S.A.\n\n'Estudio epidemiológico, prospectivo, multicéntrico y abierto\\npara valorar la frecuencia de la conjuntivitis adenovírica diagnosticada mediante el test AdenoPlus®\\nTest en pacientes enfermos de conjuntivitis aguda”\\n. National, multicenter study. Grant by: NICOX.\n\nEuropean multicentric trial: 'Evaluation of clinical outcomes following the use of Systane Hydration in patients with dry eye”. Study Phase 4. Grant by: Alcon Labs'\n\nVLPs Injection and Activation in a Rabbit Model of Uveal Melanoma. Grant by Aura Bioscience\n\nUpdating and characterization of a rabbit model of uveal melanoma. Grant by Aura Bioscience\n\nEnsayo clínico en fase IV para evaluar las variantes genéticas de la vía del VEGF como biomarcadores de eficacia del tratamiento con aflibercept en pacientes con degeneración macular asociada a la edad (DMAE) neovascular. Estudio BIOIMAGE. IMO-AFLI-2013-01\n\nEstudio In-Eye:Ensayo clínico en fase IV, abierto, aleatorizado, de 2 brazos,\nmulticçentrico y de 12 meses de duración, para evaluar la eficacia y seguridad de un régimen de PRN flexible individualizado de 'esperar y extender' versus un régimen PRN según criterios de estabilización mediante evaluaciones mensuales de inyecciones intravítreas de ranibizumab 0,5 mg en pacientes naive con neovascularización coriodea secunaria a la degeneración macular relacionada con la edad. CP: CRFB002AES03T\n\nTREND: Estudio Fase IIIb multicéntrico, randomizado, de 12 meses de\nseguimiento con evaluador de la agudeza visual enmascarado, para evaluar la eficacia y la seguridad de ranibizumab 0.5mg en un régimen de tratar y extender comparado con un régimen mensual, en pacientes con degeneración macular neovascular asociada a la edad. CP: CRFB002A2411 Código Eudra CT:\n2013-002626-23\n\n\n\nPublications\t\n\n2021\n\n\n\n\n2015\n\n\n\n\n2021\n\n\n\n\n\n2021\n\n\n\n\n2015\n\n\n\n\n2015\n\n\n2014\n\n\n\n\n2015-16\n\n\n\n2015\n\n\n2014\n\n\n2014\n\n\n\n\n2014\n\n\n\n\n\n\n\n2014\n\nJose Carlos Pastor; Jimena Rojas; Salvador Pastor-Idoate; Salvatore Di Lauro; Lucia Gonzalez-Buendia; Santiago Delgado-Tirado. Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical\nconsequences. Progress in Retinal and Eye Research. 51, pp. 125 - 155. 03/2016. DOI: 10.1016/j.preteyeres.2015.07.005\n\n\nLabrador-Velandia S; Alonso-Alonso ML; Di Lauro S; García-Gutierrez MT; Srivastava GK; Pastor JC; Fernandez-Bueno I. Mesenchymal stem cells provide paracrine neuroprotective resources that delay degeneration of co-cultured organotypic neuroretinal cultures.Experimental Eye Research. 185, 17/05/2019. DOI: 10.1016/j.exer.2019.05.011\n\nSalvatore Di Lauro; Maria Teresa Garcia Gutierrez; Ivan Fernandez Bueno. Quantification of pigment epithelium-derived factor (PEDF) in an ex vivo coculture of retinal pigment epithelium cells and neuroretina.\nJournal of Allbiosolution. 2019. ISSN 2605-3535\n\nSonia Labrador Velandia; Salvatore Di Lauro; Alonso-Alonso ML; Tabera Bartolomé S; Srivastava GK; Pastor JC; Fernandez-Bueno I. Biocompatibility of intravitreal injection of human mesenchymal stem cells in immunocompetent rabbits. Graefe's archive for clinical and experimental ophthalmology. 256 - 1, pp. 125 - 134. 01/2018. DOI: 10.1007/s00417-017-3842-3\n\n\nSalvatore Di Lauro, David Rodriguez-Crespo, Manuel J Gayoso, Maria T Garcia-Gutierrez, J Carlos Pastor, Girish K Srivastava, Ivan Fernandez-Bueno. A novel coculture model of porcine central neuroretina explants and retinal pigment epithelium cells. Molecular Vision. 2016 - 22, pp. 243 - 253. 01/2016.\n\nSalvatore Di Lauro. Classifications for Proliferative Vitreoretinopathy ({PVR}): An Analysis of Their Use in Publications over the Last 15 Years. Journal of Ophthalmology. 2016, pp. 1 - 6. 01/2016. DOI: 10.1155/2016/7807596\n\nSalvatore Di Lauro; Rosa Maria Coco; Rosa Maria Sanabria; Enrique Rodriguez de la Rua; Jose Carlos Pastor. Loss of Visual Acuity after Successful Surgery for Macula-On Rhegmatogenous Retinal Detachment in a Prospective Multicentre Study. Journal of Ophthalmology. 2015:821864, 2015. DOI: 10.1155/2015/821864\n\nIvan Fernandez-Bueno; Salvatore Di Lauro; Ivan Alvarez; Jose Carlos Lopez; Maria Teresa Garcia-Gutierrez; Itziar Fernandez; Eva Larra; Jose Carlos Pastor. Safety and Biocompatibility of a New High-Density Polyethylene-Based\nSpherical Integrated Porous Orbital Implant: An Experimental Study in Rabbits. Journal of Ophthalmology. 2015:904096, 2015. DOI: 10.1155/2015/904096\n\nPastor JC; Pastor-Idoate S; Rodríguez-Hernandez I; Rojas J; Fernandez I; Gonzalez-Buendia L; Di Lauro S; Gonzalez-Sarmiento R. Genetics of PVR and RD. Ophthalmologica. 232 - Suppl 1, pp. 28 - 29. 2014\n\nRodriguez-Crespo D; Di Lauro S; Singh AK; Garcia-Gutierrez MT; Garrosa M; Pastor JC; Fernandez-Bueno I; Srivastava GK. Triple-layered mixed co-culture model of RPE cells with neuroretina for evaluating the neuroprotective effects of adipose-MSCs. Cell Tissue Res. 358 - 3, pp. 705 - 716. 2014.\nDOI: 10.1007/s00441-014-1987-5\n\nCarlo De Werra; Salvatore Condurro; Salvatore Tramontano; Mario Perone; Ivana Donzelli; Salvatore Di Lauro; Massimo Di Giuseppe; Rosa Di Micco; Annalisa Pascariello; Antonio Pastore; Giorgio Diamantis; Giuseppe Galloro. Hydatid disease of the liver: thirty years of surgical experience.Chirurgia italiana. 59 - 5, pp. 611 - 636.\n(Italia): 2007. ISSN 0009-4773\n\nChapters in books\n\t\n' Salvador Pastor Idoate; Salvatore Di Lauro; Jose Carlos Pastor Jimeno. PVR: Pathogenesis, Histopathology and Classification. Proliferative Vitreoretinopathy with Small Gauge Vitrectomy. Springer, 2018. ISBN 978-3-319-78445-8\nDOI: 10.1007/978-3-319-78446-5_2. \n\n' Salvatore Di Lauro; Maria Isabel Lopez Galvez. Quistes vítreos en una mujer joven. Problemas diagnósticos en patología retinocoroidea. Sociedad Española de Retina-Vitreo. 2018.\n\n' Salvatore Di Lauro; Salvador Pastor Idoate; Jose Carlos Pastor Jimeno. iOCT in PVR management. OCT Applications in Opthalmology. pp. 1 - 8. INTECH, 2018. DOI: 10.5772/intechopen.78774.\n\n' Rosa Coco Martin; Salvatore Di Lauro; Salvador Pastor Idoate; Jose Carlos Pastor. amponadores, manipuladores y tinciones en la cirugía del traumatismo ocular.Trauma Ocular. Ponencia de la SEO 2018..\n\n' LOPEZ GALVEZ; DI LAURO; CRESPO. OCT angiografia y complicaciones retinianas de la diabetes. PONENCIA SEO 2021, CAPITULO 20. (España): 2021.\n\n' Múltiples desprendimientos neurosensoriales bilaterales en paciente joven. Enfermedades Degenerativas De Retina Y Coroides. SERV 04/2016. \n' González-Buendía L; Di Lauro S; Pastor-Idoate S; Pastor Jimeno JC. Vitreorretinopatía proliferante (VRP) e inflamación: LA INFLAMACIÓN in «INMUNOMODULADORES Y ANTIINFLAMATORIOS: MÁS ALLÁ DE LOS CORTICOIDES. RELACION DE PONENCIAS DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGIA. 10/2014.",institutionString:null,institution:null},{id:"265335",title:"Mr.",name:"Stefan",middleName:"Radnev",surname:"Stefanov",slug:"stefan-stefanov",fullName:"Stefan Stefanov",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/265335/images/7562_n.jpg",biography:null,institutionString:null,institution:null},{id:"318905",title:"Prof.",name:"Elvis",middleName:"Kwason",surname:"Tiburu",slug:"elvis-tiburu",fullName:"Elvis Tiburu",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Ghana",country:{name:"Ghana"}}},{id:"336193",title:"Dr.",name:"Abdullah",middleName:null,surname:"Alamoudi",slug:"abdullah-alamoudi",fullName:"Abdullah Alamoudi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Majmaah University",country:{name:"Saudi Arabia"}}},{id:"318657",title:"MSc.",name:"Isabell",middleName:null,surname:"Steuding",slug:"isabell-steuding",fullName:"Isabell Steuding",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Harz University of Applied Sciences",country:{name:"Germany"}}},{id:"318656",title:"BSc.",name:"Peter",middleName:null,surname:"Kußmann",slug:"peter-kussmann",fullName:"Peter Kußmann",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Harz University of Applied Sciences",country:{name:"Germany"}}},{id:"338222",title:"Mrs.",name:"María José",middleName:null,surname:"Lucía Mudas",slug:"maria-jose-lucia-mudas",fullName:"María José Lucía Mudas",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Carlos III University of Madrid",country:{name:"Spain"}}},{id:"147824",title:"Mr.",name:"Pablo",middleName:null,surname:"Revuelta Sanz",slug:"pablo-revuelta-sanz",fullName:"Pablo Revuelta Sanz",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Carlos III University of Madrid",country:{name:"Spain"}}}]}},subseries:{item:{id:"38",type:"subseries",title:"Pollution",keywords:"Human activity, Pollutants, Reduced risks, Population growth, Waste disposal, Remediation, Clean environment",scope:"\r\n\tPollution is caused by a wide variety of human activities and occurs in diverse forms, for example biological, chemical, et cetera. In recent years, significant efforts have been made to ensure that the environment is clean, that rigorous rules are implemented, and old laws are updated to reduce the risks towards humans and ecosystems. However, rapid industrialization and the need for more cultivable sources or habitable lands, for an increasing population, as well as fewer alternatives for waste disposal, make the pollution control tasks more challenging. Therefore, this topic will focus on assessing and managing environmental pollution. It will cover various subjects, including risk assessment due to the pollution of ecosystems, transport and fate of pollutants, restoration or remediation of polluted matrices, and efforts towards sustainable solutions to minimize environmental pollution.
",coverUrl:"https://cdn.intechopen.com/series_topics/covers/38.jpg",hasOnlineFirst:!1,hasPublishedBooks:!0,annualVolume:11966,editor:{id:"110740",title:"Dr.",name:"Ismail M.M.",middleName:null,surname:"Rahman",slug:"ismail-m.m.-rahman",fullName:"Ismail M.M. Rahman",profilePictureURL:"https://mts.intechopen.com/storage/users/110740/images/2319_n.jpg",biography:"Ismail Md. Mofizur Rahman (Ismail M. M. Rahman) assumed his current responsibilities as an Associate Professor at the Institute of Environmental Radioactivity, Fukushima University, Japan, in Oct 2015. He also has an honorary appointment to serve as a Collaborative Professor at Kanazawa University, Japan, from Mar 2015 to the present. \nFormerly, Dr. Rahman was a faculty member of the University of Chittagong, Bangladesh, affiliated with the Department of Chemistry (Oct 2002 to Mar 2012) and the Department of Applied Chemistry and Chemical Engineering (Mar 2012 to Sep 2015). Dr. Rahman was also adjunctly attached with Kanazawa University, Japan (Visiting Research Professor, Dec 2014 to Mar 2015; JSPS Postdoctoral Research Fellow, Apr 2012 to Mar 2014), and Tokyo Institute of Technology, Japan (TokyoTech-UNESCO Research Fellow, Oct 2004–Sep 2005). \nHe received his Ph.D. degree in Environmental Analytical Chemistry from Kanazawa University, Japan (2011). He also achieved a Diploma in Environment from the Tokyo Institute of Technology, Japan (2005). Besides, he has an M.Sc. degree in Applied Chemistry and a B.Sc. degree in Chemistry, all from the University of Chittagong, Bangladesh. \nDr. Rahman’s research interest includes the study of the fate and behavior of environmental pollutants in the biosphere; design of low energy and low burden environmental improvement (remediation) technology; implementation of sustainable waste management practices for treatment, handling, reuse, and ultimate residual disposition of solid wastes; nature and type of interactions in organic liquid mixtures for process engineering design applications.",institutionString:null,institution:{name:"Fukushima University",institutionURL:null,country:{name:"Japan"}}},editorTwo:{id:"201020",title:"Dr.",name:"Zinnat Ara",middleName:null,surname:"Begum",slug:"zinnat-ara-begum",fullName:"Zinnat Ara Begum",profilePictureURL:"https://mts.intechopen.com/storage/users/201020/images/system/201020.jpeg",biography:"Zinnat A. Begum received her Ph.D. in Environmental Analytical Chemistry from Kanazawa University in 2012. She achieved her Master of Science (M.Sc.) degree with a major in Applied Chemistry and a Bachelor of Science (B.Sc.) in Chemistry, all from the University of Chittagong, Bangladesh. Her work affiliations include Fukushima University, Japan (Visiting Research Fellow, Institute of Environmental Radioactivity: Mar 2016 to present), Southern University Bangladesh (Assistant Professor, Department of Civil Engineering: Jan 2015 to present), and Kanazawa University, Japan (Postdoctoral Fellow, Institute of Science and Engineering: Oct 2012 to Mar 2014; Research fellow, Venture Business Laboratory, Advanced Science and Social Co-Creation Promotion Organization: Apr 2018 to Mar 2021). The research focus of Dr. Zinnat includes the effect of the relative stability of metal-chelator complexes in the environmental remediation process designs and the development of eco-friendly soil washing techniques using biodegradable chelators.",institutionString:null,institution:{name:"Fukushima University",institutionURL:null,country:{name:"Japan"}}},editorThree:null,series:{id:"25",title:"Environmental Sciences",doi:"10.5772/intechopen.100362",issn:"2754-6713"},editorialBoard:[{id:"63465",title:"Prof.",name:"Mohamed Nageeb",middleName:null,surname:"Rashed",slug:"mohamed-nageeb-rashed",fullName:"Mohamed Nageeb Rashed",profilePictureURL:"https://mts.intechopen.com/storage/users/63465/images/system/63465.gif",institutionString:null,institution:{name:"Aswan University",institutionURL:null,country:{name:"Egypt"}}},{id:"187907",title:"Dr.",name:"Olga",middleName:null,surname:"Anne",slug:"olga-anne",fullName:"Olga Anne",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bSBE5QAO/Profile_Picture_2022-04-07T09:42:13.png",institutionString:null,institution:{name:"Klaipeda State University of Applied Sciences",institutionURL:null,country:{name:"Lithuania"}}}]},onlineFirstChapters:{paginationCount:9,paginationItems:[{id:"81493",title:"Rust Disease Classification Using Deep Learning Based Algorithm: The Case of Wheat",doi:"10.5772/intechopen.104426",signatures:"Shivani Sood, Harjeet Singh and Suruchi Jindal",slug:"rust-disease-classification-using-deep-learning-based-algorithm-the-case-of-wheat",totalDownloads:35,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"81428",title:"Observatory of Sustainable Development in Postgraduate Study Programs in Baja California",doi:"10.5772/intechopen.104641",signatures:"Rodolfo Martinez-Gutierrez, Maria Marcela Solis-Quinteros, Maria Esther Ibarra-Estrada and Angel Ernesto Jimenez-Bernardino",slug:"observatory-of-sustainable-development-in-postgraduate-study-programs-in-baja-california",totalDownloads:8,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Globalization and Sustainability - Recent Advances, New Perspectives and Emerging Issues",coverURL:"https://cdn.intechopen.com/books/images_new/11476.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"81235",title:"Global Food System Transformation for Resilience",doi:"10.5772/intechopen.102749",signatures:"Jasper Okoro Godwin Elechi, Ikechukwu U. Nwiyi and Cornelius Smah Adamu",slug:"global-food-system-transformation-for-resilience",totalDownloads:30,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"80749",title:"Analysis of the Nexus Between Coping Strategies and Resilience to Food Insecurity Shocks: The Case of Rural Households in Boricha Woreda, Sidama National Regional State, Ethiopia",doi:"10.5772/intechopen.102613",signatures:"Adane Atara Debessa, Degefa Tolossa and Berhanu Denu",slug:"analysis-of-the-nexus-between-coping-strategies-and-resilience-to-food-insecurity-shocks-the-case-of",totalDownloads:45,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"80753",title:"Toward Safe Food Systems: Analyses of Mycotoxin Contaminants in Food and Preventive Strategies Thereof for Their Formation and Toxicity",doi:"10.5772/intechopen.101461",signatures:"Dikabo Mogopodi, Mesha Mbisana, Samuel Raditloko, Inonge Chibua and Banyaladzi Paphane",slug:"toward-safe-food-systems-analyses-of-mycotoxin-contaminants-in-food-and-preventive-strategies-thereo",totalDownloads:57,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"80388",title:"Social Resilience in Local Food Systems: A Foundation for Food Security during a Crisis",doi:"10.5772/intechopen.101998",signatures:"Tanya Zerbian, Mags Adams and Neil Wilson",slug:"social-resilience-in-local-food-systems-a-foundation-for-food-security-during-a-crisis",totalDownloads:52,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"80098",title:"Bundling Weather Index Insurance with Microfinance: Trekking the Long Road between Expectations and Reality. A Study on Sub-Saharan Africa",doi:"10.5772/intechopen.101742",signatures:"Dorcas Stella Shumba",slug:"bundling-weather-index-insurance-with-microfinance-trekking-the-long-road-between-expectations-and-r",totalDownloads:67,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"79696",title:"How to Build Food Safety Resilience in Commercial Restaurants?",doi:"10.5772/intechopen.101481",signatures:"Rayane Stephanie Gomes De Freitas and Elke Stedefeldt",slug:"how-to-build-food-safety-resilience-in-commercial-restaurants",totalDownloads:107,totalCrossrefCites:1,totalDimensionsCites:1,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}},{id:"79604",title:"Perspective Chapter: Food System Resilience - Towards a Joint Understanding and Implications for Policy",doi:"10.5772/intechopen.99899",signatures:"Bart de Steenhuijsen Piters, Emma Termeer, Deborah Bakker, Hubert Fonteijn and Herman Brouwer",slug:"perspective-chapter-food-system-resilience-towards-a-joint-understanding-and-implications-for-policy",totalDownloads:121,totalCrossrefCites:1,totalDimensionsCites:2,authors:null,book:{title:"Food Systems Resilience",coverURL:"https://cdn.intechopen.com/books/images_new/10897.jpg",subseries:{id:"91",title:"Sustainable Economy and Fair Society"}}}]},publishedBooks:{paginationCount:10,paginationItems:[{type:"book",id:"10799",title:"Phenolic Compounds",subtitle:"Chemistry, Synthesis, Diversity, Non-Conventional Industrial, Pharmaceutical and Therapeutic Applications",coverURL:"https://cdn.intechopen.com/books/images_new/10799.jpg",slug:"phenolic-compounds-chemistry-synthesis-diversity-non-conventional-industrial-pharmaceutical-and-therapeutic-applications",publishedDate:"February 23rd 2022",editedByType:"Edited by",bookSignature:"Farid A. Badria",hash:"339199f254d2987ef3167eef74fb8a38",volumeInSeries:26,fullTitle:"Phenolic Compounds - Chemistry, Synthesis, Diversity, Non-Conventional Industrial, Pharmaceutical and Therapeutic Applications",editors:[{id:"41865",title:"Prof.",name:"Farid A.",middleName:null,surname:"Badria",slug:"farid-a.-badria",fullName:"Farid A. Badria",profilePictureURL:"https://mts.intechopen.com/storage/users/41865/images/system/41865.jpg",institutionString:"Mansoura University",institution:{name:"Mansoura University",institutionURL:null,country:{name:"Egypt"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9753",title:"Terpenes and Terpenoids",subtitle:"Recent Advances",coverURL:"https://cdn.intechopen.com/books/images_new/9753.jpg",slug:"terpenes-and-terpenoids-recent-advances",publishedDate:"July 28th 2021",editedByType:"Edited by",bookSignature:"Shagufta Perveen and Areej Mohammad Al-Taweel",hash:"575689df13c78bf0e6c1be40804cd010",volumeInSeries:21,fullTitle:"Terpenes and Terpenoids - Recent Advances",editors:[{id:"192992",title:"Prof.",name:"Shagufta",middleName:null,surname:"Perveen",slug:"shagufta-perveen",fullName:"Shagufta Perveen",profilePictureURL:"https://mts.intechopen.com/storage/users/192992/images/system/192992.png",institutionString:"King Saud University",institution:{name:"King Saud University",institutionURL:null,country:{name:"Saudi Arabia"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9731",title:"Oxidoreductase",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/9731.jpg",slug:"oxidoreductase",publishedDate:"February 17th 2021",editedByType:"Edited by",bookSignature:"Mahmoud Ahmed Mansour",hash:"852e6f862c85fc3adecdbaf822e64e6e",volumeInSeries:19,fullTitle:"Oxidoreductase",editors:[{id:"224662",title:"Prof.",name:"Mahmoud Ahmed",middleName:null,surname:"Mansour",slug:"mahmoud-ahmed-mansour",fullName:"Mahmoud Ahmed Mansour",profilePictureURL:"https://mts.intechopen.com/storage/users/224662/images/system/224662.jpg",institutionString:"King Saud bin Abdulaziz University for Health Sciences",institution:{name:"King Saud bin Abdulaziz University for Health Sciences",institutionURL:null,country:{name:"Saudi Arabia"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8094",title:"Aflatoxin B1 Occurrence, Detection and Toxicological Effects",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/8094.jpg",slug:"aflatoxin-b1-occurrence-detection-and-toxicological-effects",publishedDate:"June 3rd 2020",editedByType:"Edited by",bookSignature:"Xi-Dai Long",hash:"44f4ad52d8a8cbb22ef3d505d6b18027",volumeInSeries:14,fullTitle:"Aflatoxin B1 Occurrence, Detection and Toxicological Effects",editors:[{id:"202142",title:"Prof.",name:"Xi-Dai",middleName:null,surname:"Long",slug:"xi-dai-long",fullName:"Xi-Dai Long",profilePictureURL:"https://mts.intechopen.com/storage/users/202142/images/system/202142.jpeg",institutionString:"Youjiang Medical University for Nationalities",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8004",title:"Nitrogen Fixation",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/8004.jpg",slug:"nitrogen-fixation",publishedDate:"April 8th 2020",editedByType:"Edited by",bookSignature:"Everlon Cid Rigobelo and Ademar Pereira Serra",hash:"02f39c8365ba155d1c520184c2f26976",volumeInSeries:11,fullTitle:"Nitrogen Fixation",editors:[{id:"39553",title:"Prof.",name:"Everlon",middleName:"Cid",surname:"Rigobelo",slug:"everlon-rigobelo",fullName:"Everlon Rigobelo",profilePictureURL:"https://mts.intechopen.com/storage/users/39553/images/system/39553.jpg",institutionString:"São Paulo State University",institution:{name:"Sao Paulo State University",institutionURL:null,country:{name:"Brazil"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8028",title:"Flavonoids",subtitle:"A Coloring Model for Cheering up Life",coverURL:"https://cdn.intechopen.com/books/images_new/8028.jpg",slug:"flavonoids-a-coloring-model-for-cheering-up-life",publishedDate:"March 11th 2020",editedByType:"Edited by",bookSignature:"Farid A. Badria and Anthony Ananga",hash:"6c33178a5c7d2b276d2c6af4255def64",volumeInSeries:10,fullTitle:"Flavonoids - A Coloring Model for Cheering up Life",editors:[{id:"41865",title:"Prof.",name:"Farid A.",middleName:null,surname:"Badria",slug:"farid-a.-badria",fullName:"Farid A. Badria",profilePictureURL:"https://mts.intechopen.com/storage/users/41865/images/system/41865.jpg",institutionString:"Mansoura University",institution:{name:"Mansoura University",institutionURL:null,country:{name:"Egypt"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8170",title:"Chemical Properties of Starch",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/8170.jpg",slug:"chemical-properties-of-starch",publishedDate:"March 11th 2020",editedByType:"Edited by",bookSignature:"Martins Emeje",hash:"0aedfdb374631bb3a33870c4ed16559a",volumeInSeries:9,fullTitle:"Chemical Properties of Starch",editors:[{id:"94311",title:"Prof.",name:"Martins",middleName:"Ochubiojo",surname:"Emeje",slug:"martins-emeje",fullName:"Martins Emeje",profilePictureURL:"https://mts.intechopen.com/storage/users/94311/images/system/94311.jpeg",institutionString:"National Institute for Pharmaceutical Research and Development",institution:{name:"National Institute for Pharmaceutical Research and Development",institutionURL:null,country:{name:"Nigeria"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8019",title:"Alginates",subtitle:"Recent Uses of This Natural Polymer",coverURL:"https://cdn.intechopen.com/books/images_new/8019.jpg",slug:"alginates-recent-uses-of-this-natural-polymer",publishedDate:"February 5th 2020",editedByType:"Edited by",bookSignature:"Leonel Pereira",hash:"61ea5c1aef462684a3b2215631b7dbf2",volumeInSeries:7,fullTitle:"Alginates - Recent Uses of This Natural Polymer",editors:[{id:"279788",title:"Dr.",name:"Leonel",middleName:null,surname:"Pereira",slug:"leonel-pereira",fullName:"Leonel Pereira",profilePictureURL:"https://mts.intechopen.com/storage/users/279788/images/system/279788.jpg",institutionString:"University of Coimbra",institution:{name:"University of Coimbra",institutionURL:null,country:{name:"Portugal"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8504",title:"Pectins",subtitle:"Extraction, Purification, Characterization and Applications",coverURL:"https://cdn.intechopen.com/books/images_new/8504.jpg",slug:"pectins-extraction-purification-characterization-and-applications",publishedDate:"January 22nd 2020",editedByType:"Edited by",bookSignature:"Martin Masuelli",hash:"ff1acef627b277c575a10b3259dd331b",volumeInSeries:6,fullTitle:"Pectins - Extraction, Purification, Characterization and Applications",editors:[{id:"99994",title:"Dr.",name:"Martin",middleName:"Alberto",surname:"Masuelli",slug:"martin-masuelli",fullName:"Martin Masuelli",profilePictureURL:"https://mts.intechopen.com/storage/users/99994/images/system/99994.jpg",institutionString:"National University of San Luis",institution:{name:"National University of San Luis",institutionURL:null,country:{name:"Argentina"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"7953",title:"Bioluminescence",subtitle:"Analytical Applications and Basic Biology",coverURL:"https://cdn.intechopen.com/books/images_new/7953.jpg",slug:"bioluminescence-analytical-applications-and-basic-biology",publishedDate:"September 25th 2019",editedByType:"Edited by",bookSignature:"Hirobumi Suzuki",hash:"3a8efa00b71abea11bf01973dc589979",volumeInSeries:4,fullTitle:"Bioluminescence - Analytical Applications and Basic Biology",editors:[{id:"185746",title:"Dr.",name:"Hirobumi",middleName:null,surname:"Suzuki",slug:"hirobumi-suzuki",fullName:"Hirobumi Suzuki",profilePictureURL:"https://mts.intechopen.com/storage/users/185746/images/system/185746.png",institutionString:"Kogakuin University",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},testimonialsList:[{id:"27",text:"The opportunity to work with a prestigious publisher allows for the possibility to collaborate with more research groups interested in animal nutrition, leading to the development of new feeding strategies and food valuation while being more sustainable with the environment, allowing more readers to learn about the subject.",author:{id:"175967",name:"Manuel",surname:"Gonzalez Ronquillo",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/175967/images/system/175967.png",slug:"manuel-gonzalez-ronquillo",institution:{id:"6221",name:"Universidad Autónoma del Estado de México",country:{id:null,name:"Mexico"}}}},{id:"18",text:"It was great publishing with IntechOpen, the process was straightforward and I had support all along.",author:{id:"71579",name:"Berend",surname:"Olivier",institutionString:"Utrecht University",profilePictureURL:"https://mts.intechopen.com/storage/users/71579/images/system/71579.jpg",slug:"berend-olivier",institution:{id:"253",name:"Utrecht University",country:{id:null,name:"Netherlands"}}}},{id:"8",text:"I work with IntechOpen for a number of reasons: their professionalism, their mission in support of Open Access publishing, and the quality of their peer-reviewed publications, but also because they believe in equality.",author:{id:"202192",name:"Catrin",surname:"Rutland",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/202192/images/system/202192.png",slug:"catrin-rutland",institution:{id:"134",name:"University of Nottingham",country:{id:null,name:"United Kingdom"}}}}]},submityourwork:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:8,numberOfPublishedChapters:87,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:98,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:27,numberOfPublishedChapters:286,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:9,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:11,numberOfPublishedChapters:139,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:8,numberOfPublishedChapters:129,numberOfOpenTopics:0,numberOfUpcomingTopics:2,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!1},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:105,numberOfOpenTopics:3,numberOfUpcomingTopics:1,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:9,numberOfPublishedChapters:101,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:11,numberOfOpenTopics:2,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:0,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!1},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:0,numberOfPublishedChapters:9,numberOfOpenTopics:4,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],subseriesList:[{id:"4",title:"Fungal Infectious Diseases",scope:"Fungi are ubiquitous and there are almost no non-pathogenic fungi. Fungal infectious illness prevalence and prognosis are determined by the exposure between fungi and host, host immunological state, fungal virulence, and early and accurate diagnosis and treatment. \r\nPatients with both congenital and acquired immunodeficiency are more likely to be infected with opportunistic mycosis. Fungal infectious disease outbreaks are common during the post- disaster rebuilding era, which is characterised by high population density, migration, and poor health and medical conditions.\r\nSystemic or local fungal infection is mainly associated with the fungi directly inhaled or inoculated in the environment during the disaster. The most common fungal infection pathways are human to human (anthropophilic), animal to human (zoophilic), and environment to human (soilophile). Diseases are common as a result of widespread exposure to pathogenic fungus dispersed into the environment. \r\nFungi that are both common and emerging are intertwined. In Southeast Asia, for example, Talaromyces marneffei is an important pathogenic thermally dimorphic fungus that causes systemic mycosis. Widespread fungal infections with complicated and variable clinical manifestations, such as Candida auris infection resistant to several antifungal medicines, Covid-19 associated with Trichoderma, and terbinafine resistant dermatophytosis in India, are among the most serious disorders. \r\nInappropriate local or systemic use of glucocorticoids, as well as their immunosuppressive effects, may lead to changes in fungal infection spectrum and clinical characteristics. Hematogenous candidiasis is a worrisome issue that affects people all over the world, particularly ICU patients. CARD9 deficiency and fungal infection have been major issues in recent years. Invasive aspergillosis is associated with a significant death rate. Special attention should be given to endemic fungal infections, identification of important clinical fungal infections advanced in yeasts, filamentous fungal infections, skin mycobiome and fungal genomes, and immunity to fungal infections.\r\nIn addition, endemic fungal diseases or uncommon fungal infections caused by Mucor irregularis, dermatophytosis, Malassezia, cryptococcosis, chromoblastomycosis, coccidiosis, blastomycosis, histoplasmosis, sporotrichosis, and other fungi, should be monitored. \r\nThis topic includes the research progress on the etiology and pathogenesis of fungal infections, new methods of isolation and identification, rapid detection, drug sensitivity testing, new antifungal drugs, schemes and case series reports. It will provide significant opportunities and support for scientists, clinical doctors, mycologists, antifungal drug researchers, public health practitioners, and epidemiologists from all over the world to share new research, ideas and solutions to promote the development and progress of medical mycology.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/4.jpg",keywords:"Emerging Fungal Pathogens, Invasive Infections, Epidemiology, Cell Membrane, Fungal Virulence, Diagnosis, Treatment"},{id:"5",title:"Parasitic Infectious Diseases",scope:"Parasitic diseases have evolved alongside their human hosts. In many cases, these diseases have adapted so well that they have developed efficient resilience methods in the human host and can live in the host for years. Others, particularly some blood parasites, can cause very acute diseases and are responsible for millions of deaths yearly. Many parasitic diseases are classified as neglected tropical diseases because they have received minimal funding over recent years and, in many cases, are under-reported despite the critical role they play in morbidity and mortality among human and animal hosts. The current topic, Parasitic Infectious Diseases, in the Infectious Diseases Series aims to publish studies on the systematics, epidemiology, molecular biology, genomics, pathogenesis, genetics, and clinical significance of parasitic diseases from blood borne to intestinal parasites as well as zoonotic parasites. We hope to cover all aspects of parasitic diseases to provide current and relevant research data on these very important diseases. In the current atmosphere of the Coronavirus pandemic, communities around the world, particularly those in different underdeveloped areas, are faced with the growing challenges of the high burden of parasitic diseases. At the same time, they are faced with the Covid-19 pandemic leading to what some authors have called potential syndemics that might worsen the outcome of such infections. Therefore, it is important to conduct studies that examine parasitic infections in the context of the coronavirus pandemic for the benefit of all communities to help foster more informed decisions for the betterment of human and animal health.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/5.jpg",keywords:"Blood Borne Parasites, Intestinal Parasites, Protozoa, Helminths, Arthropods, Water Born Parasites, Epidemiology, Molecular Biology, Systematics, Genomics, Proteomics, Ecology"},{id:"6",title:"Viral Infectious Diseases",scope:"The Viral Infectious Diseases Book Series aims to provide a comprehensive overview of recent research trends and discoveries in various viral infectious diseases emerging around the globe. The emergence of any viral disease is hard to anticipate, which often contributes to death. A viral disease can be defined as an infectious disease that has recently appeared within a population or exists in nature with the rapid expansion of incident or geographic range. This series will focus on various crucial factors related to emerging viral infectious diseases, including epidemiology, pathogenesis, host immune response, clinical manifestations, diagnosis, treatment, and clinical recommendations for managing viral infectious diseases, highlighting the recent issues with future directions for effective therapeutic strategies.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/6.jpg",keywords:"Novel Viruses, Virus Transmission, Virus Evolution, Molecular Virology, Control and Prevention, Virus-host Interaction"}],annualVolumeBook:{},thematicCollection:[],selectedSeries:null,selectedSubseries:null},seriesLanding:{item:{id:"14",title:"Artificial Intelligence",doi:"10.5772/intechopen.79920",issn:"2633-1403",scope:"Artificial Intelligence (AI) is a rapidly developing multidisciplinary research area that aims to solve increasingly complex problems. In today's highly integrated world, AI promises to become a robust and powerful means for obtaining solutions to previously unsolvable problems. This Series is intended for researchers and students alike interested in this fascinating field and its many applications.",coverUrl:"https://cdn.intechopen.com/series/covers/14.jpg",latestPublicationDate:"May 9th, 2022",hasOnlineFirst:!0,numberOfOpenTopics:6,numberOfPublishedChapters:86,numberOfPublishedBooks:8,editor:{id:"218714",title:"Prof.",name:"Andries",middleName:null,surname:"Engelbrecht",fullName:"Andries Engelbrecht",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRNR8QAO/Profile_Picture_1622640468300",biography:"Andries Engelbrecht received the Masters and PhD degrees in Computer Science from the University of Stellenbosch, South Africa, in 1994 and 1999 respectively. He is currently appointed as the Voigt Chair in Data Science in the Department of Industrial Engineering, with a joint appointment as Professor in the Computer Science Division, Stellenbosch University. Prior to his appointment at Stellenbosch University, he has been at the University of Pretoria, Department of Computer Science (1998-2018), where he was appointed as South Africa Research Chair in Artifical Intelligence (2007-2018), the head of the Department of Computer Science (2008-2017), and Director of the Institute for Big Data and Data Science (2017-2018). In addition to a number of research articles, he has written two books, Computational Intelligence: An Introduction and Fundamentals of Computational Swarm Intelligence.",institutionString:null,institution:{name:"Stellenbosch University",institutionURL:null,country:{name:"South Africa"}}},subseries:[{id:"22",title:"Applied Intelligence",keywords:"Machine Learning, Intelligence Algorithms, Data Science, Artificial Intelligence, Applications on Applied Intelligence",scope:"This field is the key in the current industrial revolution (Industry 4.0), where the new models and developments are based on the knowledge generation on applied intelligence. The motor of the society is the industry and the research of this topic has to be empowered in order to increase and improve the quality of our lives.",annualVolume:11418,isOpenForSubmission:!0,coverUrl:"https://cdn.intechopen.com/series_topics/covers/22.jpg",editor:{id:"27170",title:"Prof.",name:"Carlos",middleName:"M.",surname:"Travieso-Gonzalez",fullName:"Carlos Travieso-Gonzalez",profilePictureURL:"https://mts.intechopen.com/storage/users/27170/images/system/27170.jpeg",institutionString:null,institution:{name:"University of Las Palmas de Gran Canaria",institutionURL:null,country:{name:"Spain"}}},editorTwo:null,editorThree:null,editorialBoard:[{id:"13633",title:"Prof.",name:"Abdelhamid",middleName:null,surname:"Mellouk",fullName:"Abdelhamid Mellouk",profilePictureURL:"https://mts.intechopen.com/storage/users/13633/images/1567_n.jpg",institutionString:null,institution:{name:"Paris 12 Val de Marne University",institutionURL:null,country:{name:"France"}}},{id:"109268",title:"Dr.",name:"Ali",middleName:null,surname:"Al-Ataby",fullName:"Ali Al-Ataby",profilePictureURL:"https://mts.intechopen.com/storage/users/109268/images/7410_n.jpg",institutionString:null,institution:{name:"University of Liverpool",institutionURL:null,country:{name:"United Kingdom"}}},{id:"3807",title:"Dr.",name:"Carmelo",middleName:"Jose Albanez",surname:"Bastos-Filho",fullName:"Carmelo Bastos-Filho",profilePictureURL:"https://mts.intechopen.com/storage/users/3807/images/624_n.jpg",institutionString:null,institution:{name:"Universidade de Pernambuco",institutionURL:null,country:{name:"Brazil"}}},{id:"38850",title:"Dr.",name:"Efren",middleName:null,surname:"Gorrostieta Hurtado",fullName:"Efren Gorrostieta Hurtado",profilePictureURL:"https://mts.intechopen.com/storage/users/38850/images/system/38850.jpg",institutionString:null,institution:{name:"Autonomous University of Queretaro",institutionURL:null,country:{name:"Mexico"}}},{id:"239041",title:"Prof.",name:"Yang",middleName:null,surname:"Yi",fullName:"Yang Yi",profilePictureURL:"https://mts.intechopen.com/storage/users/239041/images/system/239041.jpeg",institutionString:"Virginia Tech",institution:{name:"Virginia Tech",institutionURL:null,country:{name:"United States of America"}}}]},{id:"23",title:"Computational Neuroscience",keywords:"Single-Neuron Modeling, Sensory Processing, Motor Control, Memory and Synaptic Pasticity, Attention, Identification, Categorization, Discrimination, Learning, Development, Axonal Patterning and Guidance, Neural Architecture, Behaviours and Dynamics of Networks, Cognition and the Neuroscientific Basis of Consciousness",scope:"Computational neuroscience focuses on biologically realistic abstractions and models validated and solved through computational simulations to understand principles for the development, structure, physiology, and ability of the nervous system. This topic is dedicated to biologically plausible descriptions and computational models - at various abstraction levels - of neurons and neural systems. This includes, but is not limited to: single-neuron modeling, sensory processing, motor control, memory, and synaptic plasticity, attention, identification, categorization, discrimination, learning, development, axonal patterning, guidance, neural architecture, behaviors, and dynamics of networks, cognition and the neuroscientific basis of consciousness. Particularly interesting are models of various types of more compound functions and abilities, various and more general fundamental principles (e.g., regarding architecture, organization, learning, development, etc.) found at various spatial and temporal levels.",annualVolume:11419,isOpenForSubmission:!0,coverUrl:"https://cdn.intechopen.com/series_topics/covers/23.jpg",editor:{id:"14004",title:"Dr.",name:"Magnus",middleName:null,surname:"Johnsson",fullName:"Magnus Johnsson",profilePictureURL:"https://mts.intechopen.com/storage/users/14004/images/system/14004.png",institutionString:null,institution:{name:"Malmö University",institutionURL:null,country:{name:"Sweden"}}},editorTwo:null,editorThree:null,editorialBoard:[{id:"13818",title:"Dr.",name:"Asim",middleName:null,surname:"Bhatti",fullName:"Asim Bhatti",profilePictureURL:"https://mts.intechopen.com/storage/users/13818/images/system/13818.jpg",institutionString:null,institution:{name:"Deakin University",institutionURL:null,country:{name:"Australia"}}},{id:"151889",title:"Dr.",name:"Joao Luis Garcia",middleName:null,surname:"Rosa",fullName:"Joao Luis Garcia Rosa",profilePictureURL:"https://mts.intechopen.com/storage/users/151889/images/4861_n.jpg",institutionString:null,institution:{name:"University of Sao Paulo",institutionURL:null,country:{name:"Brazil"}}},{id:"103779",title:"Prof.",name:"Yalcin",middleName:null,surname:"Isler",fullName:"Yalcin Isler",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRyQ8QAK/Profile_Picture_1628834958734",institutionString:null,institution:{name:"Izmir Kâtip Çelebi University",institutionURL:null,country:{name:"Turkey"}}}]},{id:"24",title:"Computer Vision",keywords:"Image Analysis, Scene Understanding, Biometrics, Deep Learning, Software Implementation, Hardware Implementation, Natural Images, Medical Images, Robotics, VR/AR",scope:"The scope of this topic is to disseminate the recent advances in the rapidly growing field of computer vision from both the theoretical and practical points of view. Novel computational algorithms for image analysis, scene understanding, biometrics, deep learning and their software or hardware implementations for natural and medical images, robotics, VR/AR, applications are some research directions relevant to this topic.",annualVolume:11420,isOpenForSubmission:!0,coverUrl:"https://cdn.intechopen.com/series_topics/covers/24.jpg",editor:{id:"294154",title:"Prof.",name:"George",middleName:null,surname:"Papakostas",fullName:"George Papakostas",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002hYaGbQAK/Profile_Picture_1624519712088",institutionString:null,institution:{name:"International Hellenic University",institutionURL:null,country:{name:"Greece"}}},editorTwo:null,editorThree:null,editorialBoard:[{id:"1177",title:"Prof.",name:"Antonio",middleName:"J. R.",surname:"Neves",fullName:"Antonio Neves",profilePictureURL:"https://mts.intechopen.com/storage/users/1177/images/system/1177.jpg",institutionString:null,institution:{name:"University of Aveiro",institutionURL:null,country:{name:"Portugal"}}},{id:"220565",title:"Dr.",name:"Jucheng",middleName:null,surname:"Yang",fullName:"Jucheng Yang",profilePictureURL:"https://mts.intechopen.com/storage/users/220565/images/5988_n.jpg",institutionString:null,institution:{name:"Tianjin University of Technology",institutionURL:null,country:{name:"China"}}},{id:"29299",title:"Prof.",name:"Serestina",middleName:null,surname:"Viriri",fullName:"Serestina Viriri",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYOalQAG/Profile_Picture_1620817405517",institutionString:null,institution:{name:"University of KwaZulu-Natal",institutionURL:null,country:{name:"South Africa"}}},{id:"315933",title:"Dr.",name:"Yalın",middleName:null,surname:"Baştanlar",fullName:"Yalın Baştanlar",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y00002qpr7hQAA/Profile_Picture_1621430127547",institutionString:null,institution:{name:"Izmir Institute of Technology",institutionURL:null,country:{name:"Turkey"}}}]},{id:"25",title:"Evolutionary Computation",keywords:"Genetic Algorithms, Genetic Programming, Evolutionary Programming, Evolution Strategies, Hybrid Algorithms, Bioinspired Metaheuristics, Ant Colony Optimization, Evolutionary Learning, Hyperparameter Optimization",scope:"Evolutionary computing is a paradigm that has grown dramatically in recent years. This group of bio-inspired metaheuristics solves multiple optimization problems by applying the metaphor of natural selection. It so far has solved problems such as resource allocation, routing, schedule planning, and engineering design. Moreover, in the field of machine learning, evolutionary computation has carved out a significant niche both in the generation of learning models and in the automatic design and optimization of hyperparameters in deep learning models. This collection aims to include quality volumes on various topics related to evolutionary algorithms and, alternatively, other metaheuristics of interest inspired by nature. For example, some of the issues of interest could be the following: Advances in evolutionary computation (Genetic algorithms, Genetic programming, Bio-inspired metaheuristics, Hybrid metaheuristics, Parallel ECs); Applications of evolutionary algorithms (Machine learning and Data Mining with EAs, Search-Based Software Engineering, Scheduling, and Planning Applications, Smart Transport Applications, Applications to Games, Image Analysis, Signal Processing and Pattern Recognition, Applications to Sustainability).",annualVolume:11421,isOpenForSubmission:!0,coverUrl:"https://cdn.intechopen.com/series_topics/covers/25.jpg",editor:{id:"136112",title:"Dr.",name:"Sebastian",middleName:null,surname:"Ventura Soto",fullName:"Sebastian Ventura Soto",profilePictureURL:"https://mts.intechopen.com/storage/users/136112/images/system/136112.png",institutionString:null,institution:{name:"University of Córdoba",institutionURL:null,country:{name:"Spain"}}},editorTwo:null,editorThree:null,editorialBoard:[{id:"111683",title:"Prof.",name:"Elmer",middleName:"P.",surname:"Dadios",fullName:"Elmer Dadios",profilePictureURL:"https://mts.intechopen.com/storage/users/111683/images/system/111683.jpg",institutionString:"De La Salle University",institution:{name:"De La Salle University",institutionURL:null,country:{name:"Philippines"}}},{id:"106873",title:"Prof.",name:"Hongwei",middleName:null,surname:"Ge",fullName:"Hongwei Ge",profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institutionString:null,institution:{name:"Dalian University of Technology",institutionURL:null,country:{name:"China"}}},{id:"171056",title:"Dr.",name:"Sotirios",middleName:null,surname:"Goudos",fullName:"Sotirios Goudos",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bS9IuQAK/Profile_Picture_1622623673666",institutionString:null,institution:{name:"Aristotle University of Thessaloniki",institutionURL:null,country:{name:"Greece"}}},{id:"15895",title:"Assistant Prof.",name:"Takashi",middleName:null,surname:"Kuremoto",fullName:"Takashi Kuremoto",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYLrqQAG/Profile_Picture_1625656196038",institutionString:null,institution:{name:"Nippon Institute of Technology",institutionURL:null,country:{name:"Japan"}}},{id:"125844",title:"Prof.",name:"Wellington",middleName:"Pinheiro Dos",surname:"Santos",fullName:"Wellington Santos",profilePictureURL:"https://mts.intechopen.com/storage/users/125844/images/4878_n.jpg",institutionString:null,institution:{name:"Federal University of Pernambuco",institutionURL:null,country:{name:"Brazil"}}}]},{id:"26",title:"Machine Learning and Data Mining",keywords:"Intelligent Systems, Machine Learning, Data Science, Data Mining, Artificial Intelligence",scope:"The scope of machine learning and data mining is immense and is growing every day. It has become a massive part of our daily lives, making predictions based on experience, making this a fascinating area that solves problems that otherwise would not be possible or easy to solve. This topic aims to encompass algorithms that learn from experience (supervised and unsupervised), improve their performance over time and enable machines to make data-driven decisions. It is not limited to any particular applications, but contributions are encouraged from all disciplines.",annualVolume:11422,isOpenForSubmission:!0,coverUrl:"https://cdn.intechopen.com/series_topics/covers/26.jpg",editor:{id:"24555",title:"Dr.",name:"Marco Antonio",middleName:null,surname:"Aceves Fernandez",fullName:"Marco Antonio Aceves Fernandez",profilePictureURL:"https://mts.intechopen.com/storage/users/24555/images/system/24555.jpg",institutionString:null,institution:{name:"Autonomous University of Queretaro",institutionURL:null,country:{name:"Mexico"}}},editorTwo:null,editorThree:null,editorialBoard:[{id:"43680",title:"Prof.",name:"Ciza",middleName:null,surname:"Thomas",fullName:"Ciza Thomas",profilePictureURL:"https://mts.intechopen.com/storage/users/43680/images/system/43680.jpeg",institutionString:null,institution:{name:"Government of Kerala",institutionURL:null,country:{name:"India"}}},{id:"16614",title:"Prof.",name:"Juan Ignacio",middleName:null,surname:"Guerrero Alonso",fullName:"Juan Ignacio Guerrero Alonso",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002g6HB8QAM/Profile_Picture_1627901127555",institutionString:null,institution:{name:"University of Seville",institutionURL:null,country:{name:"Spain"}}},{id:"3095",title:"Prof.",name:"Kenji",middleName:null,surname:"Suzuki",fullName:"Kenji Suzuki",profilePictureURL:"https://mts.intechopen.com/storage/users/3095/images/1592_n.jpg",institutionString:null,institution:{name:"University of Chicago",institutionURL:null,country:{name:"United States of America"}}},{id:"214067",title:"Dr.",name:"W. David",middleName:null,surname:"Pan",fullName:"W. David Pan",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bSEI9QAO/Profile_Picture_1623656213532",institutionString:null,institution:{name:"University of Alabama in Huntsville",institutionURL:null,country:{name:"United States of America"}}},{id:"72920",title:"Prof.",name:"Yves",middleName:"Philippe",surname:"Rybarczyk",fullName:"Yves Rybarczyk",profilePictureURL:"https://mts.intechopen.com/storage/users/72920/images/system/72920.jpeg",institutionString:"Dalarna University, Faculty of Data and Information Sciences",institution:{name:"Dalarna University",institutionURL:null,country:{name:"Sweden"}}}]},{id:"27",title:"Multi-Agent Systems",keywords:"Collaborative Intelligence, Learning, Distributed Control System, Swarm Robotics, Decision Science, Software Engineering",scope:"Multi-agent systems are recognised as a state of the art field in Artificial Intelligence studies, which is popular due to the usefulness in facilitation capabilities to handle real-world problem-solving in a distributed fashion. The area covers many techniques that offer solutions to emerging problems in robotics and enterprise-level software systems. Collaborative intelligence is highly and effectively achieved with multi-agent systems. Areas of application include swarms of robots, flocks of UAVs, collaborative software management. Given the level of technological enhancements, the popularity of machine learning in use has opened a new chapter in multi-agent studies alongside the practical challenges and long-lasting collaboration issues in the field. It has increased the urgency and the need for further studies in this field. We welcome chapters presenting research on the many applications of multi-agent studies including, but not limited to, the following key areas: machine learning for multi-agent systems; modeling swarms robots and flocks of UAVs with multi-agent systems; decision science and multi-agent systems; software engineering for and with multi-agent systems; tools and technologies of multi-agent systems.",annualVolume:11423,isOpenForSubmission:!0,coverUrl:"https://cdn.intechopen.com/series_topics/covers/27.jpg",editor:{id:"148497",title:"Dr.",name:"Mehmet",middleName:"Emin",surname:"Aydin",fullName:"Mehmet Aydin",profilePictureURL:"https://mts.intechopen.com/storage/users/148497/images/system/148497.jpg",institutionString:null,institution:{name:"University of the West of England",institutionURL:null,country:{name:"United Kingdom"}}},editorTwo:null,editorThree:null,editorialBoard:[{id:"275140",title:"Dr.",name:"Dinh Hoa",middleName:null,surname:"Nguyen",fullName:"Dinh Hoa Nguyen",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRbnKQAS/Profile_Picture_1622204093453",institutionString:null,institution:{name:"Kyushu University",institutionURL:null,country:{name:"Japan"}}},{id:"20259",title:"Dr.",name:"Hongbin",middleName:null,surname:"Ma",fullName:"Hongbin Ma",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRhDJQA0/Profile_Picture_2022-05-02T08:25:21.jpg",institutionString:null,institution:{name:"Beijing Institute of Technology",institutionURL:null,country:{name:"China"}}},{id:"28640",title:"Prof.",name:"Yasushi",middleName:null,surname:"Kambayashi",fullName:"Yasushi Kambayashi",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYOQxQAO/Profile_Picture_1625660525470",institutionString:null,institution:{name:"Nippon Institute of Technology",institutionURL:null,country:{name:"Japan"}}}]}]}},libraryRecommendation:{success:null,errors:{},institutions:[]},route:{name:"profile.detail",path:"/profiles/441995",hash:"",query:{},params:{id:"441995"},fullPath:"/profiles/441995",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()